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Mitochondrial dysfunction causes moderate to profound hearing loss both in isolation and 
as a feature of multi-systemic mitochondrial disease. The m.1555A>G mitochondrial DNA 
(mtDNA) variant is associated with a predisposition to aminoglycoside ototoxicity and 
maternally inherited non-syndromic deafness. However, the reasons for the highly variable 
penetrance of the associated hearing loss have not yet been fully resolved. 
Aminoglycosides are a recognised modifier factor of the hearing loss, but cannot account 
for all hearing impaired carriers in multi-generational pedigrees, implicating additional co-
segregating genetic factors. By identifying and characterising the c.3G>A SSBP1 variant 
as a nuclear modifier of m.1555A>G the work detailed in this thesis extends our 
understanding of mitochondrial-nuclear interactions in human disease. 
To ascertain the frequency of the m.1555A>G variant in patients with suspected 
mitochondrial hearing loss we surveyed the laboratories within the United Kingdom that 
undertake genetic testing for this variant. We determined that the variant was not found 
more frequently in patients with known hearing impairment providing further evidence 
that m.1555A>G does not cause hearing loss in isolation. These results strengthened the 
case for nuclear genetic modifiers as important contributors to m.1555A>G pathogenesis. 
We next identified a multi-generational family that transmitted the m.1555A>G variant 
with variable clinical penetrance of hearing loss. In addition, a cohort of sporadic 
individuals carrying m.1555A>G was used to test the hypothesis that a conserved genetic 
mechanism accounted for the phenotype in all carriers. To this effect, we undertook whole 
exome sequencing in selected familial and sporadic carriers of m.1555A>G, identifying a 
heterozygous start loss mutation in the core mtDNA replisome protein gene, SSBP1, that 
co-segregated with the m.1555A>G variant and the phenotype in the family. The SSBP1 
variant lead to a perturbation of mtDNA metabolism, and was associated with multiple 
mtDNA deletions and mtDNA depletion in skeletal muscle. Fibroblasts from these patients 
also showed mitochondrial network fragmentation and reduced intra-mitochondrial protein 
synthesis in keeping with the co-existing m.1555A>G variant, leading to reduced 
proliferation rates under conditions of forced mitochondrial respiration. Our findings 
provide an explanation for the variable clinical penetrance of the disorder within these 
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Abbreviations used in this thesis are expanded in the following list. Only genes 
specifically discussed in the text are included. Gene names within tables use standard 
nomenclature as specified by the HUGO Gene Nomenclature Committee. 
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µl  Microlitre 
µm  Micrometre 
µM  Micromolar 
τm5U 5-taurinomethyluridine 
τm5s2U 5-taurinomethyl-2-thiouridine 
2D-AGE  Two-dimensional agarose gel electrophoresis 
4EBP1  Eukaryotic initiation factor 4E binding protein 1 
8-OHdG  8-hydroxydeoxyguanosine 
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AMPK  5’ adenosine monophosphate-activated protein kinase 
ANOVA  Analysis of variance 
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ATF6  Activating transcription factor 6 
ATP  Adenosine triphosphate 
xx 
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CPEO  Chronic progressive external ophthalmoplegia 
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xxi 
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CT  Computed tomography 
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dbSNP  Single nucleotide polymorphism database 
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DMEM  Dulbecco’s Modified Eagle Medium 
DMSO  Dimethyl sulphoxide 
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DOA  Dominant optic atrophy 
DPOAE  Distortion product otoacoustic emissions 
DRP1  Dynamin-related protein 1 
E- Exit 
E2F1 Transcription factor E2F1 
ECAR Extracellular acidification rate 
ECL  Enhanced chemiluminescence 
EDTA  Ethylenediaminetetraacetic acid 
Eif2! Eukaryotic Translation Initiation Factor 2A 
ELISA  Enzyme linked immunosorbent assay 
EQTL Expression quantitative trait loci 
ER  Endoplasmic reticulum 
xxii 
EtBr  Ethidium bromide 
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Fe/S  Iron-sulphur 
FIS1  Fission protein 1 
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FRET  Fluorescence resonance energy transfer 
G Relative centrifugal force 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GATK Genome Analysis Toolkit 
GJB2 Gap junction beta 2 
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GPx  Glutathione peroxidase 
GPx1  Glutathione peroxidase 1 
Grp78  Glucose-regulated protein 78 kDa 
GSSG  Oxidized glutathione 
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GTPBP3  GTP binding protein 3 
H+  Proton 
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xxiii 
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H2O2 Hydrogen peroxide 
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HSF1  Heat shock factor 1 
HSP  Heavy strand promoter 
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IMM  Inner mitochondrial membrane 
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IVA  Ingenuity Variant Analysis 
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KSS  Kearns-Sayre Syndrome 
LC3 Microtubule associated protein 1A/1B light chain 3 
LHON  Leber’s hereditary optic neuropathy 
LKB1  Liver kinase B1 
LOXHD1  Lipoxygenase Homology Domains 1 
xxiv 
LSP  Light strand promoter 
LRT  Likelihood ratio test 
l-OPA1  Long OPA1 
L-strand  Light strand 
M Molar 
mM  Milimolar 
MAF  Minor allele frequency 
MAPK  Mitogen-activated protein kinase 
MDS  Mitochondrial depletion syndrome 
MELAS  Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like 
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MERRF  Myoclonic epilepsy and ragged red fibres 
MET  Mechanotransducer 
MFF  Mitochondrial fission factor 
MFN1  Mitofusin-1 
MFN2  Mitofusin-2 
mg  Milligram 
MGAM  Maltase glucoamylase 
MGME1 Mitochondrial genome maintenance exonuclease 1 
Mid49  Mitochondrial dynamics protein of 49 kDa 
Mid51  Mitochondrial dynamics protein of 51 kDa 
MIDD Maternally inherited diabetes and deafness 
Min  Minute 
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MOTS-c Mitochondrial open reading frame of the12S rRNA-c 
xxv 
MPV17  Mitochondrial inner membrane protein MPV17 
MRG Mitochondrial RNA granules 
MRI Magnetic resonance imaging 
mRNA  Messenger RNA 
MRP  Mitochondrial ribosomal protein 
MRPS12  Mitochondrial Ribosomal Protein S12 
MRPS16  Mitochondrial Ribosomal Protein S16 
MRPS18CP2  Mitochondrial Ribosomal Protein S18C Pseudogene 2 
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mtDNA  Mitochondrial DNA 
mtEFTU  Mitochondrial translation elongation factor Tu 
xxvi 
mtEFTs  Mitochondrial translation elongation factor Ts 
mtEFG1  Mitochondrial translation elongation factor G1 
mTERF1  Mitochondrial transcription termination factor 1 
MTO1  Mitochondrial tRNA translation optimisation 1 
mTOR  Mechanistic target of rapamycin 
mTORC1  Mechanistic target of rapamycin complex I 
mTORC2  Mechanistic target of rapamycin complex II 
MTRRF1 Mitochondrial ribosomal recycling factor 1 
MTS  Mitochondrial targeting sequence 
MYO6  Myosin VI 
n.a  Not applicable 
n.d Not determined 
NaCl Sodium chloride 
NaOH Sodium hydroxide 
NAD+  Oxidised nicotinamide dinucleotide 
NADH  Nicotinamide adenine dinucleotide 
NADPH nicotinamide adenine dinucleotide phosphate 
NCBI National Centre for Biotechnology Information 
NCR  Non-coding region 
NFκB Nuclear factor kappa-light-chain enhancer of activated B cells 
NHLBIESP National Heart Lung and Blood Institute Exome Sequencing Project 
NGS  Next-generation sequencing 
NUMT  Nuclear mitochondrial DNA 
O2  Oxygen 
O2- Superoxide 
OH  Origin of heavy strand replication 
OL  Origin of light strand replication 
xxvii 
OAEs  Otoacoustic emissions 
OCR  Oxygen consumption rate 
OCT Optimum cutting temperature 
OHC Outer hair cell 
OLB  Oligonucleotide labelling buffer 
OMA1 Mitochondrial metalloendopeptidase OMA1 
OMIM Online Mendelian Inheritance in Man 
OMM  Outer mitochondrial membrane 
OPA1  Optic atrophy 1 
ORF  Open reading frame 
OriZ  Single zone of replication initiation 
OXA1 Mitochondrial oxidase assembly protein 
OXPHOS  Oxidative phosphorylation 
P Patient 
P-  Peptidyl 
pMole  Picomole 
pS:pHS  Densitometric quantification steady state: heat shock  
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PERK  Protein kinase RNA (PKR)-like kinase 
PEO  Progressive external ophthalmoplegia 
Pi  Inorganic phosphate 
PI3K-AKT Phosphoinositide 3-kinase –AKT (protein kinase B) 
PIKK Phosphatidylinositol 3-kinase related kinases 
PMF  Proton motive force 
PMSF Phenylmethylsulphonyl fluoride 
POLG  Polymerase DNA gamma 
xxviii 
POLG2  Polymerase DNA gamma 2 
POLRMT  Mitochondrial RNA polymerase 
Pol  DNA polymerase 
PS  Pearson syndrome 
PTA  Pure tone audiogram 
PVDF  Polyvinylidene difluoride 
qPCR Quantitative polymerase chain reaction 
R2  Coefficient of determination 
rCRS  Revised Cambridge Reference Sequence 
RFU  Relative fluorescent units 
RITOLS  Ribonucleotide incorporation throughout the lagging strand 
RL  Repopulation level 
RNA Ribonucleic acid 
RNAi RNA interference 
RNAseH1  Ribonuclease H1 
RNAse P  Ribonuclease P 
RNAse Z Ribonuclease Z 
ROS  Reactive oxygen species 
RPM  Revolutions per minute 
RRM2B  p53 inducible ribonucleotide reductase M2 B 
rRNA  Ribosomal RNA 
S Sulphur 
s-OPA1  Short OPA1 
sORF Short open reading frame 
S6K  p70-S6 kinase 
SANDO  Sensory ataxia neuropathy dysarthria and ophthalmoparesis 
SD  Standard deviation 
xxix 
SDH  Succinate dehydrogenase 
SDS Sodium dodecyl sulphate 
SIFT  Sorting tolerant from intolerant 
SMAC Second mitochondrial derived activator of caspases 
SNP  Single nucleotide polymorphism 
SNV  Single nucleotide variant 
SOD Superoxide dismutase 
SSBP1  Single stranded binding protein  
SSC  Saline-sodium citrate 
SUCLA2  Succinate-coA ligase 
SUMO Small ubiquitin like modifier 
TAE Tris-acetate EDTA 
TAS   Termination associated sequence 
TBST  Tris Buffer Saline Tween 20 
TBq Terabecquerel 
TCA  Tricarboxylic acid 
TE Tris-EDTA 
TEFM Transcription elongation factor 
TFAM  Mitochondrial transcription factor A 
TFB1M  Transcription factor B1 
TFB2M  Transcription factor B2 
TIC  Translation initiation codon 
TIFF Tagged image file format 
TOAEs  Transient otoacoustic emissions 
TOMM20 Translocase of outer mitochondrial membrane 20 
TOP1MT  DNA topoisomerase I mitochondrial precursor 
TOP3A  DNA topoisomerase 3-alpha 
xxx 
TP Thymidine phosphorylase 
TRMU  tRNA 5-methylaminomethyl-2-thiouridylate methyltransferase 
TRMT61B tRNA (adenine(58)-N(1))-methyltransferase 
tRNA  Transfer RNA 
TSC  Tuberous sclerosis complex 
TSC1  Tuberous sclerosis complex 1 
TSC2  Tuberous sclerosis complex 2 
TTP Thymidine triphosphate 
TWNK Twinkle mtDNA helicase 
UCLH  University College London Hospitals 
UK United Kingdom 
UPR  Unfolded protein response 
USB Universal Serial Bus 
V  Voltage 
VCF  Variant call format 
VDAC  Voltage dependent anion channels 
v/v  Volume/volume 
WES  Whole exome sequencing 
WGS Whole genome sequencing 
w/v  Weight/volume 






1.1! Chapter overview 
This chapter reviews and contextualises the central concepts of this thesis. Firstly, it 
provides an overview of current mitochondrial biology, focussing primarily on the 
contribution of dysfunctional mitochondrial DNA (mtDNA) maintenance and expression 
to human disease. Following this, there is an exploration of the role of mitochondria in 
hearing loss, a symptom that causes a significant reduction in the quality of life of patients 
with mitochondrial disease. Next, the mtDNA variant, m.1555A>G, is presented together 
with the current evidence for the mechanisms underpinning the associated hearing loss. 
The introduction then concludes with a synopsis of next generation sequencing 
technologies detailed as justification for the approach adopted in this thesis aiming to 
identify and characterise novel nuclear modifier genes underlying the variable penetrance 
of the m.1555A>G variant. 
1.2! The mitochondrion 
Mitochondria are subcellular organelles that form a dynamic reticular network in 
eukaryotic cells (Sukhorukov, Dikov et al. 2012). Although characterised by their role in 
the generation of cellular energy, throughout their evolutionary history mitochondria have 
acquired numerous additional cellular functions (Huynen, Duarte et al. 2013). 
Mitochondrial dysfunction therefore compromises many aspects of cellular physiology and 
leads to a range of human diseases, including hearing loss, that to date remain largely 
untreatable (Scarpelli, Todeschini et al. 2014). 
1.3! The origins of mitochondria 
Until the characterisation of the flagellate Excavata Monocercomonodies, mitochondria 
had been identified in every studied eukaryotic organism (Karnkowska, Vacek et al. 2016). 
Mitochondria are believed to have arisen approximately two billion years ago from the 
endosymbiotic integration of an aerobic α-proteobacterium into the proto-eukaryotic host 
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(Margulis 1971, Karnkowska, Vacek et al. 2016). Phylogenetic studies, comparing the 
sequence of human mtDNA and the genome of the α-proteobacteria Rickettsia prowazekii 
have provided evidence of a common origin for mitochondria and the α-proteobacteria 
lineages (Andersson, Zomorodipour et al. 1998, Emelyanov 2001, Gray 2012). The origin 
of the host cell, however, remains more controversial. Currently, the most accepted theory, 
the ‘hydrogen hypothesis’ posits the host cell was a prokaryotic, hydrogen dependent 
archaeon possibly resembling modern methanogenic archaea (Martin and Muller 1998). 
1.4! Structure 
Mitochondria, resembling their bacteria predecessors, are bound by two phospholipid 
membranes; the inner and outer mitochondrial membrane (IMM; OMM respectively). 
These membranes establish two distinct organellar sub-compartments; the intermembrane 
space and the matrix contained by the IMM (Figure 1.1). The mitochondrial matrix is the 
site of the site of numerous metabolic processes (discussed in Section 1.5) and houses 
multiple copies of the mtDNA and mitochondrial ribosomes and hence contains the site of 
mtDNA replication, transcription and translation (discussed in Section 1.8) (Frey and 
Mannella 2000). The OMM encloses the organelle and consists of a phospholipid bilayer 
punctuated by voltage dependent anion channels (VDAC). These channels result in the 
OMM being highly permeable to molecules smaller than 10 kDa (Guo and Mannella 1993, 
Bayrhuber, Meins et al. 2008). The OMM also functions to engage other cellular 
components including the endoplasmic reticulum (ER), ribosomes and the nucleus 
facilitating mitochondrial functional integration into cellular physiologic processes (Pernas 
and Scorrano 2016). 
The IMM is divided into two functionally distinct zones: the inner boundary membrane 
and the cristae membrane that are linked by cristae junctions (Pernas and Scorrano 2016). 
The inner boundary membrane lies parallel with the OMM, forming interaction sites 
containing specific machinery for protein import (Reichert and Neupert 2002). The cristae 
membrane forms folds into the matrix and contains the majority of the electron transport 
chain responsible for oxidative phosphorylation (OXPHOS). The IMM is rich in protein, 
specifically cardiolipin, that necessitates the active transport of molecules from the 
intermembrane space into the matrix by interaction with a number of mitochondrial carrier 
proteins (Paradies, Paradies et al. 2014). This lack of permeability enables the creation of a 
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transmembrane electrochemical gradient, a key requirement for OXPHOS (discussed in 
Section 1.5.1). 
 
Figure 1.1. The ultrastructure of the mitochondria. A 3D tomogram of a mitochondrion 
with structural features and dimensions. Adapted from Frey and Mannella 2000. 
1.5! Mitochondrial function 
Mitochondria are responsible for a number of metabolic processes including the 
tricarboxylic acid (TCA) cycle, biosynthesis of cellular pyrimidines, steroids and heme 
and the β-oxidation of fatty acids (Voet 2011). Mitochondria also play a fundamental role 
in the regulation of cellular calcium, the regulation of apoptosis, adaptive thermogenesis 
and the generation of reactive oxygen species (ROS) and reactive nitrogen species 
(Wallace 2005). However, the most recognised role of mitochondria is the use of a 
transmembrane electrochemical gradient to convert adenosine diphosphate (ADP) and 
inorganic phosphate (Pi) into adenosine triphosphate (ATP) through the process of 
OXPHOS (Kadenbach 2012). 
1.5.1! Oxidative phosphorylation (OXPHOS) 
The OXPHOS respiratory chain consists of four structurally distinct multi-subunit 
complexes (Complex I-IV), ATP synthase (Complex V) and two electron carriers: 
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coenyzyme Q10 and cytochrome c located in the cristal membrane (Smeitink, van den 
Heuvel et al. 2001) (Figure 1.2). 
Complex I (nicotinamide adenine dinucleotide (NADH)-ubiquinone oxidoreductase) 
contains 45 subunits, seven of which are encoded by the mtDNA (Zhu, Vinothkumar et al. 
2016). Complex II (succinate dehydrogenase, SDH) by comparison comprises four 
subunits (A-D) all of which are nuclear encoded. Complex II is unique amongst the 
respiratory chain complexes, functioning both in OXPHOS and the TCA cycle where it 
oxidises succinate to fumarate (Sun, Huo et al. 2005). Complex III (ubiquinol-cytochrome 
c oxidoreductase) is composed of ten nuclear encoded subunits and one mitochondrial 
encoded subunit (cytochrome b) whilst Complex IV (cytochrome c oxidase, COX) consists 
of 14 subunits, three of which are encoded by the mtDNA (mitochondrially encoded 
cytochrome c oxidase I-III, MT-COI, MT-CO II, MT-CO III) (Tsukihara, Aoyama et al. 
1995, Iwata, Lee et al. 1998). Finally, Complex V (ATP synthase) consists of 19 subunits; 
two of which (ATP6 and ATP8) are encoded by the mitochondria (Jonckheere, Smeitink et 
al. 2012). 
A prerequisite for OXPHOS is the availability of coenzyme NADH and flavin adenine 
dinucleotide (FADH2) produced during glycolysis, the TCA cycle and β-oxidation of fatty 
acids. Electrons from these cofactors are transferred into the respiratory chain to drive 
OXPHOS. Initially, Complex I oxidizes NADH to NAD+ whilst FADH2 is reduced to FAD 
by Complex II. Both Complex I and Complex II reduce ubiquinone (Coenzyme Q10) to 
ubiquinol that is then transferred to Complex III (ubiquinol-cytochrome c oxidoreductase) 
via the IMM (Kim, Khalimonchuk et al. 2012). Complex III is responsible for the Q cycle 
that results in the oxidation of ubiquinol with the concurrent reduction of cytochrome c 
(Mitchell and Moyle 1967). Complex IV then accepts an electron from each of the four-
cytochrome c molecules reduced by Complex III. These electrons are then transferred to a 
molecule of oxygen that binds four protons to form two molecules of H2O. The reactions 
of Complex I, III and IV all couple the transfer of elections to the transport of protons into 
the intermembrane space thus creating the proton-motive force (PMF) (Mitchell and 
Moyle 1967). Complex V subsequently can use this electrochemical gradient to produce 
ATP from ADP and Pi by a process of rotary catalysis (Stock, Gibbons et al. 2000). 
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Figure 1.2. The mitochondrial respiratory chain. Electrons enter the respiratory chain 
through the oxidation of NADH to NAD+ by Complex I and via the oxidation of succinate to 
fumarate with the reduction of FADH2 to FAD by Complex II. Electrons are transferred by 
coenzyme Q10 (Q) and cytochrome c (C) to Complex IV, the final electron acceptor, that converts 
oxygen to water. The electron transfer of Complex I, III and IV is coupled to translocation of 
protons into the intermembrane space. This establishes a proton gradient that drives ATP synthesis 
by Complex V. 
1.6! Generation of Reactive Oxygen Species 
ROS play an essential role in cellular redox signalling, however, in excess they are 
responsible for oxidative damage to the cell. ROS are formed by one-electron transfer 
from a redox donor to oxygen and the majority of cellular ROS, particularly superoxide 
(O2.-) is produced by Complex I and III (Murphy 2009, Bleier and Drose 2013). However, 
recent studies indicate that numerous other mitochondrial enzymes also contribute to ROS 
generation, including complex II, nicotinamide adenine dinucleotide phosphate (NADPH)-
oxidase and monoaminoxidases (Zhang, Yu et al. 1998, Zorov, Juhaszova et al. 2014). O2.- 
is subsequently metabolised to hydrogen peroxide, H2O2, by dismutation in a reaction 
catalysed by superoxide dismutases (SOD). H2O2 is then able to modulate cellular 
signalling by altering cell signalling molecules by orchestrating redox dependent 
modification of thiol groups on cysteine residues (Go, Chandler et al. 2015). There is also 
evidence that ROS stimulate several intracellular signalling pathways including mitogen-
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activated protein kinase (MAPK), NFκB and the PI3K-Akt pathway (Schoonbroodt, 
Ferreira et al. 2000, Lee, Yang et al. 2002, McCubrey, Lahair et al. 2006). Cellular ROS 
are therefore vital for organismal homeostasis and play a fundamental role in numerous 
cellular processes including metabolism, energy expenditure and the immune system 
(Shadel and Horvath 2015). 
Importantly, however, excessive ROS act as primary mediators of oxidative damage to 
cellular DNA, lipids and proteins. Oxidative damage to DNA is mediated by single and 
double strand DNA breaks and modifications of purine and pyrimidine bases to DNA 
(Bohr 2002). Lipids can also react with ROS to form lipid hydroperoxides and numerous 
other secondary products including propanal, hexanal and 4-hydroxynonenal (Marrocco, 
Altieri et al. 2017). Oxidative modifications of proteins include carbonylation, s-
nitrosylation and disulphide formation (Gao, Laude et al. 2008, Cai and Yan 2013). Given 
these important cellular effects of ROS, mitochondria possess a complex ROS defence 
network consisting of enzymatic and non-enzymatic antioxidants. These include SODs, 
catalase, peroxiredoxin and most importantly, glutathione (GSH) (Ott, Gogvadze et al. 
2007, Sena and Chandel 2012). GSH serves as the major scavenger of cellular hydroxyl 
radicals by reducing hydrogen and organic peroxides in the presence of glutathione 
peroxidase (GPx) (Gao, Laude et al. 2008). 
1.7! Mitochondrial genetics 
1.7.1! Mitochondrial genome 
As a product of their evolutionary heritage, mitochondria have retained their own genome, 
the mtDNA, which exists separately from the nuclear DNA. Human mtDNA is a 16,569 
base pair (bp) double stranded circular molecule that is packed into DNA-protein 
complexes termed nucleoids (discussed in Section 1.8.1) (Bogenhagen, Rousseau et al. 
2008). mtDNA was first sequenced in 1981 and later corrected and published as the 
‘revised Cambridge Reference Sequence (rCRS)’ in 1999 (Anderson, Bankier et al. 1981, 
Andrews, Kubacka et al. 1999, Bandelt, Kloss-Brandstatter et al. 2014). 
During evolution, the vast majority of mitochondrial genes have been transferred to the 
nucleus; evidenced by the presence of NUMTs (nuclear sequence of mitochondrial origin) 
(Hazkani-Covo, Zeller et al. 2010). Two main theories attempt to explain the reason the 
cell maintains a separate mtDNA at energetic expense despite this mass transfer of 
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mitochondrial genes. Firstly, it has been suggested that hydrophobic membrane proteins 
may be difficult to import into mitochondria or be targeted to the ER if expressed in the 
cytoplasm (Claros, Perea et al. 1995, Bjorkholm, Ernst et al. 2017). Alternatively, the co-
location for redox regulation (CoRR) hypothesis proposes that mtDNA is essential to 
provide a sufficiently sensitive redox regulatory system that could not be provided by a 
nuclear transcription signal (Allen 2015). 
 
Figure 1.3. The human mitochondrial genome. The human mitochondrial genome is a 
circular 16,569 bp molecule that encodes 13 protein-coding genes (Genes encoding Complex I 
proteins in dark blue, Complex III in red, Complex IV in light blue and Complex V in orange), two 
ribosomal RNAs (12S and 16S in green) and 22 transfer RNAs (marked in yellow identified by 
their respective amino acid abbreviation). The mtDNA also contains a non-coding region (NCR) 
that incorporates a third strand, named the D-loop (discussed in Section 1.7.2). 
The mtDNA consists of a purine-rich heavy (H-) strand and a pyrimidine-rich light (L-) 
strand. Each cell contains multiple copies of mtDNA and depending on bioenergetic 
8 
demand each cell can contain hundreds to thousands of copies of mtDNA (Chinnery and 
Hudson 2013). mtDNA is densely packed with 37 coding genes: 13 protein coding, 22 
transfer ribonucleic acids (tRNAs) and 2 ribosomal ribonucleic acids (rRNA) genes, the 
12S and 16S (Figure 1.3). The 13 encoded proteins are components of the OXPHOS 
system and the rRNA products are core components of mitochondrial translation. The 
majority of mtDNA proteins coding genes are found on the H- strand whereas the L- 
strand only codes for the ND6 (nicotinamide adenine dinucleotide dehydrogenase 
subunit 6) component of Complex I and 8 tRNA genes. The mtDNA is remarkably 
compact, with none of the genes containing introns and only one non coding region 
(NCR) that extends between the mt-tRNA phenylalanine (F) and proline (P) genes and 
contains the transcriptional promoters of both the light and heavy strands (LSP and HSP) 
as well as the origin of heavy strand replication (OH), three conserved sequence blocks 
(CSB1, CSB2, CSB3) and a termination associated sequence (TAS) (discussed further in 
Section 1.7.2) (Sbisa, Tanzariello et al. 1997, Andrews, Kubacka et al. 1999). The L- 
strand origin (OL) is located in a cluster of five tRNAs and the intervening section 
between OH and OL defines the ‘major arc’ whilst the remaining section of the molecule 
is classed the ‘minor arc’. 
1.7.2! Mitochondrial D loop and 7S DNA 
The NCR incorporates a third strand, the 7S DNA, that forms a displacement loop (D-
loop) structure of approximately 650 nucleotides from OH at the variable 5’ end of 7S 
DNA to the TAS at the 3’ end of 7S DNA (Figure 1.4) (Doda, Wright et al. 1981). 7S 
DNA is primed by 7S RNA transcribed from the LSP and although this transition from 
RNA to DNA is incompletely understood it has been suggested it occurs in CSB2 
(Kang, Miyako et al. 1997). A number of studies have shown 7S DNA synthesis is 
promoted by various factors, including transcription factor A (TFAM), single stranded 
binding protein (SSBP1) and Twinkle helicase (discussed in Section 1.8.2) (Gensler, 
Weber et al. 2001, Ruhanen, Borrie et al. 2010, Milenkovic, Matic et al. 2013). 
The exact function of the D-loop however, that exists at an energetic expense to the 
mitochondria, is not yet fully characterised. It has been proposed that it serves to organise 
the mtDNA into nucleoids (discussed in Section 1.8.1), maintain deoxynucleotide (dNTP) 
pools during the cell cycle and play a critical role in mtDNA replication. It is proposed that 
the D-loop represents a product of aborted replication of the H- strand according to the 
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strand displacement model of mtDNA replication (see Section 1.8.2.5.1) (Clayton 1982, 
He, Mao et al. 2007, Antes, Tappin et al. 2010). In this model H- strand replication is 
initiated using 7S DNA as a primer or by synthesising a 7S DNA that is not terminated at 
the TAS. It has also been suggested that the D-loop triple strand structure may act to 
inhibit replication fork progression and hence prevent replication fork collisions that 
would be detrimental to genome stability (Rudolph, Upton et al. 2013, Nicholls and 
Minczuk 2014). 
 
Figure 1.4. Structure of the mitochondrial NCR and D-loop. The NCR contains the LSP 
and HSP required for mitochondrial transcription, three conserved sequence blocks (CSB 1-3) 
between HSP/LSP and the origin of heavy strand replication OH, two hypervariable segments 
(HVS) and 7S DNA extending from OH to the termination associated sequence (TAS). Figure 
adapted from Nicholls and Minczuk 2014. 
1.7.3! Mitochondrial DNA inheritance 
A central dogma of mitochondrial biology is the exclusive maternal inheritance of mtDNA 
(Pyle, Hudson et al. 2015). It is thought two major processes account for the lack of 
transmission of sperm mtDNA. Firstly, mtDNA copy number is greatly down-regulated in 
spermatogenesis (Larsson, Oldfors et al. 1997). Secondly, the paternal mtDNA is tagged 
with ubiquitin and degraded early in embryonic development (Hutchison, Newbold et al. 
1974, Sutovsky, Moreno et al. 2000). Interestingly, there has been an isolated description 
of patient with a 2 bp deletion within MT-ND2 (mitochondrial nicotinamide adenine 
dinucleotide dehydrogenase subunit 2, Complex I) in skeletal muscle inherited from the 
father. This suggests dual parental inheritance of mtDNA is possible, although it is likely 
to be an exceptionally rare occurrence (Schwartz and Vissing 2002). 
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1.7.4! Mitochondrial haplogroups 
Human mtDNA has a mutation rate estimated to be 45 times that of the autosomes largely 
due to the proximity to free radical production from the OXPHOS respiratory chain, the 
continuous nature of mtDNA replication and the reduced capacity for mtDNA repair 
(Lagouge and Larsson 2013, Fu, Li et al. 2014). Given this greater mutation rate, a 
number of non-pathogenic protein altering variants have arisen that can then be stably 
transmitted down the maternal lineage. Sequence analysis has allowed the phylogenetic 
grouping of common single nucleotide polymorphisms (SNPs) into regionally and 
ethnically specific haplogroups. For example, analysis of European populations has 
identified 10 major haplogroups (H, I, J, K, M, T, U, V, W and X) (Torroni, Huoponen et 
al. 1996). Haplogroups can be used to map worldwide population distributions and may 
alter mitochondrial function and hence modify the risk of various diseases (Gomez-
Duran, Pacheu-Grau et al. 2010, Hudson, Gomez-Duran et al. 2014, Stewart and 
Chinnery 2015). 
1.7.5! Mitochondrial DNA mutations and heteroplasmy 
Cells contain multiple copies of mtDNA, a proportion of which may contain polymorphic 
or pathogenic variants (Lightowlers, Chinnery et al. 1997). In a state of homoplasmy the 
cell contains mtDNA of a single genotype. Heteroplasmy occurs when there exists a 
subpopulation of mtDNA defined by a variance in mtDNA sequence, either caused by 
point mutations or deletions. The level of heteroplasmy is defined relative to the level of 
wild type molecules present in the cell (Figure 1.5 A). In the case of a pathological 
variant, there is a threshold effect where at lower heteroplasmy levels the wild type 
mitochondria can compensate and no functional deficit results (Hayashi, Ohta et al. 1991). 
Once the threshold level is reached, there is failure of compensation and subsequent 
OXPHOS dysfunction (Figure 1.5 B). Threshold levels vary among mutations with tRNA 
mutations requiring high levels of mutant DNA (>80%) although the m.14723 T>C 
substitution in tRNAGlu has been reported to be pathogenic at only 7% heteroplasmy 
(Alston, Lowe et al. 2010). Heteroplasmy levels can vary among tissue types, which may 
account for tissue specific phenotypes observed in some mitochondrial diseases (Chinnery, 
Zwijnenburg et al. 1999). 
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Figure 1.5. Mitochondrial heteroplasmy and the threshold model of disease. (A) A 
homoplasmic wild type cell consists of 100% wild type mtDNA (unfilled circles), increasing 
mtDNA mutation load leads to heteroplasmy and finally to a state of homoplasmy when mtDNA is 
100% mutant (filled circles) (B) The threshold model of mitochondrial disease. Depicted are 3 
cells and corresponding OXPHOS function. Each cell contains mitochondria carrying either 
mutant mtDNA (filled circles) or wild type (unfilled circles). As mtDNA mutation load increases 
above a threshold (e.g. >80% for tRNA point mutations) wild type mtDNA fails to compensate and 
respiratory chain function declines. 
1.8! Mitochondrial DNA maintenance and expression 
mtDNA expression is a multistage process with numerous control points (Shadel 2008). 
These include the maintenance of stable mtDNA (mtDNA replication and repair, termed 
mtDNA maintenance), mtDNA transcription including post-transcriptional regulation and 
finally, mitochondrial translation by the mitochondrial ribosome (mitoribosome). 
1.8.1! Mitochondrial nucleoids 
mtDNA is packaged into protein-DNA complexes termed nucleoids containing essential 
proteins for mtDNA replication and transcription akin to the packaging of nuclear DNA by 
histones into the structural units called nucleosomes (Kornberg 1974, Brown, Tkachuk et 
al. 2011). Fluorescence microscopy reveals nucleoids as compact scattered foci localised 
primarily at the cristae junctions but also throughout the mitochondrial network (Satoh and 
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Kuroiwa 1991). TFAM is the most comprehensively characterised component of the 
nucleoid and has been shown to induce negative supercoiling and compaction of the 
genome (Kaufman, Durisic et al. 2007). 
Microscopy studies have revealed most nucleoids have an irregular ellipsoidal shape and 
contain a single molecule of mtDNA coated with approximately 1000 copies of TFAM 
(Kukat, Wurm et al. 2011, Kukat, Davies et al. 2015). Numerous additional proteins have 
been identified that co-purify with mtDNA or TFAM. These include mtDNA polymerase 
gamma (polγ), Twinkle helicase, transcription factor B1M (TFB1M), transcription factor 
B2M (TFB2M), mitochondrial transcription termination factor 1 (mTERF1) and SSBP1 
(Bogenhagen, Rousseau et al. 2008, Gilkerson, Bravo et al. 2013). As well as these 
interactions with mitochondrial transcription and replication proteins, a number of studies 
have revealed interactions with molecular chaperones, proteases, lipid metabolic enzymes, 
mitochondrial ribosomal proteins and cytoskeletal proteins (Bogenhagen 2012). A layered 
structure of the nucleoid has been proposed where mtDNA replication and transcription 
occur in the central core whereas complex assembly and translation are peripherally 
located (Bogenhagen, Rousseau et al. 2008). 
1.8.2! Mitochondrial DNA replication 
mtDNA replication is a vital process in maintaining mtDNA copy number throughout cell 
division and occurs independently of the cell cycle (Bogenhagen and Clayton 1977). The 
minimal constituents of the mtDNA replisome have been reconstituted in vitro and consist 
of polγ, Twinkle helicase and SSBP1 (Figure 1.6) (Korhonen, Pham et al. 2004). 
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Figure 1.6. The mtDNA replisome. mtDNA replication proceeds in a 5’ to 3’ direction. 
Twinkle helicase unwinds double stranded DNA and SSBP1 stabilises the single stranded DNA 
whilst stimulating the processivity of polγ. POLRMT synthesises the RNA primer that primes DNA 
synthesis. Adapted from Wanrooij and Falkenberg 2010. 
1.8.2.1! DNA polymerase gamma 
Mammalian mitochondria contain a single DNA polymerase, polγ, that functions as a 
heterotrimer with a catalytic subunit (polγA) encoded by POLG and two accessory polγB 
subunits encoded by POLG2 (Ropp and Copeland 1996). PolγA primarily functions to 
facilitate 5’!3’ DNA polymerisation with the polγB subunits increasing the 
polymerisation processivity and substrate binding (Johnson, Tsai et al. 2000). Polγ is 
unable to use dsDNA as a template and hence requires the unwinding of DNA to provide a 
single stranded template before replication can begin (Korhonen, Pham et al. 2004). 
1.8.2.2! Twinkle DNA helicase 
Twinkle, encoded by the nuclear TWNK gene is the only replicative DNA helicase in 
mammalian mitochondria and shares homology with the helicase domain of the T7 phage 
gp4 protein (Spelbrink, Li et al. 2001, Korhonen, Gaspari et al. 2003). Twinkle catalyses 
5’!3’ unwinding of DNA in vitro, forming the single stranded template for polγ mediated 
DNA polymerisation. 
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1.8.2.3! Mitochondrial single stranded binding protein (SSBP1) 
In humans the 7 exon SSBP1 gene is located on chromosome 7q34 and codes for the 148 
amino acid SSBP1, a mitochondrial targeted protein that functions to maintain mtDNA 
stability (Tiranti, Rossi et al. 1995). SSBP1 shares structural homology with the 
Escherichia coli ssDNA-binding protein and crystal structural studies reveal mtDNA 
wraps around the protein in electropositive channels (Lohman and Ferrari 1994, Yang, 
Curth et al. 1997). Functioning as a homotetramer of 16kDa subunits, SSBP1 binds single 
stranded DNA to prevent the formation of stable secondary structures after unwinding by 
Twinkle. SSBP1 also stimulates the activity of polγ thus increasing the processivity of the 
polγ/Twinkle complex from 2kb to 16kb and facilitating the complete replication of the 
mitochondrial genome (Korhonen, Pham et al. 2004). Mutational analysis reveals SSBP1 
uses exclusive structural elements to interact with other replisome proteins and these 
variants correlate with defects in mtDNA replication (Oliveira and Kaguni 2011). The 
significance of SSBP1 to mtDNA maintenance has been demonstrated by the deletion of 
the yeast SSBP1 homolog, RIM1, resulting in complete loss of mtDNA (Van Dyck, Foury 
et al. 1992). Similarly, RNAi knockdown of SSBP1 in Drosophila S2 cells also resulted in 
a severe depletion of mtDNA (Farr, Matsushima et al. 2004). Recent work has also 
demonstrated SSBP1 plays an important role in the cellular heat shock response (Tan, 
Fujimoto et al. 2015) (discussed in Sections 1.10.2 and 5.3.21.4). 
1.8.2.4! Other mitochondrial replication proteins 
Although polγ, Twinkle and SSBP1 represent the minimal replisome in vitro, in vivo an 
expanding number of other proteins have been shown to be required for mtDNA 
replication. These include, but are not limited to, the topoisomerases, TOP1MT (Zhang, 
Meng et al. 2007) and TOP3A (Wang, Lyu et al. 2002), the RNA polymerase POLRMT 
(Tiranti, Savoia et al. 1997) and RNASEH1 (Cerritelli, Frolova et al. 2003). Additionally, 
mtDNA replication requires the availability of balanced pool of dNTPs that must be 
maintained by mitochondrial salvage pathways (discussed further in Section 1.11.2.3). 
1.8.2.5! Models of replication 
Currently there is no consensus on the mechanism of mtDNA replication. Three models 
have been described (i) strand displacement model, (ii) strand coupled replication (iii) 
ribonucleotide incorporation throughout the lagging strand (RITOLS) (Figure 1.7). 
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Figure 1.7. Mechanisms of mtDNA replication. (A) Strand displacement model  
(B) Strand coupled model (C) RITOLS model. A detailed description of the models is presented in 
the text below. Adapted from Kasiviswanathan, Collins et al. 2012. 
1.8.2.5.1! Strand displacement model 
According to the strand displacement model, mtDNA replication is initiated at OH and 
proceeds around the major arc until OL is exposed as a stretch of single-stranded DNA that is 
then coated in SSBP1. Second strand synthesis is then initiated back towards OH (Clayton 
1982). The exposed OL sequence then forms a hairpin structure that can be used by POLRMT 
to create a primer for polγ to commence second strand synthesis (Wanrooij, Miralles Fuste et 
al. 2012). This delay in second strand synthesis means that one daughter molecule will 
complete replication before the other molecule has completed L- strand synthesis. This results 
in two open circle molecules, one complete and one with a single stranded gap on the minor 
arc (gapped circle, GpC) that requires completion after replication. 
1.8.2.5.2! Ribonucleotide incorporation throughout the lagging strand (RITOLS) 
The RITOLS model can be considered a modification of the strand displacement model 
and is based on the observation that mitochondrial replication intermediates seen by two-
dimensional agarose gel electrophoresis (2D-AGE) are likely to be RNA/DNA hybrid 
structures that are degraded by RNASEH1 (Holt and Reyes 2012). The RITOLS model is 
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largely analogous with the strand displacement model with both models predicting 
asynchronous initiation of strand replication. However, the RITOLS model predicts the 
lagging strand is not single stranded and coated with SSBP1 as stipulated by the strand 
displacement model. Instead, the lagging strand is coated in RNA derived from processed 
mitochondrial transcripts that are later converted to DNA (Reyes, Kazak et al. 2013). 
1.8.2.5.3! Strand coupled replication 
The model of strand coupled replication is predicated on the detection of classical features 
of synchronous strand coupled replication detected by 2D-AGE that cannot be accounted 
for by the strand displacement model (Holt, Lorimer et al. 2000). In this model 
bidirectional replication initiates downstream of OH in a region termed OriZ. This model 
predicts continuous leading strand synthesis, coupled with discontinuous synthesis of the 
lagging strand. This necessitates the generation of Okazaki fragments on the lagging 
strand, although these have currently not been detected in living mitochondria. However, 
mitochondria do contain specialised flap endonucleases and helicases that are homologous 
to the nuclear Okazaki fragment processing machinery, implying the possible relevance of 
this replication model (Zheng and Shen 2011). 
1.8.3! Mitochondrial copy number 
The maintenance of mitochondrial copy number is vital for cellular homeostasis and 
maintaining cellular energy requirements. mtDNA copy number is highly tissue specific 
with high energy consuming tissues such as muscle and neurons acquiring high copy 
number compared to less energy demanding tissue such as kidney (Miller, Rosenfeldt et 
al. 2003, D'Erchia, Atlante et al. 2015). This implies there must exist a mechanism that 
balances mtDNA synthesis with degradation (Berk and Clayton 1974). Currently, there 
is no consensus on the cellular mechanism underlying copy number regulation, however 
one proposed theory is the ‘copy number threshold hypothesis’ (Clay Montier, Deng et 
al. 2009). This postulates that copy number is regulated by feedback loops where 
synthesis or degradation of mtDNA is stimulated as copy approaches respectively a 
lower or upper threshold limit. A number of mechanisms have been proposed to 
orchestrate mtDNA copy number changes, including mtDNA compaction, control of 
primer transcription from LSP and abortion of replication in the TAS with the creation of 
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7S DNA (Falkenberg, Gaspari et al. 2002, Pohjoismaki, Wanrooij et al. 2006, Jemt, 
Persson et al. 2015). 
A number of studies have shown that maintenance of mtDNA copy number is dependent 
on the availability of the minimal replisome proteins SSBP1, Twinkle and polγ (Van 
Dyck, Foury et al. 1992, Tyynismaa, Sembongi et al. 2004, Stewart, Schoeler et al. 2011, 
Ikeda, Ide et al. 2015). Further studies have shown mtDNA maintenance is dependent on a 
host of diverse proteins including, RNASEH1, the DNA-binding AAA protein, TFAM, 
mitochondrial dynamics proteins and exonucleases (Ekstrand, Falkenberg et al. 2004, He, 
Mao et al. 2007, Kornblum, Nicholls et al. 2013, Vielhaber, Debska-Vielhaber et al. 2013). 
Furthermore, recent work using a comprehensive RNA interference (RNAi) screen in 
Drosophila has identified almost a hundred proteins that are required to maintain mtDNA 
copy number, implying the mechanism of mtDNA copy number regulation is highly 
complex and requires further investigation (Fukuoh, Cannino et al. 2014). 
1.8.4! Mitochondrial transcription 
Mitochondrial transcription is initiated from three promoters located in the NCR. Transcription 
of the L- strand initiates from the LSP, whereas transcription of the H- strand begins from 
HSP1 and HSP2 (Montoya, Christianson et al. 1982). The HSP-1 initiated transcript contains 
tRNAPhe tRNAVal, 16S and 12S rRNA whereas the HSP-2 initiated transcript produces large 
polycistronic transcripts covering almost the entire coding strand. The majority of transcripts 
from LSP terminate at the guanine tract of CSB2 and this RNA is used as the primer for D-
loop synthesis (Zheng, Wu et al. 2014, Tan, Wellesley et al. 2016) (Section 1.7.2). 
The core mitochondrial transcription machinery consists of POLRMT, TFAM and TFB2M 
(Masters, Stohl et al. 1987, Litonin, Sologub et al. 2010, Shi, Dierckx et al. 2012). 
Initially, TFAM binds upstream of the transcription start site where it bends and unwinds 
DNA (Falkenberg, Larsson et al. 2007). TFAM then recruits POLRMT followed by 
TFB2M to the promoter via its C-terminal domain (Rubio-Cosials, Sidow et al. 2011). 
Additional proteins are then required for control of the transcription process including the 
transcription elongation factor (TEFM) and the termination factors mTERF1-4 (Linder, 
Park et al. 2005, Posse, Shahzad et al. 2015). 
Following transcription, the polycistronic transcripts are processed by RNAse P and 
RNAse Z to release the individual RNAs (Puranam and Attardi 2001, Brzezniak, Bijata et 
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al. 2011). mRNAs are then 3’ polyadenylated by the mitochondrial poly (A) polymerase 
(Tomecki, Dmochowska et al. 2004). The rRNAs, 12S and 16S also require post-
transcriptional modification to enable the assembly of the mitoribosome. Modifications of 
the 16S subunit are not well characterised, although include the recently identified m1A 
modification at position m.947, catalysed by the mitochondrial methyltransferase 
TRMT61B (Bar-Yaacov, Frumkin et al. 2016). There are currently five identified post-
transcriptional modifications of the 12S rRNA. These include dimethylation of adenine 
m.1584 and m.1583 (N6, N6- dimethyladenosine (m62A)) by TFB1M and TFB2M 
(Cotney and Shadel 2006) (Figure 1.16). It is has been shown that TFB1M functions as 
the main 12S rRNA methyltransferase and ablation of TFB1M decreases steady state 
levels of 12S rRNA resulting in impaired mitochondrial translation (further discussed in 
Section 1.8.5) (Metodiev, Lesko et al. 2009). The function of m62A and 12S rRNA 
modifications including m4C846, m5U429 is currently unresolved but may play a role in 
mitoribosomal assembly and stability (Rorbach and Minczuk 2012). 
tRNAs must also undergo post-transcriptional modifications including methylation, 
taurination and pseudouridylation and these modifications have been shown to increase 
tRNA stability and folding (Suzuki and Suzuki 2014). Following this, the tRNAs must be 
charged with the their cognate amino acid in a process catalysed by the appropriate 
aminoacyl-tRNA synthase (Chaliotis, Vlastaridis et al. 2016). Recent work has demonstrated 
that these post-transcriptional events occur in mitochondrial RNA granules (MRGs). These 
specialised sub-compartments of the mitochondrion provide a defined focus for the 
spatiotemporal regulation required for mitochondrial gene expression (Antonicka and 
Shoubridge 2015, Jourdain, Koppen et al. 2015). 
1.8.5! Mitoribosomes and mitochondrial translation 
Mitochondria possess a complete gene expression machinery required to translate the 
mitochondrial mRNAs of the 13 protein coding genes. 
Human mitochondrial mRNAs are translated by the mitoribosome, 55S, consisting of 
small (mt-SSU, 28S) and a large (mt-LSU, 39S) subunits (Figure 1.8) (O'Brien 1971). The 
mitoribosome contains three rRNAs (12S and 16S and mt-tRNAVal) and 80 mitochondrial 
ribosomal proteins (MRPs) encoded by the nucleus (Amunts, Brown et al. 2015). The 
mitoribosome contains three RNA binding sites, named aminoacyl (A), peptidyl (P) and 
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exit (E). The A-site binds the aminoacylated tRNA, the P-site binds the peptide linked 
tRNA and the E-site harbours the deacylated tRNA exiting the ribosome. 
 
Figure 1.8. Structure of the 55S mammalian mitoribosome. The 55S mitoribosome consists 
of the large 39S and small 28S subunits. The 28S subunit is represented in yellow, 12S rRNA in 
green, 16S rRNA in orange, 39S subunit in blue, central protuberance (CP) tRNA in brown. 
Reproduced from Greber, Bieri et al. 2015. 
Mitochondrial translation occurs by a conserved series of stages divided into (i) initiation (ii) 
elongation (iii) termination and (iv) mitoribosome recycling (Christian and Spremulli 2012) 
(Figure 1.9). Initiation occurs by the selection of an mRNA start codon by the SSU in 
complex with initiation factors (mtIF2 and mtIF3) and the initiator tRNA (fMet-tRNAMet) 
paired to the start codon in the ribosomal P-site (Christian and Spremulli 2009, Kuzmenko, 
Atkinson et al. 2014). Elongation is facilitated by three elongation factors: mtEFTu, mtEFTs 
and mtEFG1. Firstly, mtEFTu binds an aminoacylated tRNA in conjunction with guanosine 
triphosphate (GTP) recruiting it to the mitoribosomal A-site. A codon-anticodon interaction 
causes GTP hydrolysis and peptide bond formation between the amino acid occupying the 
P- site and the amino acid in the A-site thus extending the polypeptide chain. mtEFG1 
facilitates the removal of the deacylated tRNA form the P-site and translocates the peptidyl 
tRNA to the P-site. Elongation continues with sequential addition of amino acids until a stop 
codon is encountered (UAA, AGA, UAG or AGG) in the A-site. This triggers the binding of 
the mitochondrial release factor, mtRF1, the hydrolysis of the peptidyl-tRNA bond in the A-
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site and the release of the nascent polypeptide (Lind, Sund et al. 2013). Following 
termination and release of the polypeptide, the mitoribosome is recycled by the action of  the 
mitochondrial ribosomal recycling factors, mtRRF1 and mtEFG2 (Rorbach, Richter et al. 
2008, Tsuboi, Morita et al. 2009). Interestingly, the mitoribosome has been shown to interact 
directly with the IMM facilitating the co-translational insertion of proteins into the 
membrane aided by a number of proteins including the mitochondrial oxidase assembly 
protein, Oxa1 (Ott and Herrmann 2010, Kruger, Deckers et al. 2012). 
 
Figure 1.9. Schematic of mitochondrial translation. The mitoribosomal subunits are depicted 
as blue (39S) and brown (28S) ovals. Mitochondrial translation is divided into initiation requiring mtIF2 
and mtIF3 (blue circles), mRNA transcript (grey rectangles, start codon in green) and initiator tRNA 
fMet-tRNAMet; elongation by addition of amino acids (black circles) requires mtEFTu, mtEFTs and 
mtEFG1 (green circles) and termination/mitoribosome recycling by mtRF1a and mtRRF/mtEFG2 (pink 
circles) respectively. 
1.9! Mitochondrial dynamics 
Mitochondria are dynamic organelles that exist in complex networks undergoing 
morphological changes through the processes of fusion, fission, movement and mitophagy 
(Archer 2013, Wai and Langer 2016). The ability of mitochondria to respond by these 
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mechanisms is vital for cellular function and perturbations in mitochondrial dynamics are 
thus both a cause and consequence of mitochondrial disease (discussed in Section 1.11). 
1.9.1! Mitochondrial fusion 
Mitochondrial fusion is governed by the dynamin GTPases mitofusin 1 and 2 (MFN1 and 
MFN2) and optic-atrophy 1, OPA1 (Westermann 2010). The mitofusins synchronise to 
appose adjacent mitochondria enabling GTP dependent fusion of the OMM, followed by 
the fusion of the IMM mediated by OPA1 (Mishra, Carelli et al. 2014). Alternative 
splicing and proteolytic cleavage of OPA1 by the metalloendopeptidases, OMA1 and 
YME1L have recently been shown to give rise to long (l-OPA1) and short (s-OPA1) 
isoforms (Anand, Wai et al. 2014). Interestingly, l-OPA1 has been shown to be sufficient 
for mitochondrial fusion whereas s-OPA1 plays an important role in fission (Wai and 
Langer 2016). 
1.9.2! Mitochondrial fission 
Mitochondrial fission is primarily orchestrated by the dynamin like GTPase, dynamin 
related protein 1 (DRP1). In response to cellular signals including phosphorylation, 
ubiquitylation and SUMOylation DRP1 translocates from the cytosol to the OMM where it 
interacts with a number of binding partners including mitochondrial fission protein 1 
(FIS1), mitochondrial fission factor (MFF) and mitochondrial dynamics proteins of 49 and 
51kDa (MiD49 and MiD51) (van der Bliek, Shen et al. 2013, Wai and Langer 2016). At 
the OMM, DRP1 forms ring-like structures with FIS1 at division sites where it hydrolyses 
GTP, promoting membrane constriction (Mears, Lackner et al. 2011). 
1.9.3! Functions of mitochondrial dynamics 
Mitochondrial fusion and fission permit the adaptation of the mitochondrial network to 
changing cellular conditions and facilitate the removal of dysfunctional organelles. 
Mitochondrial fusion is important for complementation of mtDNA products in 
heteroplasmic cells, whilst fission plays a vital role in cell division, apoptosis, network 
distribution and mitochondrial quality control, also termed mitophagy (Westermann 2010). 
Fusion is correlated with increased ATP generation and may act to counter the effects of 
decreased nutrient availability, whilst fragmentation of the mitochondrial network, when 
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fission outweighs fusion events, is associated with dysfunctional OXPHOS and cellular 
stress (Figure 1.10) (Liesa and Shirihai 2013). 
 
Figure 1.10. The functions of mitochondrial dynamics. Mitochondrial fission is important for 
mitochondrial quality control (mitophagy), the release of cytochrome c in the initiation of 
apoptosis (depicted by red circles), distribution by cytoskeletal transport and for the segregation of 
mitochondria during cell division. Mitochondrial fusion is of primary importance in 
complementing mtDNA products in heteroplasmic cells. Adapted from Westermann 2010. 
1.10! Mitonuclear communication 
In addition to their crucial function in cellular energy generation, mitochondria fulfil a 
range of other cellular functions (as discussed in Section 1.5). To maintain cellular 
homeostasis, mitochondria require tight control by the nucleus, so-called ‘antegrade 
regulation’. Additionally, mitochondria illicit a ‘retrograde response’ that can re-
programme cellular metabolism in response to cellular demand (Quiros, Mottis et al. 
2016). 
Mitochondrial dysfunction can directly affect the cytosolic milieu, including increasing 
cytosolic calcium flux, adenosine monophosphate (AMP) levels and ROS (Quiros, Mottis 
et al. 2016). These perturbations can then directly activate retrograde signalling pathways 
from the mitochondria to the nucleus. These pathways lead to a plethora of downstream 
consequences including cell cycle control, cell growth, apoptosis and mitochondrial 
biogenesis; placing the mitochondrion as a central node in cellular energy control 
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(Wallace, Fan et al. 2010). The following section highlights two important elements of 
mitonuclear communication that are further explored in Chapter 5: the 5’ adenosine 
monophosphate activated protein kinase (AMPK) signalling pathway and the regulation of 
cellular protein homeostasis, termed proteostasis. 
1.10.1! The AMPK signalling pathway 
A key sensor of cellular metabolic status, AMPK is a heterotrimeric serine/threonine 
kinase consisting of an α catalytic subunit (α1 or α2), a β regulatory subunit (β1 or β2) and 
γ adenosine monophosphate (AMP) binding subunits (γ1, γ2 or γ3) (Gowans and Hardie 
2014). AMPK is activated via phosphorylation of threonine 172 (pT172) by upstream 
AMPK kinases, including liver kinase B1 (LKB1) (Hawley, Boudeau et al. 2003) (Figure 
1.11). High cellular AMP causes allosteric activation of AMPK by increasing pT172, a 
process that is reversed by higher levels of ATP (Xiao, Sanders et al. 2011). Impaired 
energy generation in cells with suboptimal respiratory chain function leads to inefficient 
generation of ATP and over production of ROS, including H2O2, hydroxyl groups and 
superoxide anions. These species are known to directly activate AMPK in human cell lines 
(Choi, Song et al. 2008) and excess cellular ROS levels have been shown to lead to AMPK 
activation in fibroblasts from a patient with myoclonic epilepsy with ragged red fibres 
(MERRF) (Wu and Wei 2012). 
AMPK acts as a central signalling node to detect whole cell bioenergetics and as such the 
downstream signalling pathways that it activates are complex and context dependent. There 
has been burgeoning interest in AMPK and its cellular effects in recent years and it has 
been the subject of a number of excellent reviews (Mihaylova and Shaw 2011, Hardie, Ross 
et al. 2012, Hardie, Schaffer et al. 2016). Ultimately, in times of energy deficiency, AMPK 
acts to increase catabolic processes whilst inhibiting energy demand to restore cellular ATP 
balance. AMPK achieves this by modulating a host of cellular functions including glucose 
and fatty acid metabolism (Marcinko and Steinberg 2014). Importantly, protein synthesis 
constitutes the most energy demanding cellular process (Lane and Martin 2010). When 
nutrients are scarce, AMPK signals via suppression of the mechanistic target of rapamycin 
(mTOR) pathway to inhibit the production of proteins (Xu, Ji et al. 2012). mTOR is a 
member of the phosphatidylinositol 3-kinase related kinases (PIKK) superfamily that serves 
as a central regulator of cellular metabolism, growth and survival (Laplante and Sabatini 
2012). mTOR is present in the cell in two distinct complexes, mechanistic target of 
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rapamycin complex 1 (mTORC1) and complex 2 (mTORC2). AMPK primarily controls the 
activity of the mTORC1 complex by activation of the tuberous sclerosis complex (TSC) 
proteins (TSC1 and TSC2) that subsequently inactivate the GTP binding protein, Ras 
homolog enriched in brain (Rheb), an important upstream activator of mTORC1 (Avruch, 
Long et al. 2009). This inhibits mTORC1 mediated phosphorylation of p70-S6 kinase 
(S6K) and eukaryotic initiation factor 4E binding protein 1 (4EBP1), important potentiators 
of protein synthesis and cellular proliferation (Showkat, Beigh et al. 2014). 
 
Figure 1.11. The AMPK and mTOR signalling pathways. AMPK is activated by increased 
cellular levels of AMP and ADP owing to a variety of physiological stresses and the activity of the 
upstream kinase, LKB1. Once activated AMPK directly phosphorylates a number of substrates to 
acutely affect cellular metabolism and growth, including inhibiting the mTOR pathway via 
phosphorylation of TSC1/2. Decreased activity of the mTOR pathway results in a reduction in the 
phosphorylation of 4E-BP1 and S6K1, reducing protein synthesis and cell proliferation. 
1.10.2! Proteostasis 
Proteostasis is an integrated cellular response to maintain the integrity of the proteome 
whilst minimising protein aggregation (Sala, Bott et al. 2017). Unfolded proteins 
compromise cellular function and therefore cells have evolved pathways to protect against 
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this potentially toxic insult. These pathways include the unfolded protein response (UPR) 
in the mitochondria and ER and heat shock response (HSR) in the nucleus and cytoplasm 
(Hetz, Chevet et al. 2015). The UPR in the ER (UPRER) is triggered by a number of factors 
including toxins and altered calcium homeostasis leading to the activation of inositol-
requiring 1 (IRE-1), the activating transcription factor 6 (ATF6) and protein-like 
endoplasmic reticulum kinase (PERK). This results in the induction of binding 
immunoglobulin protein (BiP, Grp78), a molecular chaperone that actively refolds proteins 
(Bravo, Parra et al. 2013). 
The HSR, a conserved cellular mechanism, maintains cytosolic proteostasis by regulating 
the transcription factor Heat Shock Factor 1 (HSF1) (Trinklein, Chen et al. 2004). In an 
unstressed cell, HSF1 associates with cytosolic chaperones HSP70 and HSP90 (Zou, Guo 
et al. 1998). With cellular stress, unfolded proteins increase and HSF1 dissociates allowing 
it to trimerize and interact with the promoters of HSR genes, particularly HSP70 (Liu and 
Thiele 1999). Mitochondria depend on the nucleus to reduce the effect of proteotoxic 
stressors such as heat shock by eliciting the mitochondrial UPR (UPRmt) (Haynes and Ron 
2010). This process has recently been shown to be dependent on SSBP1. Work by Tan et 
al demonstrated that heat shock triggers the nuclear translocation of SSBP1 where it forms 
a complex with HSF1. This complex can then recruit the chromatin remodelling factor 
BRG1 that subsequently upregulates transcription of mitochondrial chaperones including 
HSP60 and HSP10 (Tan, Fujimoto et al. 2015). 
1.11! Mitochondrial disease 
1.11.1! Overview of mitochondrial disease 
Mitochondrial dysfunction is an established contributor to human disease, both in the form 
of primary mitochondrial disorders but also in a range of complex diseases including 
neurodegeneration and cancer (Wallace 2011, Keogh and Chinnery 2015, Zong, 
Rabinowitz et al. 2016). Mitochondrial disorders often manifest as multisystem disease 
causing significant morbidity and mortality by affecting tissues with high metabolic 
demand, for example, skeletal muscle, the heart and the central nervous system including 
the auditory system (discussed in Section 1.13.1). 
Mitochondrial disease can be classified as (i) primary mtDNA disease caused by point 
mutations or large-scale mtDNA rearrangements or (ii) nuclear mitochondrial disorders 
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caused by mutations in nuclear genes that code for mitochondrial proteins. As of May 
2017, there are 666 reported mtDNA mutations and 89 nuclear genes associated with 
mitochondrial disease (Mitomap 2017). This genetic heterogeneity means mitochondrial 
diseases can follow any pattern of inheritance including autosomal dominant (AD), 
autosomal recessive (AR) and X-linked for nuclear mutations and maternal inheritance for 
mutations of the mtDNA (Gorman, Chinnery et al. 2016). 
The complexity of mitochondrial genetics together with variable genotype-phenotype 
relationships mean the prevalence of mitochondrial disease has historically been difficult 
to define. However, a number of recent genetic and epidemiologic studies have 
demonstrated that pathological mitochondrial mutations are common in the general 
population and mitochondrial diseases are among the most prevalent neuromuscular 
diseases affecting up to 1 in 5000 (Elliott, Samuels et al. 2008, Schaefer, McFarland et al. 
2008, Gorman, Schaefer et al. 2015). 
1.11.2! Mitochondrial disease genetics 
1.11.2.1! Mitochondrial DNA point mutations 
Pathological mtDNA point mutations can occur within protein coding, tRNA, rRNA or 
the NCR regions (Figure 1.12) (Tuppen, Blakely et al. 2010, Connor, Hoer et al. 2017). 
However, over half of disease related point mutations are found in the mt-tRNA genes, 
for example m.8344A>G tRNALys associated with MERRF and m.3243A>G tRNALeu 
the major cause of mitochondrial encephalomyopathy with lactic acidosis and stroke like 
episodes (MELAS). Mutations localised to genes coding for all of the respiratory chain 
complexes have been identified to cause a range of phenotypes including MELAS, Leigh 
syndrome and Leber’s hereditary optic neuropathy (LHON). In contradistinction, 
mutations affecting mitochondrial tRNAs and rRNAs affect the expression of all 
mitochondrial proteins through compromising mitochondrial translation (Holt, Harding 
et al. 1990, Kirino, Yasukawa et al. 2004). 
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Figure 1.12. Primary mtDNA mutations linked to human disease. A selection of clinically 
relevant primary mtDNA mutations linked to mitochondrial disease with their associated 
phenotypes. LHON – Leber’s hereditary optic neuropathy, NARP – neurogenic weakness, ataxia 
and retinitis pigmentosa, KSS – Kearns-Sayre Syndrome, CPEO – chronic progressive external 
ophthalmoplegia, MERRF – myoclonic epilepsy and ragged red fibres, MELAS – mitochondrial 
myopathy lactic acidosis and stroke like episodes, MIDD – maternally inherited diabetes and 
deafness. 
The majority of disease causing mutations are heteroplasmic, although homoplasmic 
mutations constitute an important subset of mitochondrial disease. It is likely that the severity 
of the biochemical insult mediated by some homoplasmic mutations mean they are a 
relatively rare occurrence in the population (Tiranti, Corona et al. 2000, McFarland, Clark et 
al. 2002, Limongelli, Schaefer et al. 2004). Interestingly, a number of identified homoplasmic 
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mutations share a common feature of limited tissue expression and incomplete penetrance, for 
example:  
(i) m.4300A>G in tRNAile causing hypertrophic cardiomyopathy (Taylor, Giordano et al. 
2003) 
(ii) m.547A>T in the mtDNA control region causing tubulointerstitial kidney disease 
(Connor, Hoer et al. 2017)  
(iii) m.3640G>A in MT-ND1, m.11778G>A in MT-ND4, m.14484T>C in MT-ND6 that 
account for up to 95% of cases of LHON (a maternally inherited blinding disease) (Hudson, 
Yu-Wai-Man et al. 2008) 
 (iv) m.1555A>G in MT-RNR1 (causing hearing loss) (Prezant, Agapian et al. 1993) 
(discussed in Section 1.13).  
The tissue-specificity of mitochondrial disease is an important, yet currently unresolved issue. 
However, it is believed pathogenic mechanisms causing tissue specific effects may depend on 
cell specific mitochondrial dysfunction and differential cell specific metabolic requirements 
(Nunnari and Suomalainen 2012). 
1.11.2.2! Mitochondrial deletions 
Mitochondrial deletions are an important cause of mitochondrial disease and occur in three 
distinct clinical settings (i) mtDNA deletions can be present at birth and be distributed 
throughout all somatic tissues (ii) mtDNA deletions can be associated with a defect in 
mtDNA maintenance proteins leading to the development of deletions in post mitotic 
tissues such as muscle and brain (iii) mtDNA deletions can be associated with aged post 
mitotic tissue and neurodegenerative disease (Chen, Prosser et al. 1995, Bender, Krishnan 
et al. 2006).  
As with point mutations, there exists a threshold effect whereby low levels of mtDNA 
deletions can be compensated for by the effect of wild type mtDNA but with accumulating 
levels of mtDNA deletion an OXPHOS defect will become apparent (Wallace and Chalkia 
2013). This process of accumulating a single mtDNA species that comes to predominate 
within the cell is known as clonal expansion. 
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A number of mechanisms have been proposed to explain the clonal expansion of mtDNA 
mutations. Firstly, it has been postulated that mtDNA molecules with mitochondrial 
deletions are able to replicate faster than wild type molecules and hence accumulate in the 
cell due to this replicative advantage (Fukui and Moraes 2009). Secondly, it has been 
proposed that reduced free radical production by dysfunctional mitochondria reduces 
natural turnover and hence accumulation of mutant mtDNA species (Campbell, Krishnan 
et al. 2014). A third hypothesis proposes that relaxed replication of mtDNA and genetic 
drift leads to the clonal expansion of a single mutant mtDNA species (Elson, Samuels et 
al. 2001). Further insights into the cellular mechanisms of clonal expansion have been 
provided by recent work demonstrating the expansion of mtDNA deletions may involve 
the up-regulation of UPRmt by increasing mtDNA copy number and reducing 
mitochondrial quality control mechanisms specifically, mitophagy (discussed in Section 
1.9) (Gitschlag, Kirby et al. 2016). 
The majority of mtDNA deletions occur in the major arc between the origins of 
replication, OH and OL and most are flanked by short direct repeats (Samuels, Schon et al. 
2004). Initially, it was proposed that mtDNA deletions are a product of faulty replication 
through a slipped strand mechanism (Shoffner, Lott et al. 1989). This hypothesis assumes 
the strand displacement model of replication, as it requires large regions of single stranded 
DNA that are not predicted the RITOLS model. This model also predicts that mitotic cells, 
where replication is a frequent event should accrue deletions at a greater rate than post 
mitotic cells (Krishnan, Reeve et al. 2008). An alternative hypothesis proposes that 
mtDNA deletions are generated through exonuclease activity at double strand breaks 
resulting in single strands that can misanneal with homologous sequences ultimately 
resulting in the formation of deleted mtDNA species (Krishnan, Reeve et al. 2008). 
Multiple deletions arise from mutations in genes coding for mtDNA maintenance proteins 
whereas single deletions tend to arise as de novo events that undergo clonal expansion in 
post mitotic tissue (Tuppen, Blakely et al. 2010). A clinically important deletion, named 
the ‘common deletion’ removes 4977 bp of mtDNA between two 13 bp direct repeats at 
m.13447-13459 and m.8470-8482. This deletes a number of tRNA and protein coding 
genes resulting in impairment of OXPHOS and a range of phenotypes including, chronic 
progressive external ophthalmoplegia (CPEO), Kearns-Sayre syndrome (KSS) and 
Pearson syndrome (PS) (Figure 1.12) (Fischel-Ghodsian, Bohlman et al. 1992, Superti-
Furga, Schoenle et al. 1993, Meissner, Bruse et al. 2008). 
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1.11.2.3! Nuclear mitochondrial diseases 
Given over 99% of mitochondrial proteins (1395 of 1408 proteins in the mitochondrial 
proteome) are encoded in the nucleus (Integrated Mitochondrial Protein Index 2016), it is 
unsurprising that mutations in nuclear genes encoding mitochondrial proteins are an 
important cause of human disease (Gorman, Chinnery et al. 2016). Broadly, these can be 
divided into (i) genes encoding structures of the respiratory chain (ii) genes encoding non- 
structural proteins involved in a range of mitochondrial processes that include mtDNA 
maintenance, protein synthesis and import, complex assembly, mitochondrial dynamics and 
iron homeostasis (Mitomap 2017). 
The commonest mutations in the nuclear encoded respiratory chain are found in genes 
coding for subunits of Complex I that primarily cause Leigh syndrome (Benit, Chretien et 
al. 2001, Benit, Slama et al. 2004). However, mutations in all nuclear encoded subunits of 
Complex II, III, IV and V have also been identified (Bourgeron, Rustin et al. 1995, Haut, 
Brivet et al. 2003, Massa, Fernandez-Vizarra et al. 2008, Mayr, Havlickova et al. 2010). 
Similarly, disease causing mutations have been identified in assembly factors of each 
respiratory chain complex (Ghezzi and Zeviani 2012). 
As discussed in Section 1.8, maintenance of stable mtDNA that can be both expressed and 
replicated requires numerous nuclear encoded proteins. Mutations in these genes cause 
disease through both qualitative (point mutations and deletions) and quantitative (alteration 
in mtDNA copy number) mechanisms. The first nuclear gene underlying mitochondrial 
disease, POLG, was identified in 2001 in families with autosomal-dominant CPEO (Van 
Goethem, Dermaut et al. 2001). Since this time, numerous other nuclear genes underlying 
mitochondrial mtDNA maintenance have been identified, including POLG2 (the polγ 
accessory subunit) (Longley, Clark et al. 2006), the replicative helicase Twinkle 
(Spelbrink, Li et al. 2001) and adenine nucleotide translocator isoform 1 (ANT1) that 
transports ATP across the IMM (Kaukonen, Juselius et al. 2000). mtDNA replication is 
uncoupled from the replication of the nuclear genome and thus requires a steady supply of 
dNTPs to maintain genome integrity. Reflecting this, there are several genes regulating 
dNTP pools that have been shown to be causative for mitochondrial disease. These include 
thymidine phosphorylase (TP) (Nishino, Spinazzola et al. 1999) deoxyguanosine kinase 
(DGUOK) (Mandel, Szargel et al. 2001), p53 inducible ribonucleotide reductase (RRM2B) 
(Spinazzola, Viscomi et al. 2006) and  mitochondrial inner membrane protein MPV17 
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(MPV17) (Bourdon, Minai et al. 2007). Mutations in these genes have all been linked to 
mitochondrial depletion syndrome (MDS) presenting with myopathic, hepatopathic and 
encephalomyopathic symptoms (Elpeleg 2003). 
A number of mutations in the mitochondrial translation machinery, causing a combined 
OXPHOS deficiency that presents as early onset multi-system disease, have also been 
identified. These include the small ribosomal subunit components, mitochondrial 
ribosomal proteins S16 and S22 (MRPS16 and MRPS22) and translation elongation 
factors mtEFTu and mtEFTS (Miller, Saada et al. 2004, Saada, Shaag et al. 2007, Valente, 
Tiranti et al. 2007). Similarly, mutations in genes responsible for the post-transcriptional 
modifications of tRNA have been isolated as important causes of human disease. These 
include a number of mutations in the aminoacyl-tRNA synthesases that are responsible for 
the attachment of tRNAs to the correct amino acid (Yao and Fox 2013). 
As discussed in Section 1.9 the regulation of mitochondrial dynamics is integral to optimal 
cellular function and it hence follows mutations in proteins controlling mitochondrial 
dynamics are responsible for a subset of mitochondrial disease. Specifically, mutations in 
MFN2 are associated with Charcot-Marie-Tooth disease type 2A while OPA1 mutations 
are causative for Dominant Optic Atrophy (DOA) (Burte, Carelli et al. 2015). 
1.11.3! Diagnosis of mitochondrial disease 
The diagnosis of mitochondrial disease is primarily made by a combination of (i) 
biochemical assessments including the measurement of individual respiratory chain 
complex activities and analysis of mitochondrial biomarkers in urine, blood, or cerebral 
spinal fluid and (ii) molecular genetic tests including mtDNA sequencing, whole genome 
or whole exome sequencing (WGS and WES respectively) (in cases of suspected nuclear 
mitochondrial disease) and the assessment of mtDNA rearrangements using long-range 
polymerase chain reaction (PCR), Southern blotting or quantitative real time PCR (qPCR) 
(Parikh, Goldstein et al. 2015). 
Additionally, histochemical analysis of skeletal muscle is a reliable method for the 
detection of OXPHOS dysfunction. Common diagnostic practice includes staining with 
haematoxylin & eosin (H&E) to assess overall muscle histology and sequential staining to 
determine the activity of SDH (Complex II) and COX (Complex IV). SDH is entirely 
nuclear encoded whereas COX contains both nuclear and mtDNA encoded subunits, 
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therefore in the case of mtDNA point mutations or deletions COX activity may decrease 
however SDH will remain unaffected. Following sequential COX/SDH staining, COX-
negative fibres are revealed as blue whereas COX positive fibres remain brown. In patients 
with disorders of mitochondrial maintenance, secondary mtDNA depletion or deletions 
can result in a mosaic pattern of enzyme deficiency, displaying both COX-positive and 
COX-negative fibres in the same muscle biopsy (Murphy, Ratnaike et al. 2012) 
1.12! Overview of the physiology of hearing 
Hearing is the ability to perceive sound by the detection of vibrations. In humans, the 
hearing mechanism can be subdivided into three components: the outer ear, the middle ear 
and the inner ear (Figure 1.13). The outer ear serves to focus sound energy to the tympanic 
membrane whose vibrations transfer energy to the middle ear ossicles (malleus, incus and 
stapes). These function to overcome the impedance mismatch between the air/fluid 
interface of the middle and inner ear. The stapes then transmits sound energy via the oval 
window to the inner ear. The inner ear houses the spiral shaped cochlea, the organ of 
hearing, as well as the vestibular system, responsible for balance. The cochlea is divided 
into the scala vestibuli, scala tympani and scala media, containing the Organ of Corti that is 
responsible for the mechanotransduction of sound by its constituent inner and outer hair 
cells (IHC and OHC respectively) (Purves 2008). The OHC and IHC are the auditory 
sensory receptors serving distinct roles within the auditory system as a consequence of 
spatial segregation and morphological variation (Dallos, Billone et al. 1972). 
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Figure 1.13  The human auditory system. (A) Sound is collected by the pinna and transmitted 
to the middle ear ossicles via vibration of the tympanic membrane (B) The cochlear duct is divided 
into the scala vestibuli, scala media and scala tympani. (C) The Organ of Corti containing the inner 
and outer hair cells and supporting cells. (D) The hair cells project stereocilia attached by tip links 
that mechanically gate mechanotransducer (MET) channels responsible for the generation of 
auditory nerve activity. Reproduced from Brown, Hardisty-Hughes et al. 2008. 
OHCs contain contractile proteins, such as prestin, that can convert changes in membrane 
potential into rapid shifts in cell length through the process of electromotility (Zheng, Shen 
et al. 2000). This phenomenon drives the cochlear amplifier, the process whereby the 
sensitivity and frequency selectivity of hearing is enhanced (Ashmore, Avan et al. 2010). 
On the other hand, IHC are the primary transducers of the inner ear that convert the 
vibration of the basilar membrane into neural signals encoded in the auditory nerve. This 
occurs via the deflection of stereocilia that project from the surface of the hair cells 
causing the opening and closing of mechanotransducer (MET) channels (Arnadottir and 
Chalfie 2010). The opening of the MET channels causes the influx of potassium and 
calcium ions and depolarisation of the hair cell causing release of neurotransmitters, 
primarily L-glutamate, which is converted into specific neural activity of the auditory 
nerve (Nordang, Cestreicher et al. 2000). 
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1.13! Pathophysiology of hearing loss 
Hearing loss is a dynamic, multifactorial process affecting 11 million people in the United 
Kingdom (UK) with varying degrees of disability (Action on Hearing Loss 2017). Hearing 
loss can result from any process that interferes with the faithful communication of 
correctly encoded neural signals from cochlea to the auditory cortex. Broadly, this can be 
classified into sensorineural loss resulting from dysfunction of the cochlea hair cells and/or 
auditory nerves or cortex and conductive loss caused by disease of the outer or middle ear 
which prevents sound transmission to the cochlea. Epidemiological studies have indicated 
that approximately 1 in 500 at birth and more than 70% of those over the age of 70 are 
affected by some degree of hearing loss. In those affected at birth it is estimated that over 
50% have a genetic aetiology with mutations found in a diverse range of genes associated 
with the development, structure and function of the auditory system inherited in an AR, 
AD, X-linked or mitochondrial mode of inheritance (Dror and Avraham 2009). 
1.13.1! The role of mitochondria in hearing loss 
Mitochondrial mutations contribute significantly to cases of genetic hearing loss and are 
estimated to be causative in approximately 5% of non-syndromic post lingual hearing loss 
as well as 1% of pre-lingual cases (Jacobs, Hutchin et al. 2005, Morton and Nance 2006). 
Additionally, mitochondrial mutations may also contribute to age associated hearing loss 
(Bai, Seidman et al. 1997). 
Anecdotally, hearing loss is a well-recognised feature of mitochondrial disease although 
ascertaining its prevalence in patients with confirmed mitochondrial disease is complicated 
by both clinical and genetic heterogeneity. Moreover, the true burden of disease may be 
further disguised by under diagnosis, particularly in patients with complex neuromuscular 
phenotypes. In one study of 23 patients with mitochondrial disease, including 10 with the 
m.3243 A>G variant, 74% were found to have hearing loss (Chinnery, Elliott et al. 2000). 
Additional studies investigating patients with a range of mitochondrial diseases have 
further confirmed the high rate of hearing impairment in patients with mitochondrial 
disease (Sue, Lipsett et al. 1998, Kuzmenko, Atkinson et al. 2014). 
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Figure 1.14. A cross-section through the human cochlea. The stria vascularis is responsible 
for the production of the potassium rich endolymph in the scala media. Reduction in ATP 
generation resulting from mitochondrial dysfunction causes both a loss of the endocochlear 
potential, compromising hair cell function and a degradation of auditory neural signalling. 
Together, these are thought to account for the hearing loss associated with mitochondrial disease. 
Figure adapted from Rahman, Ecob et al. 2012. 
Mitochondrial dysfunction can be causative for hearing loss both in isolation (non-
syndromic) and as a feature of systemic mitochondrial disease (syndromic). A number of 
studies have implicated the cochlea as the primary origin of disease with a corresponding 
loss of both outer and inner hair cells (Chinnery, Elliott et al. 2000, Sue, Lipsett et al. 
1998). However, auditory neuropathy (i.e. dysfunction of the auditory nerve with preserved 
cochlear function) has also been recognised as an important factor in a subset of 
mitochondrial diseases (Ceranic and Luxon 2004, Santarelli, Rossi et al. 2015). It has been 
shown that the cells of the auditory sensory axis, including the cochlea hair cells, stria 
vascularis (primarily responsible for maintaining the endocochlear potential) and auditory 
neurones are highly metabolically active and therefore contain an abundance of 
mitochondria (Karnes, Scaletty et al. 2010). Therefore, the sensitivity of the auditory 
pathway to mitochondrial dysfunction may result from inadequate mitochondrial oxidative 
phosphorylation in these metabolically active tissues however detailed histological analyses 
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of cochlear tissue from patients with mitochondrial disease have not yet been performed 
(Xing, Chen et al. 2007) (Figure 1.14). The initiation of apoptosis by ROS activated 
caspases may partially explain the link between mitochondrial mis-translation and 
subsequent cochlea hair cell death (Priuska and Schacht 1997). Although to date, the 
underlying molecular mechanisms, including those governing tissue specificity, remain 
unresolved. 
1.13.2! Clinical presentation of mitochondrial hearing loss 
The hearing loss of mitochondrial disease is sensorineural, symmetrical and primarily 
affects the higher frequencies although progressive disease can lead to pan-frequency 
hearing loss (Kokotas, Petersen et al. 2007). The incidence of conductive hearing loss, 
where sound conduction to the cochlea is reduced by disease of the middle or outer ear, for 
example in otitis media with effusion, has been shown to be comparable to the general 
population (Edmonds, Kirse et al. 2002). 
Hearing loss onset tends to be in early life and be gradually progressive, although sudden 
hearing loss has been described in stroke like episodes in patients carrying the m.3243 
A>G variant (Chen, Tsai et al. 2007). Predominantly, hearing loss occurs in later 
childhood or adulthood after the acquisition of speech, however, broad phenotypic 
variation means there is often a range of hearing loss onset and severity even in family 
members carrying the same genetic variants. It has also been shown that hearing thresholds 
decline at a faster rate in m.3243A>G carriers compared to the general population. 
Therefore, patients with mitochondrial hearing loss should receive regular audiology 
assessment (Uimonen, Moilanen et al. 2001). 
1.13.3! Clinical diagnosis of mitochondrial hearing loss 
A mitochondrial cause for hearing loss may be suspected in cases that appear to show 
maternal transmission or where hearing loss is a known association of systemic 
mitochondrial disease. There are two main groups of patients presenting with potential 
mitochondrial associated deafness: (i) children with hearing loss of unknown origin (who 
may or may not have passed Newborn Hearing Screening due to the variability in onset of 
hearing loss) (ii) adults with progressive hearing loss with or without a known background 
of mitochondrial disease. 
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Although management of the hearing loss is the primary focus of clinicians, fully 
understanding the aetiology is important to determine (i) the risk of recurrence in future 
offspring, (ii) the risk of progression and (iii) to exclude syndromic forms of deafness 
where associated symptoms may require further management. 
In both children and adults a detailed history should be undertaken to determine the onset, 
progression and impact of symptoms on quality of life. A specific enquiry should be made 
about family history, ethnicity and consanguinity. A general medical history should also be 
obtained (e.g. visual symptoms, diabetes, renal and cardiovascular disease that may 
indicate a syndromic cause) and exposure to aminoglycosides should be noted. In 
paediatric cases it is important to cover the pregnancy and perinatal period and to exclude 
other important causes of hearing loss by enquiring specifically about toxoplasmosis, 
rubella, cytomegalovirus (CMV), herpes and syphilis infections (Graham 2008). General 
developmental progression should be charted against milestones as delays may indicate 
global or specific language or motor delays indicative of syndromic mitochondrial disease. 
In children, clinical examination should include inspection of the craniofacial region 
including physical measurements, to exclude a number of non-mitochondrial hearing loss 
syndromes that are associated with defects in craniofacial development. A computed 
tomography (CT) scan of the petrous temporal bones may be performed to rule out congenital 
abnormalities of the cochlea, particularly in cases where cochlear implantation is being 
considered (Graham 2008). 
Examination of the peripheral (outer/middle ear and cochlear) and central (auditory nerve 
and auditory cortex) auditory sensory axis is undertaken using both age-appropriate 
behavioural tests and physiologic tests that can be undertaken at any age (Figure 1.15). 
Combining information from these tests can both quantify the degree of hearing loss and 
differentiate between sensory and neural components. 
1.13.3.1! Behavioural audiology tests 
Pure tone audiometry (PTA), the cornerstone of diagnostic audiology, is a subjective 
behavioural test of a patient’s ability to detect a pure tone signal presented over a range of 
frequencies (typically 0.25 KHz-8 KHz). This allows the examination of the whole 
auditory axis from cochlea to brain. Hearing thresholds are presented as an audiogram, a 
graphical representation of threshold intensity as a function of tone frequency (Figure 1.15 
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ii (b)). PTA tests both air and bone conduction enabling the differentiation between 
sensorineural and conductive hearing losses (bone conduction bypasses the outer and 
middle ear and hence mitigates the effect of conductive losses). Typically mitochondrial 
hearing loss produces isolated high frequency loss (down sloping audiogram) or in more 
severe cases a pan-frequency loss with no difference between the air and bone thresholds 
consistent with a sensorineural hearing loss (Figure 1.15 ii (b)). 
1.13.3.2! Physiological audiology tests 
Otoacoustic emissions (OAEs) are cochlea generated sound waves resulting from the 
mechanical frequency selectivity of the outer hair cells (Kemp 1978). These can be either 
spontaneous or evoked (by a signal frequency applied by an earphone) and are measured 
using a flexible indwelling ear probe (Figure 1.15 i). In clinical practice, evoked emissions 
(either transient, TEOAEs, or distortion product, DPOAEs) are routinely used to determine 
cochlear auditory function. The presence of OAEs confirms that the cochlear sensitivity in 
the relevant region is 20-40 dB HL or better (normal hearing thresholds are classified as 
between -10 and +20 dB HL) (Manley 2010). 
Auditory brainstem response (ABR) is an evoked electrophysiological response generated 
by an auditory stimulus, usually a tone pip or broadband click, which can be used to 
measure the resulting neural activity of the cochlea-brain axis (Watson, McClelland et al. 
1996). The amplitude of the response is measured through surface electrodes placed at the 
vertex and ear lobe. Responses are then plotted against time, giving five morphologically 
characteristic waveforms (I-V) representing sequential stimulation of the components of 
the central auditory pathway (Figure 1.15 ii (a)). The resulting waveforms can be 
examined for amplitude, inter-peak latency, absolute latency and inter-aural latency 
difference. The diagnosis of an auditory neuropathy depends on increased inter-peak 
latencies in the presence of OAEs with increased thresholds on pure tone audiometry 
(Berlin, Hood et al. 2003). 
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Figure 1.15. Audiological assessment for diagnosis of hearing loss. (A) Schematic 
representation of the auditory conduction pathway from the cochlea via neuronal auditory brain 
structures to the auditory cortex. (i) OAEs: A speaker generated tone is delivered to the ear by an 
indwelling ear probe which also measures the modulated product (in the case of DPOAEs) 
generated by the stimulated cochlear outer hair cells. Cochlea function is specifically measured 
(represented by blue diagrammatic brackets in Panel A). (ii) (a) Auditory brainstem response 
(ABR): position of skull electrodes and representation of electrophysiological response of auditory 
pathway (waves I-V marked). (ii) (b) PTA: Audiograms of the right and left ears showing pan-
frequency hearing loss with raised thresholds at high frequencies (lower limit of normal hearing 
marked with horizontal blue line). Subject responds to different frequency tones presented by 
headphones. (ii) Both ABR and PTA measure response of the entire auditory pathway (represented 
by red diagrammatic brackets in Panel A). 
1.13.4! Genetic aetiology of mitochondrial associated hearing loss 
Mitochondrial associated hearing loss results from mutation in nuclear genes encoding 

















Subsequently, mitochondrial hearing loss can be inherited following either a Mendelian or 
maternal inheritance pattern. 
1.13.4.1! mtDNA mutations associated with non-syndromic hearing loss 
Mutations causing non-syndromic hearing loss are found in genes encoding components of 
the mitochondrial translation machinery including MT-RNR1, encoding the mitochondrial 
12S rRNA and the MT-TS1 gene encoding the tRNA for Ser(UCN). Variants in the 
mitochondrial MT-RNR1 gene have been linked to both maternally transmitted non-
syndromic and aminoglycoside associated deafness (Estivill, Govea et al. 1998). These 
variants include m.1555A>G (discussed in Section 1.14), m.1095T>C, m.1494C>T and 
variants at position 961 (Guan 2011). Several mutations in the MT-TS1 gene encoding 
tRNA Ser(UCN), including m.7445A>G, 7472insC, m.7510T>C and m.7445G>A have also 
been associated with non-syndromic mitochondrial hearing loss. These variants are 
proposed to lead to a reduction in tRNA processing and a decline in cellular oxidative 
phosphorylation (Bykhovskaya, Shohat et al. 1998). Variants in MT-TS1 have also been 
associated with syndromic cases, for example the m.7445A>G variant causes hearing loss 
combined with palmoplantar keratoderma whilst m.7512A>G has also been associated 
with forms of MERRF (Nakamura, Nakano et al. 1995, Sevior, Hatamochi et al. 1998). 
1.13.4.2! mtDNA mutations associated with syndromic hearing loss 
The commonest forms of mitochondrial syndromic hearing loss are associated with the 
complex neuromuscular syndromes KSS, MELAS and MERRF that are caused by large 
mtDNA rearrangements and variants in mitochondrial tRNA genes including MT-TL1 
(tRNALeu(UUR)), MT-TK (tRNALys), and MT-TE (tRNAGlu) respectively. The common 
MELAS variant, m.3243A>G, is also associated with maternally inherited diabetes and 
deafness (MIDD) consisting of a triad of maternally inherited diabetes with a normal body 
mass index, hearing impairment and retinal dystrophy. MIDD can also be associated with 
mutations in MT-TK and MT-TE genes (Naing, Kenchaiah et al. 2014). 
1.13.4.3! Nuclear genes associated with mitochondrial hearing loss 
Given that the majority of mitochondrial proteins are encoded by the nuclear genome it 
follows that nuclear encoded mitochondrial proteins may act to modify the phenotype of 
primary mtDNA mutations (discussed in Section 1.11.2) or cause hearing loss directly. 
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Most commonly, nuclear gene mutations cause hearing loss as a feature of syndromic 
mitochondrial disease by dysregulating mtDNA replication or repair (mtDNA 
maintenance). 
Mutations in OPA1 (discussed in Section 1.9.1 and 1.11.2.3) are associated with DOA, a 
selective degeneration of retinal ganglion cells, however a subset of missense mutations 
cause a DOA-plus phenotype presenting with optic atrophy in conjunction with myopathic 
features, progressive external ophthalmoplegia (PEO) and hearing impairment (Yu-Wai-
Man, Griffiths et al. 2010). Interestingly, it has been shown that different mutations within 
the gene result in hearing loss through divergent mechanisms with haploinsufficiency 
mutations primarily causing a cochlear loss whereas missense mutations cause primarily 
an auditory neuropathy (Santarelli, Rossi et al. 2015). Mutations in POLG, that encodes 
the unique replicative mtDNA polymerase (discussed in Section 1.8.2.1 and Section 
1.11.2.2) cause hearing loss in the context of complex neurological phenotypes including 
PEO, Alper’s disease and Sensory Ataxic Neuropathy, Dysarthria and Ophthalmoparesis 
(SANDO) (Chan and Copeland 2009). Other mtDNA maintenance genes associated with 
mitochondrial deafness include MPV17, SUCLA2 (succinate-CoA ligase), RRM2B and 
TWNK (Luo, Hou et al. 2013). Similarly, mutations in genes involved in apoptosis SMAC 
(second mitochondrial activator of capsases) and DIABLO (Diablo IAP-Binding 
mitochondrial protein) and OXPHOS complex assembly, BCS1L (BCS1 S.Cerevisiae 
homolog like) and COX10 (Cytochrome c oxidase assembly factor 10) have also been 
implicated (Antonicka, Leary et al. 2003, Fernandez-Vizarra, Bugiani et al. 2007, Cheng, 
Zhu et al. 2011). 
1.13.5! The role of mitochondrial dysfunction in acquired hearing loss 
Mitochondria are an important source of cellular ROS generated as a by-product of 
OXPHOS (discussed in Section 1.5.1). Noise exposure has been demonstrated to drive 
increased mitochondrial ROS production that may exceed the buffering capacity of 
cellular antioxidants leading to oxidative stress (Henderson, Bielefeld et al. 2006). 
Subsequent cochlea hair cell death is then driven in part by mitochondrial mediated 
activation of cellular apoptosis (Le Prell, Yamashita et al. 2007). Interestingly, there is 
some evidence that treatment with antioxidants is able to attenuate hair cell death and 
subsequent threshold shifts (Wong and Ryan 2015). 
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In addition, given the vulnerability of the mitochondrial genome to mutation, genetic 
changes are known to accumulate throughout life and hence mitochondria have been 
suggested to play a fundamental role in human ageing (Payne and Chinnery 2015). 
However, dissecting which of these genetic changes is specific to age induced hearing loss 
has proved challenging. The common 4977bp deletion (discussed in Section 1.11.2.3) has 
been seen to be over represented in temporal bone material from patients with age onset 
hearing loss as compared to aged-matched controls (Bai, Seidman et al. 1997). This work 
has paralleled studies in several mouse models that suggest accumulation of mtDNA 
mutations and increased oxidative stress in the cochlea contribute to age related hearing 
loss (ARHL) (Crawley and Keithley 2011). However, a recent larger analysis of the 
mitochondrial genome in 400 individuals (200 with normal hearing and 200 with poor 
hearing) found no association between mtDNA mutation load and ARHL (Bonneux, 
Fransen et al. 2011). 
1.13.6! Clinical management of mitochondrial hearing loss 
There is currently no specific medical treatment for sensorineural hearing loss. 
Amplification by hearing aids used with or without hearing assistive technology systems 
(e.g. infrared/FM systems, induction loop systems) are the mainstay of treatment (Action 
on Hearing Loss 2017). In cases of severe hearing loss, cochlear implantation may be 
indicated and has been used effectively in patients carrying the m.3243A>G variant and 
individuals with DOA, KSS and mitochondrial neurogastrointestinal encephalopathy 
(MNGIE) syndrome (Yamaguchi, Himi et al. 1997, Li, Han et al. 2011, Scarpelli, Zappini 
et al. 2012, Santarelli, Rossi et al. 2015). 
1.14! The m.1555A>G variant 
The homoplasmic m.1555A>G mutation in the mitochondrial MT-RNR1 gene that codes for 
the 12S rRNA component of the mitoribosome has been linked to both maternally 
transmitted non-syndromic and aminoglycoside associated deafness (Prezant, Agapian et al. 
1993, Guan 2011). The variant was first identified in three Chinese families with maternally 
inherited aminoglycoside associated hearing loss and a large Arab-Israeli kindred with 
maternally inherited non-syndromic deafness (Prezant, Agapian et al. 1993). Subsequently, 
m.1555A>G has been found in populations throughout the world including Asia, Africa and 
Europe (Matthijs, Claes et al. 1996, Pandya, Xia et al. 1997, Jacobs, Hutchin et al. 2005). 
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1.14.1! Aminoglycoside antibiotics 
Aminoglycoside antibiotics such as gentamicin, streptomycin and kanamycin are 
bactericidal antibiotics used in the treatment of a broad range of diseases including 
genito-urinary and respiratory tract infections (Avent, Rogers et al. 2011). Although in 
recent decades the use of aminoglycosides in the developed world has fallen, in part due 
to the development of other broad spectrum antibiotics such as cephalosporins and 
fluoroquinolones, there has been renewed clinical interest in these drugs due to the 
emergence of multi-drug resistant bacteria (Xie, Talaska et al. 2011). Administration of 
aminoglycosides must be considered with regard to the prominent associated adverse 
effects, notably nephrotoxicity and ototoxicity. Importantly, it has been demonstrated 
that up to 10% of patients receiving aminoglycosides develop a clinically significant 
hearing loss that is likely mediated via the generation of intra-hair cell ROS (Ariano, 
Zelenitsky et al. 2008, Huth, Ricci et al. 2011). Aminoglycosides mediate their 
therapeutic action via interaction of their 2-deoxystreptamine moiety with the A-site of 
the 16S rRNA (at m.1409-1491) (Purohit and Stern 1994) in the 30S subunit of the 
mitoribosome (Purohit and Stern 1994, Recht, Fourmy et al. 1996). Once bound, they 
affect all 3 stages of protein synthesis; impairing initiation, elongation and translational 
proofreading. This leads to mRNA misreading and premature termination of translation 
(Lambert 2012). The subsequent disruption to protein synthesis causes global cellular 
dysfunction and ultimately results in bacterial cell death (Mingeot-Leclercq, 
Glupczynski et al. 1999). 
1.14.2! Epidemiology of the m.1555A>G variant 
Understanding the epidemiology of m.1555A>G requires an appreciation that the 
frequency of the variant differs depending on the population sampled i.e. depending on 
whether the individuals under test have hearing loss or a prior exposure to 
aminoglycosides with subsequent hearing loss. Genotyping of individuals from the general 
population, unbiased by hearing status, have estimated the frequency of m.1555A>G at 
between 0.21 and 0.26% (Bitner-Glindzicz, Pembrey et al. 2009, Vandebona, Mitchell et 
al. 2009). Whereas, with regard to individuals with confirmed aminoglycoside ototoxicity, 
the incidence of the mutation ranged between 5% and 33% in Chinese and Spanish 
cohorts, possibly reflecting the increased use of aminoglycosides in these populations 
(Estivill, Govea et al. 1998, Lu, Li et al. 2010). Alternatively, in cohorts of individuals 
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with non-syndromic deafness the incidence has been reported to range from 0.6% to 2.9% 
(Li, Li et al. 2005, Bae, Lee et al. 2008, Kullar, Alston et al. 2016). In one study the 
penetrance of the hearing loss associated with m.1555A>G was shown to be 50% by 30 
years and 88% by 65 years (Estivill, Govea et al. 1998). Interestingly, in this study only 
17.7% of the patients with hearing loss and m.1555A>G had received aminoglycosides. 
On the other hand, in ten families from Taiwan the penetrance of hearing loss ranged from 
13 to 78% (Wu, Chiu et al. 2007), while a lower penetrance between 4 and 18% has been 
reported in Chinese families (Dai, Yuan et al. 2006). Additionally, recent work in a British 
cohort has demonstrated that hearing in m.1555A>G carriers is not significantly different 
from the general population and preserved to at least the age of 44-45 years (Rahman, 
Ecob et al. 2012). Taken together, this variability in the expression of the phenotype 
strongly suggests that environmental or genetic factors are important determinants of 
hearing loss associated with m.1555A>G. 
1.14.3! Clinical features of the m.1555A>G mutation 
The hearing loss associated with m.1555A>G is bilateral, sensorineural loss at high 
frequencies without vestibular dysfunction (Noguchi, Yashima et al. 2004, Lu, Li et al. 
2010). Predominantly, hearing loss is the sole presenting phenotype. However, there are 
documented incidences of associated symptoms including pigmentary abnormalities and 
cardiomyopathy (Santorelli, Tanji et al. 1999, Nye, Hayes et al. 2000). It is possible, 
however, the broader phenotypes demonstrated in these studies could be accounted for by 
nuclear alleles co-segregating within the families. Hearing loss with aminoglycoside 
administration is believed to be 100% penetrant in carriers with more profound loss 
occurring in patients receiving aminoglycosides under 10 years of age, however there have 
been accounts of carriers receiving multiple dose of aminoglycosides with normal hearing 
(Al-Malky, Suri et al. 2014). 
The penetrance and age of onset of hearing loss in carriers of m.1555A>G not exposed to 
aminoglycosides is variable with reports of a range of hearing levels from profound loss to 
normal hearing. For example, in a Spanish cohort of m.1555A>G carriers naïve to 
aminoglycosides, hearing loss was diagnosed with a median age of 20 years (Estivill, 
Govea et al. 1998). Whereas, in a large Arab-Israeli family the majority of patients 
developed profound hearing loss in infancy (Prezant, Agapian et al. 1993). 
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1.14.4! Pathophysiology of the m.1555A>G mutation 
The pathological mechanism of m.1555A>G is incompletely understood but two main 
hypotheses have been proposed: mRNA misreading and 12S hypermethylation (Hutchin, 
Haworth et al. 1993, Seidel-Rogol, McCulloch et al. 2003, Hobbie, Bruell et al. 2008). A 
long-standing and widely accepted hypothesis centres on the effect of mRNA misreading 
reducing mitochondrial translation below a minimum threshold compatible with normal 
cochlear physiology (Hobbie, Bruell et al. 2008). Further work has demonstrated the 
m.1555A>G leads to a 7-fold increase in mRNA misreading and that this deficit can be 
further exacerbated by aminoglycosides (Hobbie, Akshay et al. 2008). However, in 2012, 
Raimundo et al provided an intriguing insight into the mechanistic link between 
m.1555A>G and hearing loss (Raimundo, Song et al. 2012). This study built on the 
observation that m.1555A>G transmitochondrial cybrids (cells constructed to carry mtDNA 
variants on a constant nuclear background) are hypermethylated at the 12S rRNA stem loop 
by TFB1M at m.1583 and m.1584A (m62A) (Figure 1.16) (Cotney, McKay et al. 2009). 
The authors report that this modification disrupts efficient mitochondrial respiration; 
leading to the generation of excess ROS that then activate AMPK triggering E2F1 mediated 
cellular apoptosis. In this and a further study, a transgenic mouse strain overexpressing 
TFB1M on a C57BL/6J background demonstrated 12S rRNA hypermethylation in multiple 
tissues causing a progressive hearing loss mediated by E2F1 induced apoptosis of stria 
vascularis and spiral ganglion neurones of the inner ear (McKay, Yan et al. 2015). 
The current prevailing view holds that mRNA misreading is the most physiologically 
relevant model accounting for m.1555A>G associated hearing loss, but the role of AMPK 
in the pathophysiology of m.1555A>G clearly merits further study. 
The mechanism of m.1555A>G mediated aminoglycoside ototoxicity depends on the 
novel G-C base pair created between m.1555G and m.1494C, that decreases the flexibility 
of the ribosomal decoding centre and causes the rRNA to parallel the bacterial 16S rRNA. 
(Figure 1.16) (Bottger 2010, Amunts, Brown et al. 2015). Ultimately, this leads to 
increased binding of aminoglycosides to the mitoribosome with subsequent effect on 
mitochondrial translation (Qian and Guan 2009). It has been proposed that the reduction in 
protein synthesis in the stria vascularis of the cochlea leads to an energetic crisis resulting 
in loss of the endocochlear potential (Figure 1.14) (Rahman, Ecob et al. 2012). Positively 
charged aminoglycosides then become concentrated in the endolymph, where they can 
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pass into hair cells via the MET channels and lead to the generation of ROS resulting in 
cell death by apoptosis (Richardson and Russell 1991, Gale, Marcotti et al. 2001). In a 
transmitochondrial cybrid model, cell lines from both symptomatic and asymptomatic 
individuals carrying m.1555A>G show near identical reductions in mitochondrial protein 
synthesis, highlighting the importance of the nuclear background in the manifestation of 
the phenotype (Guan, Fischel-Ghodsian et al. 2001). 
 
Figure 1.16. The structure of human 12S rRNA. The nucleotide sequences and structure of 
helix 44 and 45 in the stem loops at the 3’end of the 12S rRNA including the aminoglycoside 
binding domain that overlaps the m.1555A and m.1494C residues linked to deafness. The di-
methylated adenosines m.1583A and m.1584A are shown (discussed in Section 1.14.4). Adapted 
from Lee, Rose et al. 2015. 
1.14.5! The role of mtDNA haplogroups in m.1555A>G associated hearing loss 
mtDNA variations have also been reported to influence the variable phenotype of hearing 
loss in m.1555A>G carriers. Studies have demonstrated an excess of haplogroups D and H 
in m.1555A>G hearing impaired Chinese and Spanish patients (Torroni, Cruciani et al. 
1999, Lu, Qian et al. 2010). A number of haplogroup specific tRNA variants may directly 
contribute to increase expression of the phenotype, including, tRNAThr m.15927G>A of 
haplogroups B5, tRNACys m.5802T>C of haplogroup D4 and tRNAGlu14693A>G of 
haplogroups Y2, as well as the ND5 variant m.12338T>C of haplogroup F2 and the ND4 
variant m.11696G>A of haplogroups D4 (Lu, Qian et al. 2010). Biochemical evidence 
adds weight to the assertion that these secondary mutations worsen the mitochondrial 
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dysfunction primarily caused by m.1555A>G and account for some of the phenotypic 
variation (Wang, Lu et al. 2008). However, other studies have shown m.1555A>G arises 
on a number of haplotype backgrounds, caused by independent mutations, and the severity 
of disease varies irrespective of the haplotype background (Torroni, Cruciani et al. 1999, 
Otaegui, Irizar et al. 2008, Rahman, Ecob et al. 2012). 
1.14.6! Role of heteroplasmy in m.1555A>G associated hearing loss 
The m.1555A>G variant is classically described as homoplasmic, however some studies 
report families with varying levels of heteroplasmy. These studies have proposed that 
heteroplasmy levels may influence disease manifestation and have proposed a threshold 
mechanism where increasing levels of heteroplasmy worsen the phenotype (del Castillo, 
Rodriguez-Ballesteros et al. 2003, Zhu, Huang et al. 2014). These studies present a range 
of heteroplasmy levels (3.75% – 96.6%) with a threshold for hearing loss of 50%. 
However, within these and other studies there are patients homoplasmic for the mutation 
without hearing loss and it is therefore unlikely that heteroplasmy can account for all of 
the phenotypic variation (Otaegui, Irizar et al. 2008). 
1.14.7! Evidence for nuclear modifiers of the m.1555A>G phenotype 
Epistasis, whereby the phenotypic effect of an allele is dependent on the allelic status of 
another gene, is emerging as an important contributor to human health and disease (Phillips 
2008, Moore and Williams 2009). In considering the role of nuclear modifiers of 
m.1555A>G it is useful to review the evidence for their contribution in LHON, another 
tissue specific mitochondrial disease caused by a homoplasmic mtDNA variant. As 
described in Section 1.11.2.1, LHON is a maternally inherited cause of vision loss where 
the mtDNA variants m.11778G>A, m.3460G>A and m.14484T>C are necessary but not 
sufficient to develop optic neuropathy. The majority of carriers remain asymptomatic, with 
males more likely than females to convert to the disease state (Carelli, d'Adamo et al. 
2016). This male predominance and incomplete penetrance suggest the role of additional 
environmental or genetic factors. Tobacco smoking and alcohol intake are established 
triggers of disease (Tsao, Aitken et al. 1999, Newman 2009), however the role of genetic 
factors remains an area of intense investigation. mtDNA haplogroups, specifically 
haplogroup J, have been shown to increase the risk of visual failure in carriers of the 
mtDNA variants (Hudson, Carelli et al. 2007). There has also been a substantial amount of 
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effort in recent years to isolate nuclear susceptibility alleles for LHON. However, despite 
strong statistical evidence of linkage of a number of genetic regions with the disease there 
has been limited success in identifying causative mutations (Hudson, Keers et al. 2005, 
Shankar, Fingert et al. 2008, Phasukkijwatana, Kunhapan et al. 2010, Jiang, Jin et al. 2016). 
 
Figure 1.17. Trans-acting modifier effects. The mtDNA genes encoding 16S rRNA (green) 
and 12S rRNA (pink) and a nuclear trans-acting modifier (blue) are shown. Two potential 
mechanisms for the effect of a trans-acting modifier can be envisaged: (A) The trans-acting 
modifier encodes a separate gene product that in conjunction with the m.1555A>G (represented by 
black line in 12S rRNA gene) causes a pathogenic effect (B) The trans-acting modifier directly 
modulates the gene expression of 12S rRNA leading to an altered gene product and manifestation 
of the phenotype. 
The incomplete penetrance and mild biochemical dysfunction associated with the 
m.1555A>G variant implies it is a necessary but not sufficient cause of maternally 
inherited hearing loss. Aminoglycosides are causative for hearing loss in some carriers, 
however the presence of hearing loss in carriers unexposed to aminoglycosides suggests 
the possible importance of epistatic mechanisms. Specifically, trans-acting nuclear 
modifiers acting in conjunction with m.1555A>G to cause disease (Figure 1.17) (Estivill, 
Govea et al. 1998, Hakli, Luotonen et al. 2013). 
The first report of a putative nuclear modifier of m.1555A>G was based on a segregation 
analysis in a large Arab-Israeli kindred that suggested an undefined autosomal recessive 
locus may interact with the primary mtDNA variant in determining disease manifestation 
(Bu, Shohat et al. 1993). 
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Thus far, work to define nuclear modifiers of m.1555A>G has largely been 
inconclusive. An initial study using a genome-wide linkage approach suggested the 
variable phenotype of m.1555A>G may be attributable to a complex interaction of 
nuclear genes (Bykhovskaya, Shohat et al. 1998). A follow up study employing non-
parametric linkage analysis suggested chromosome 8p23.1 may contain a possible 
modifier gene (Bykhovskaya, Estivill et al. 2000). From this gene dense region, 
MRPS18CP2 (mitochondrial ribosomal protein S18V pseudogene 2) and DEFA3 
(defensin alpha 3) were initially prioritised based on their position within the linkage 
region and their predicted biological function (Bykhovskaya, Estivill et al. 2000, 
Ballana, Mercader et al. 2007); however no mutations have been found within these or 
any other genes in this region (Finnila and Majamaa 2003, Otaegui, Irizar et al. 2008). 
To date, five nuclear genes have been suggested as potential modifiers of m.1555A>G 
(Figure 1.18). 
1.14.7.1! TFB1M 
TFB1M, as discussed in Section 1.8.4, encodes the primary 12S rRNA methyltransferase. 
Non-parametric linkage analysis in 214 individuals from 41 families highlighted TFB1M 
as a potential modifier gene, however no causative mutation was found (Bykhovskaya, 
Mengesha et al. 2004). 
1.14.7.2! MTO1 and GTPBP3 
A further linkage study in the same families identified MTO1 (mitochondrial tRNA 
translation optimisation 1) and GTPBP3 (GTP binding protein 3), encoding proteins that 
function as a heterodimer responsible for the 5-taurinomethyluridine (τm5U) modification 
found at position 34 (U34) of mt-tRNALeuUUR, mt-tRNALys, mt-tRNAGlu, mt-tRNAGln and mt-
tRNATrp (Bykhovskaya, Mengesha et al. 2004). The potential importance of the MTO1 and 
GTPBP3 was extended by work with Saccharomyces cerevisiae carrying null alleles of these 
proteins. These strains only manifested reduced growth when coupled with a homolog of the 
m.1555A>G (Saccharomyces cerevisiae 15S rRNA 1409C>G), which could be corrected by 
introduction of human MTO1 or GTPBP3 cDNA (Li, Li et al. 2002). However, presently no 
causative mutations have been found in MTO1 or GTPBP3 in m.1555A>G carriers. 
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1.14.7.3! TRMU 
TRMU encodes a highly conserved 5-methylaminomethyl-2-thiouridylate-
methyltransferase responsible for the 5-taurinomethyl-2-thiouridine (τm5s2U) 
modification of mt-tRNALys, mt-tRNAGlu, mt-tRNAGln in the wobble position that results 
in an increased functional stability of the tRNAs (Guan, Yan et al. 2006). A homozygous 
c.28G>T transversion altering an invariant amino acid (p.A10S) has been suggested to 
cause profound deafness in 18 of 210 Spanish families carrying m.1555A>G (Guan, Yan 
et al. 2006, Yan, Bykhovskaya et al. 2006). This mutation did not affect importing of 
TRMU precursors into the mitochondria but was demonstrated to lead to a marked failure 
in mitochondrial tRNA metabolism resulting in a reduction in mitochondrial protein 
synthesis (Guan, Yan et al. 2006). However, it is noteworthy that this mutation is also 
found in 20% of controls and was not present in 31 Chinese pedigrees in the same study 
or a cohort of 281 Korean m.1555A>G carriers (Bae, Kim et al. 2012). In a further 
Spanish study of 38 hearing impaired individuals carrying m.1555A>G, 14 were 
heterozygous for the TRMU mutation and 1 carried the homozygous variant. However, 
the authors conclude that TRMU is not modulating the expression of the phenotype in 
these individuals given the presence of heterozygotes with and without hearing loss and 
symptomatic individuals carrying wild type TRMU (Otaegui, Irizar et al. 2008). 
1.14.7.4! MRPS12 
The primate family Cercopthecidae (old world monkeys) carry the 12S rRNA variant 
m.1494C>T but are known to have normal hearing. Emperador et al determined the R68L 
variant in MRPS12 (mitochondrial ribosomal protein S16), that encodes a 28S 
mitochondrial ribosomal subunit, protects primary fibroblasts derived from a 
Cercopthecidae species from aminoglycoside mediated compromise of complex IV and a 
reduction of mitochondrial protein synthesis (Emperador, Pacheu-Grau et al. 2014). The 
authors then confirm this protective effect by overexpressing the variant in human 
transmitochondrial cybrids carrying the m.1494C>T or m.1555A>G variants thus 
mitigating the cellular effect of aminoglycosides. These data demonstrate that nuclear 
alleles may also play a protective role in carriers of 12S rRNA variants. 
It is also important to consider the possibility that hearing loss in m.1555A>G carriers may 
be caused by a second mutation in a gene known to be associated with hearing function 
whereby the m.1555A>G variant can be regarded as a ‘bystander’ mutation. For example, 
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deleterious mutations in gap junction beta 2, GJB2, the commonest cause of AR deafness, 
have been previously identified as causative for hearing loss in m.1555A>G carriers (Abe, 
Kelley et al. 2001). 
 
Figure 1.18. Putative nuclear modifiers of m.1555A>G. The protein products of five 
suggested nuclear modifiers of m.1555A>G are shown with their respective functions in 
mitochondrial protein synthesis as described in Section 1.14.7. Adapted from Luo, Hou et al. 2013. 
1.15! Finding disease genes 
Until the advent of next generation sequencing (discussed in Section 1.15.1) the 
identification of causal pathogenic variants in monogenic diseases, including hearing loss, 
was focussed on two Sanger (‘first generation’) sequencing approaches (i) genetic linkage 
analysis and (ii) candidate gene analysis. Genetic linkage analysis capitalises on the 
phenomenon of linkage disequilibrium, defined as the non-random association of alleles at 
different chromosomal loci (Slatkin 2008). By genotyping polymorphic markers in 
affected and unaffected members in large multi-generational pedigrees, it is possible to 
identify a chromosomal region that segregates with the disease. This strategy is often 
hampered by the size of the region isolated, given that they are often very large and 
contain numerous genes, making the subsequent prioritisation of candidate genes 
unfeasible. This is particularly true in consanguineous families that share large genetic 
regions identical by descent (Woods, Cox et al. 2006). 
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Candidate gene analysis relies on the prior knowledge of disease causing mutations 
associated with the relevant phenotype. Suitable genes can also be selected based on 
putative functional or biological relevance to the disease. However, this requirement for a 
priori knowledge can seriously hinder the selection of causative alleles that could be 
identified by a hypothesis-free approach (Zhu and Zhao 2007). Since 2005, the advent of 
next generation sequencing technology (NGS) has to a large extent circumvented the 
methodological limitations of these approaches ushering in the post-genomic era 
(Goodwin, McPherson et al. 2016). 
1.15.1! Next generation sequencing technology 
NGS refers to high throughput technologies that allow massively parallel DNA sequencing 
(Shendure and Ji 2008). For large scale genome analyses these technologies have 
supplanted traditional chain terminating dideoxynucleotide sequencing first described by 
Frederick Sanger (Sanger, Nicklen et al. 1977). A number of different NGS platforms 
currently exist with the most widely used being Illumina HiSeq 2000 (Illumina®), Roche 
454 sequencing (Roche Applied Science) and Ion torrent: Proton/Personal Genome 
Machine sequencing (Thermo Fisher Scientific). 
1.15.2! The human exome and whole exome sequencing 
The exome is the part of the genome that is formed by the exons. These sequences once 
transcribed, form the mature mRNA after removal of the introns by RNA splicing (Voet 
2011). The human exome consists of 180,000 exons constituting approximately 1% of the 
genome, however, it is estimated that 85% of disease causing mutations are exonic (Ng, 
Turner et al. 2009, Gilissen, Hoischen et al. 2012). A mandatory prerequisite for isolating 
pathogenic variants by exome sequencing is a clear definition of the exome, however 
presently; delineating which sequences are protein-coding remains problematic (Kellis, 
Wold et al. 2014). To maximise exome coverage, current commercially available exome 
capture kits use exon lists defined by the CCDS (Consensus Coding Sequence Project), 
RefSeq and GENCODE databases and target up to 64 Mb of coding sequence 
(Chilamakuri, Lorenz et al. 2014). 
Exome sequencing employs NGS technologies to simultaneously couple targeted exon 
capture with massively parallel DNA sequencing that can be used to isolate candidate 
variants in a hypothesis free approach (Yang, Muzny et al. 2013). This allows the 
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identification of disease causing variants without prior knowledge of gene function, hence 
overcoming some of the difficulties of finding causal alleles in conditions where 
pathophysiology is incompletely understood (Rabbani, Tekin et al. 2014). 
1.15.3! Exome sequencing methodology 
 
Figure 1.19. Ilumina exome sequencing methodology. Genomic DNA (gDNA) is sheared and 
prepared into a shotgun library. The library is then enriched in exonic sequences (dark blue 
fragments). After washing the exons are captured by biotinylated DNA (orange fragments). The 
hybridized fragments are recovered by biotin-streptavidin pulldown, amplified and sequenced 
(HiSeq 2000 Sequencing System depicted). Sequence reads are mapped and variants called. 
Biologically plausible candidate variants can then be prioritised for functional validation. Adapted 
from (Bamshad, Ng et al. 2011). 
Although there are specific technical differences between the individual NGS platforms, 
exome sequencing largely follows a common workflow of (i) sample preparation, (ii) exon 
capture by hybridisation to biotinylated bait probes, (iii) enrichment by biotin-streptavidin 
pull down, sequencing, alignment followed by variant detection and identification of 
causal alleles (Metzker 2010) (Figure 1.19). 
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1.15.3.1! Illumina HiSeq Sequencing 
In this study exome sequencing was performed using Illumina HiSeq 2000 technology 
(Illumina 2016) (Figure 1.19). Illumina technology employs bridge amplification PCR to 
create clonal clusters on the surface of a glass flow cell that can then be subjected to 
massively parallel sequencing. Firstly, DNA is fragmented into 200-300 bp lengths that are 
ligated to adapters creating a sequencing library. These adapters contain universal priming 
sites, which following the loading of the linked fragments on to a flow cell, can be used to 
amplify the fragments using common PCR primers. The Illumina platform then utilises a 
sequencing-by-synthesis approach to sequence the clusters. Sequences are then aligned to 
the reference sequence for variant detection (Metzker 2010). 
1.15.3.2! Approaches to filtering 
The primary challenge in the analysis of exome sequencing data is distinguishing novel 
disease causing variants from a vast background of sequencing errors and non-pathogenic 
polymorphisms. The exome sequence of a typical individual consists of 5-9 gigabases and 
approximately 20,000- 25,000 variants (Bamshad, Ng et al. 2011, Cherukuri, Maduro et al. 
2015). The principle of filtering this data is to find rare (minor allele frequency, (MAF) 
≤1%) or novel variants shared between affected individuals. This is undertaken by exome 
sequencing a defined number of affected individuals and comparing isolated variants to 
sets of polymorphisms available in public datasets such as 1000 Genomes project, dbSNP 
137 and ExaC databases (Exome Aggregation Cohort) (National Center for Biotechnology 
Information, Genomes Project, Auton et al. 2015, Lek, Karczewski et al. 2016). This 
approach assumes that variants found in these databases at a MAF above the defined 
threshold are not causative, a justified assumption given that only approximately 2% of 
single nucleotide variants (SNVs) identified in an individual are novel (Bamshad, Ng et al. 
2011). This approach therefore allows the prioritisation of a manageable number of 
variants that can be taken forward for further analysis. 
1.15.3.3! Use of inheritance mode in filtering 
The inheritance pattern of the disease in question must be considered both in the 
experimental design, but also in the subsequent analysis of the sequencing data. For 
example, recessive conditions necessitate the sequencing of fewer individuals than 
dominant conditions, given the genome of any individual has approximately 50-fold fewer 
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genes with two, rather than one deleterious variant per allele (Bamshad, Ng et al. 2011). 
For AD diseases only single heterozygous variants shared between affected and absent in 
unaffected individuals should be considered. On the other hand, for AR conditions 
homozygous or compound heterozygous variants are considered (Farwell, Shahmirzadi et 
al. 2015). 
1.15.3.4! Identification of deleterious variants 
Candidate variants are further prioritised as recommended by the ‘Macarthur criteria’ to 
determine predicted pathogenicity (MacArthur, Manolio et al. 2014). These widely 
accepted guidelines provide a robust framework for establishing causality of sequence 
variants. For example, variants causing nonsense or frameshift mutations alter protein 
function and hence are prioritised over synonymous mutations that are not directly protein 
altering. Variants can also be analysed by bioinformatic tools designed to predict 
pathogenicity, e.g. Sorting Intolerant from Tolerant (SIFT), Polymorphism Phenotyping 
(Polyphen2), Likelihood ratio test (LRT) and MutationTaster (Kumar, Henikoff et al. 
2009, Adzhubei, Schmidt et al. 2010, Schwarz, Rodelsperger et al. 2010). These tools 
attempt to assign a pathogenicity prediction by computing evolutionary sequence 
constraints across species as well as predicting the effect of amino acid changes on overall 
protein function. Subsequently, candidate genes can be prioritised for further analysis 
based on their known biological characteristics and function, for example in establishing 
variants potentially causative for mitochondrial associated hearing loss, known deafness 
genes would be initially prioritised before pursuing genes with defined mechanistic links 




1.16! Research aims 
This research project was undertaken to define nuclear genetic variants that account for the 
variable penetrance of hearing loss associated with the m.1555A>G variant. Specifically, 
there were three aims: 
●! To ascertain the frequency of the m.1555A>G variant in patients in the UK with 
suspected mitochondrial deafness by undertaking a survey of the UK laboratories 
performing genetic testing for the m.1555A>G variant. 
 
●! To define nuclear gene variants that co-segregate with hearing loss and the 
m.1555A>G variant by using a whole exome sequencing approach followed by 
iterative filtering and prioritisation of selected variants. 
 
●! To functionally assess the pathogenic effect of the m.1555A>G variant on mtDNA 
translation and interrogate identified novel nuclear modifier genes focussing on their 
known biological function. This will be performed using a number of experimental 




Materials and Methods 
2.1! Cell culture methodology 
2.1.1! Fibroblast and myoblast cell maintenance 
Fibroblasts and myoblasts were maintained in high glucose Dulbecco Minimal Essential 
Medium (DMEM) (Gibco, Thermo Fisher Scientific, MA. USA) supplemented with 10% 
(v/v) heat inactivated Fetal Calf Serum (FCS, Sigma-Aldrich, MO. USA), 2 mM L-
glutamine, 1 × MEM vitamin solution, 1 mM sodium pyruvate (Thermo Fisher Scientific); 
and 50 µg/ml uridine (Sigma-Aldrich). This medium is referred to as ‘supplemented high 
glucose DMEM’ throughout this thesis. Cells were grown in either T25 or T75 cell culture 
vessels (VWR, Lutterworth, UK) in a humidified incubator at 37ºC and 5% CO2. Cells 
were examined using an inverted Leica DM IL LED microscope (Leica, Wetzlar, 
Germany). 
2.1.2! Cell propagation 
Cells were frequently examined and media refreshed approximately every 4 days. Cells 
were passaged once they reached 90% confluency. To passage cells the medium was 
aspirated and the cells were rinsed in 1X Phosphate Buffered Saline (PBS, Thermo Fisher 
Scientific) until the medium was completely removed. The cells were then treated with 
0.05% Trypsin ethylenediaminetetraacetic acid (EDTA) (Gibco, Thermo Fisher Scientific) 
and replaced into the culture incubator for 5 minutes. The culture vessel was examined 
under the microscope and once all cells had detached a double volume of fresh medium 
was added to inactive the trypsin. This mixture was then collected using a serological 
pipette, transferred into a 15 ml Falcon Conical Centrifuge Tube (Thermo Fisher 
Scientific) and centrifuged at 1300 × g for 3.5 minutes in a bench top centrifuge (Heraeus 
Megafuge 16, Thermo Fisher Scientific). After centrifugation the supernatant was poured 
off and the pellet of cells was dissolved in fresh medium. This cell solution was then split 
between 1 in 2 and 1 in 4 into fresh culture vessels depending on the number of cells 
obtained. 
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2.1.3! Cell counting 
Cells were either counted using a haemocytometer (AC1000 Improved Neubauer, 
HawksleyVet, Lancing, UK) or Countess II FL Automated Cell Counter (Thermo Fisher 
Scientific). For both methods, cells were collected as described in Section 2.1.2 and re-
suspended in fresh medium. For the haemocytometer method, 10 µl of the cell suspension 
was applied to the haemocytometer chamber and covered with a glass coverslip. Cells were 
counted in the large four corner squares and an average number of cells per square was 
calculated. This value was multiplied by 1 × 104 to calculate the total number of cells in the 
original suspension. For the automated method, 10 µL of the cell suspension was combined 
with 10 µl of 0.4% Trypan Blue (Thermo Fisher Scientific); 10 µl of this solution was 
loaded into a Countess Cell Counting Chamber Slide and placed into the Countess II FL 
Automated Cell Counter to derive the number of cells per ml in the original suspension. 
2.1.4! Cryopreservation of cells 
A bank of cells was created for future experiments by cryopreservation in liquid nitrogen. 
Cells were first harvested as described in Section 2.1.2. The pelleted cells were then re-
dissolved in pre-made freezing medium (90% FCS and 5% dimethyl sulfoxide (DMSO; 
Sigma-Aldrich) at a concentration of 1 × 106 cells per ml of freezing medium. The cell 
suspension was added to a cryovial pre-labelled with cell line details, passage number and 
freezing date. The cryovial was then placed in a ‘Mr Frosty’ Freezing Container (Thermo 
Fisher Scientific) filled with 100% isopropyl alcohol to the fill line. This procedure 
ensures the cells are cooled at approximately 1ºC/minute. The ‘Mr Frosty’ was placed in 
the -80ºC freezer and after a minimum of 24 hours the cryovial was removed from the ‘Mr 
Frosty’ and transferred to liquid nitrogen for extended storage. To thaw cells a cryovial 
was taken from liquid nitrogen and rapidly warmed under running warm water. The 
thawed cells were then transferred into a 15 ml Falcon tube Conical Centrifuge Tube 
containing 5 ml of medium. The suspension was centrifuged for 4 minutes at 1300 × g in a 
bench top centrifuge (Heraeus Megafuge 16). The supernatant was removed and the pellet 
was re-suspensed in fresh medium that was then transferred into a fresh culture vessel. 
2.1.5! Immortalisation of primary fibroblasts 
Primary fibroblasts were immortalised by Dr Aurelio Reyes (Mitochondrial Biology Unit, 
Cambridge, UK) using lentiviral transduction of pLOX-Ttag-iresTK (Addgene #12246, 
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Tronolab, Lausanne, Switzerland). For the generation of lentiviral particles, human 293T 
cells (2.5 × 106) were plated 24 hours before co-transfection with 10 µg of transfer vector 
(pLOX-Ttag-iresTK), 7.5 µg of second-generation packaging plasmid (pCMVdR8.74) and 
3 µg of envelope plasmid (pMD2.VSVG) (Naldini, Blomer et al. 1996). FuGENE 6 
Transfection Reagent (Roche, Basel, Switzerland) was used as transfectant reagent. 
Infectious particles were collected 24 and 48 hours after transfection. Transduced 
fibroblasts were grown for at least six passages in order to make sure immortalized cells 
were selected. Changes in cell shape and doubling time were observed as part of the 
normal process of immortalization. 
2.1.6! Analysis of cell growth 
Fibroblast cells were plated in 24 well plates (Corning Costar®, Sigma-Aldrich) at 2.5 × 
104 cells/well in high glucose DMEM including 2 mM L-glutamine, 1 mM sodium 
pyruvate and supplemented with 10% (v/v) FCS (Sigma-Aldrich) or glucose free DMEM 
including 2 mM L-glutamine, 1 mM sodium pyruvate and supplemented with 5mM 
galactose (Sigma-Aldrich). The IncuCyte® Live Cell Imager (Essen Bioscience, MI, 
USA) was used to generate growth curves using IncuCyte® ZOOM software (Essen 
Bioscience). 
2.2! Histopathology methodology 
2.2.1! Mitochondrial histochemistry 
Skeletal muscle biopsies were snap frozen in liquid nitrogen and maintained at -80ºC by 
Kari Majamaa (Oulu University, Finland). The sectioning and staining of muscle biopsies 
was performed in collaboration with Miss Zoe Golder (Mitochondrial Biology Unit, 
Cambridge, UK). The tissue was mounted in optimum cutting temperature medium (OCT) 
and adjusted to -20ºC in the cryostat chamber. Sections were cut with Microm HM 560 
Cryostat (Thermo Fisher Scientific) at 10 µm and collected on Single Frost microscope 
slides (VWR Polysine™ Microscope Adhesion slides, Thermo Fisher Scientific) were then 
used to attach the section. Sections were then dried for 1 hour to minimise freezing 
artefacts. 
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2.2.2! Haematoxylin and eosin staining 
Slides were fixed in Formol Calcium solution (40% Formaldehyde, 10% CaCl2, both 
Sigma-Aldrich) for 10 minutes and then were washed for 2 minutes in running tap water. 
Slides were then placed in Mayers Haemalum (LAMB/170-D, Raymond Lamb, Thermo 
Fisher Scientific) solution for 1 minute. Slides were washed again for 2 minutes in running 
tap water and placed in 1% aqueous eosin solution for 1 minute (LAMB/100-D, Raymond 
Lamb). Slides were washed for 2 minutes in dH2O before being dehydrated in graded 
alcohol: 70% ethanol for 30 seconds, 95% ethanol for 30 seconds, 100% ethanol for 2 
minutes. Sections were covered in D.P.X. solution (VWR, Product 360294H) and a glass 
coverslip was placed on top. 
2.2.3! COX/SDH dual staining 
COX activity staining was undertaken by incubating sections for 35 minutes at 37ºC in 
medium containing 20% (v/v) 500 µM cytochrome c (Sigma-Aldrich), 80% (v/v) 3,3’- 
diaminobenzidine tetrahydrochloride (Sigma-Aldrich) and a few grains of catalase (Sigma-
Aldrich). Following incubation, sections were washed twice for 1 minute in PBS. Staining 
for SDH was undertaken by incubation for 45 minutes at 37ºC in medium containing 80% 
(v/v) 1.875mM nitroblue tetrazolium (Sigma-Aldrich), 10% (v/v) 1.3 M sodium succinate 
(Sigma-Aldrich), 10% (v/v) 2 mM, phenazine methosulphate (Sigma-Aldrich) and 0.01% 
(v/v) 100 mM sodium azide (Sigma-Aldrich). Following this, the sections were washed 
twice for 1 minute in PBS. 
2.3! Genetic analysis methodology 
2.3.1! Genomic DNA extraction from cultured cells 
Total genomic DNA was extracted from a pellet of cultured fibroblast or myoblast cells 
(maximum 5 × 106 cells per pellet) using the DNeasy® Blood & Tissue Kit (Qiagen, 
Hilden, Germany). All reagents used were provided with the kit. Firstly, the pellet was re-
suspended in 200 µl PBS. Following this, 20 µl of Proteinase K and 200 µl of Buffer AL 
was added and the whole mixture was vortexed and incubated at 56oC for 10 minutes. The 
sample was then precipitated by the addition of 200 µl of 100% ethanol. This mixture was 
vortexed to ensure a homogenous solution and added to a DNeasy® Mini spin column in a 
2 ml collection tube. The sample was centrifuged at 6797 × g at room temperature. The 
flow through was discarded and the spin column was placed in a new collection tube. The 
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sample was washed with 500 µl of Buffer AW1 and centrifuged for 1 minute at 6797 × g 
rpm at room temperature. The flow through was discarded and the column was placed in a 
fresh collection tube. The sample was then washed in 500 µl of Buffer AW2 and 
centrifuged at 20817 × g for 3 minutes to dry the DNeasy® membrane. The spin column 
was then placed in a 1.5 ml Eppendorf microcentrifuge tube (Eppendorf, Hamburg, 
Germany) and eluted with the AE elution buffer. The volume of elution used was 
determined by the amount of starting material (range 35 µl-100 µl). The concentration and 
purity (determined by the A260/A280 ratio) of the eluate DNA was determined by the 
NanoDrop 2000 UV-Vis spectrophotometer (Thermo Fisher Scientific). DNA was placed 
at 4ºC for short-term or -20ºC for long-term storage. 
2.3.2! Genomic DNA extraction from muscle homogenate 
The extraction of total genomic DNA from muscle homogenate was performed using the 
DNeasy® Blood & Tissue Kit (Qiagen). All reagents used were provided with the kit. 
Muscle biopsy tissue was sectioned at 10 µm thickness using the Microm HM 560 
Cryostat (Thermo Fisher Scientific). Approximately 10 sections were placed in a 1.5 ml 
Eppendorf microcentrifuge tube and 180 µl Buffer ATL was added. Following this, 20 µl 
of Proteinase K and was added and the whole mixture was vortexed and incubated at 56ºC 
for 5 hours until the tissue was completely lysed. Next, 200 µl of Buffer AL was added 
and the whole mixture was vortexed followed by the addition of 200 µl of 100% ethanol. 
This mixture was vortexed to ensure a homogenous solution and added to a DNeasy® 
Mini spin column in a 2 ml collection tube. The sample was centrifuged at 6797 × g at 
room temperature. The flow through was discarded and the spin column was placed in a 
new collection tube. The sample was washed with 500 µl of Buffer AW1 and then 
centrifuged for 1 minute at 6797 × g rpm at room temperature. The flow through was 
discarded and the column was placed in a fresh collection tube. The sample was then 
washed in 500 µl of Buffer AW2 and centrifuged at 20817 × g for 3 minutes to dry the 
DNeasy® membrane. The spin column was then placed in a 1.5 ml Eppendorf 
microcentrifuge and eluted with 35 µl AE elution buffer. The concentration and purity 
(determined by the A260/A280 ratio) of the eluate DNA was determined by the NanoDrop 
2000 UV-Vis spectrophotometer (Thermo Fisher Scientific). DNA was placed at 4ºC for 
short-term or -20ºC for long-term storage. 
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2.3.3! Genomic amplification 
When required for DNA sequencing reactions, total genomic DNA was amplified using 
the REPLI-g Ultrafast Mini Kit (Qiagen). All reagents were supplied with the kit. Firstly, 
Buffer D1 was prepared by adding 5 µl of Buffer DLB to 35 µl nuclease free water and 1 
µl of Buffer D1 was combined with 1 µl template DNA in a PCR tube (Bio-Rad, Hemel 
Hempstead, UK). This solution was vortexed and incubated at room temperature for 3 
minutes. Buffer N1 was prepared by combining 8 µl Stop solution to 72 µl nuclease free 
water and 2 µl of this was added to the incubated solution. A master mix of 15:1 Ultrafast 
Reaction Buffer and Ultrafast DNA polymerase was prepared and 16 µl was added to the 4 
µl of denatured DNA. This solution was incubated at 30ºC for 1.5 hours and the reaction 
was then inactivated by heating for 5 minutes at 65ºC in a Veriti® 96-well Thermocycler 
(Thermo Fisher Scientific). DNA was stored as in Section 2.3.1. 
2.3.4! Polymerase chain reaction (PCR) 
All PCR reactions were performed in a Veriti® 96-well Thermocycler in 96 well plates 
(Star Lab, Hamburg, Germany) or PCR tubes (Bio-Rad). PCR reactions were performed in 
a final reaction volume of 25 µL containing 1 µL MyTaq™ DNA Polymerase (Bioline, 
London, UK), 10 µL 5x MyTaq Reaction Buffer (Bioline), 1 µL of specific forward and 
reverse primers (10 µM, Integrated DNA Technologies, IA, USA) and 2-4 µL of total 
genomic DNA extract containing on average 50 ng DNA. The sample was made up to 25 
µL by the addition of dH2O. The product was amplified using the following conditions: 
95ºC for 1 minute, followed by 30 cycles of denaturation at 95ºC for 15 seconds, annealing 
at the appropriate primer annealing temperature for 15 seconds and then extension at 72ºC 
for 10 seconds. The final extension step was performed at 72ºC for 10 minutes. The PCR 
reactions were cooled to 4ºC and stored at -20ºC. The optimal annealing temperature was 
determined by running a gradient PCR with temperatures ranging from 58ºC to 62ºC at 
2ºC intervals for each primer pair. 
2.3.5! Agarose gel electrophoresis 
Amplified DNA fragments were separated using electrophoresis on an agarose gel. 
Depending on the product size a 0.6-2% (w/v) agarose gel was used. Agarose (0.6-2g) 
(Helena Biosciences Europe, Gateshead, UK) was dissolved in 100 ml 1X TAE buffer 
(0.04M Tris acetate, 0.001M EDTA; Sigma-Aldrich). The mixture was boiled in an 800 W 
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microwave for approximately 1.5 minutes and then cooled under running water. Once 
cooled, 0.4 µg/ml of ethidium bromide (Sigma-Aldrich) or 100 µl Safeview Nucleic Acid 
Stain (NBS Biologicals, Huntingdon, UK) was added for visualisation of the resolved 
products. The mixture was then poured into a gel-casting tray with an inserted gel comb 
and allowed to solidify for 30 minutes at room temperature. For gel loading, 5 µl of PCR 
product was mixed with 5 µl of Orange G loading buffer (50% glycerol (Sigma-Aldrich), 
50% H2O, Orange G (Sigma-Aldrich) and loaded along with 5 µl of Hyperladder IV DNA 
marker (Bioline). These were run in a gel tank (Scie-Plas, Cambridge, UK) in 1X TAE 
buffer at a voltage of 90 V for 30 minutes. The gel was then imaged using the UV GelDoc-
It®2 Imager (UVP, Upland, California, USA). 
2.3.6! Agarose gel extraction of PCR amplicons 
Standard PCR technique was used to generate DNA amplicons that were then separated on 
a 1% (w/v) TAE agarose gel as described in Section 2.3.5. Under UV illumination the 
appropriate fluorescent band was identified by size and excised from the gel with a scalpel, 
subdivided and placed in a 1.5 ml Eppendorf microcentrifuge tube. Each tube was weighed 
so that it held a maximum of 200 mg of gel. The QIAquick® Gel Extraction Kit (Qiagen) 
was then used to extract DNA. All reagents were supplied with the kit and all 
centrifugation steps were undertaken at 10000 x g at room temperature in an Eppendorf 
Centrifuge 5430R. Initially, 900 µL QG buffer was added to the tube and the mixture was 
then incubated at 50ºC for 10 minutes. The mixture was frequently vortexed to aid 
dissolving the gel. Following this, 100 µl isopropanol was added to precipitate the DNA. 
The sample was then added to a QIAquick® spin column placed in 2 ml collection tube 
and centrifuged for 1 minute. The flow through was discarded and 750 µl of buffer PE was 
added and the mixture was centrifuged at for 1 minute. The spin column was then placed 
into a fresh collection tube and centrifuged for 1 minute to dry the membrane. The column 
was then placed in a clean 1.5 ml Eppendorf microcentrifuge tube and 30 µl EB elution 
buffer was added. The mixture was incubated at room temperature for 1 minute and 
centrifuged for 1 minute to elute the DNA. The DNA was quantified and stored for future 
use as described in Section 2.3.1. 
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2.3.7! Sequencing of nuclear genes 
PCR products were amplified as described in Section 2.3.4 using appropriate primer pairs 
(Integrated DNA Technologies) and then visualised as described in Section 2.3.5. 
2.3.7.1! Exonuclease I/FastAP treatment 
Before sequencing, PCR products must be cleaned by the removal of unincorporated 
primers and nucleotides that would otherwise reduce sequencing fidelity. Firstly, 0.5 µl of 
Exonuclease I (Thermo Fisher Scientific) and 1 µl of FastAP Thermosensitive Alkaline 
Phosphatase (Thermo Fisher Scientific) were mixed with approximately 20 ng PCR 
product per well in a 96 well plate (Star Lab) on ice. The mixture was then incubated at 
37ºC for 15 minutes and then at 80ºC for 15 minutes to inactivate the enzymes. All 
reactions were performed in a Veriti® 96-well Thermal Cycler (Thermo Fisher Scientific). 
2.3.7.2! BigDye ™ sequencing 
Sequencing of the PCR amplicons was performed using the BigDye® Terminator v3.1 
Cycle Sequencing Kit (Thermo Fisher Scientific). After clean up of the PCR product, 1 µl 
of BigDye® Terminator v3.1 Ready Reaction Mix, 2 µl of BigDye® Terminator v3.1 5X 
Sequencing Buffer and 1 µl of appropriate forward or reverse primer (10 µM) was added 
to 5 µl PCR product and made up to 20 µl with dH2O. The BigDye® Terminator cycle 
sequencing was performed in a Veriti® 96-well Thermal Cycler (Thermo Fisher Scientific). 
The PCR reaction conditions were an initial denaturing step at 96ºC for 1 minute, followed 
by 25 cycles of 96ºC for 10 seconds, 50ºC for 5 seconds and 60ºC for 4 minutes. 
2.3.7.3! Ethanol precipitation 
Ethanol precipitation was used to remove unincorporated dye-labelled nucleotides and excess 
salt. 2 µl of 125 mM EDTA (Sigma-Aldrich), 2 µl of 3M sodium acetate (Sigma-Aldrich) and 
70 µl of 100% ethanol (Sigma-Aldrich) was added to each sample. These were then mixed 
and incubated at room temperature for 15 minutes. The plate was then centrifuged at 2060 × g 
for 30 minutes. The supernatant was removed by inverting the plate on tissue followed by a 
brief centrifugation at 100 × g. Following this, 70 µl of 70% ethanol (Sigma-Aldrich) was 
added and the sample centrifuged at 1650 × g for 15 minutes. The supernatant was removed 
by again inverting the plate on tissue and centrifuging at 100 × g. The sample was then air 
dried in the dark for 10 minutes to allow the evaporation of all the ethanol. 
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2.3.7.4! Capillary electrophoresis sequencing 
The precipitated DNA pellets were re-suspended in 10 µL Hi-Di™ Formamide (Thermo 
Fisher Scientific) and incubated for 2 minutes at 95ºC in a Veriti® 96-well Thermal Cycler 
(Thermo Fisher Scientific) followed by rapid cooling on ice. Sequencing was performed 
on the ABI PRISM® 3100 Genetic Analyser (Thermo Fisher Scientific). 
2.3.7.5! Sequence analysis 
SeqScape® v2.6 Software (Thermo Fisher Scientific) was used to analyse the generated 
sequencing data. Sequencing results were aligned to the reference GenBank reference 
sequences available from the Ensembl Genome Browser (http://www.ensembl.org/index.html). 
2.3.8! Long-range PCR of mitochondrial DNA 
For the investigation of mitochondrial DNA deletions an approximately 16 kB fragment 
encompassing almost the complete mitochondrial genome was amplified. Each sample 
was amplified in a 20 µl PCR master mix containing 5 µl TaKaRa PrimerSTAR GXL 
buffer (Takara, Saint Germaine-en-Laye, France), 2 µl dNTP mixture (Takara), 0.5 µl of 
10 µM forward or reverse primers (see Table 2.1), 0.5 µL TaKaRa PrimerSTAR GXL 
DNA Polymerase (Takara) and 15.5 µl water. DNA was amplified in a Veriti® 96-well 
Thermal Cycler under the following conditions: 94ºC for 1 minute, then 30 cycles of 98ºC 
for 10 seconds and 68ºC for 13 minutes and then followed by 72ºC for 10 minutes. The 
mixture was then cooled to 4ºC. For gel loading, 5 µL of the PCR amplicons were mixed 
with 5 µL Orange G loading buffer (Sigma-Aldrich) and were separated by electrophoresis 
on a 0.7% (w/v) agarose gel at 40 V for 90 minutes as described in Section 2.3.5. In 
parallel, 5 µL of GeneRuler 1Kb Plus DNA Ladder premixed with 6X loading buffer 
(Thermo Fisher Scientific) was run to aid sizing of the DNA amplicons. The PCR products 
were then visualised as described in Section 2.3.1. 
Table 2.1. Details of primers used for Long Range PCR 
Name Sequence Size mtDNA position 
16kb mtDNA_1 D2F - TTAAAACTCAAAGGACCTGGC 
D1R- AGGGTGATAGACCTGTGATC 
15432 bp m.1650-1671 
m.19-1 
16kb mtDNA_2 16F- CTCAAAGGACCTGGCGGTGCTTC 
16R- GTAGTGTTCTGGCGAGCAGTTTTG 




2.3.9! Quantification of mitochondrial DNA copy number 
Quantification of mtDNA copy number in fibroblasts and blood was performed in a duplex 
qPCR assay with primers specific to the mtDNA gene, MT-ND1 and the nuclear 
housekeeping genes, B2M. mtDNA copy number in muscle samples used the mtDNA gene 
MT-CO3 and the nuclear gene, RNAseP. The assay was performed on the CFX96 C1000 
Touch Thermocycler (Bio-Rad). The assay employs the use of TaqMan probes (Applied 
Biosystems, CA, USA) designed to bind a specific region of a gene of interest. Target 
probes specific to a region of the gene of interest are designed with an attached fluorescent 
reporter dye at the 5’ end and a non-fluorescent quencher dye on the 3’ end. When the 
reporter and quencher are in proximity the fluorescence of the reporter is quenched by 
Förster resonance energy transfer (FRET). As the PCR product extends the fluorescent 
reporter is cleaved by Taq exonuclease and ceases to be quenched. The signal generated is 
proportional to the amount of target DNA present in the sample. The in-built detector of 
the CFX96 detects the signal and the CFX manager software (Bio-Rad) is able to 
determine the level of fluorescence exceeding the background fluorescence. The threshold 
cycle (Ct) is defined as the number of cycles in which the fluorescence exceeds the 
background noise. This occurs when there was a linear increase in the amplification curve 
that corresponds to exponential increase in the PCR product. All qPCR reactions were set 
up was performed in a UV-sterilised Aura PCR workstation (Bioair Instruments, Milan, 
Italy). 
To assess technical reliability and efficiency standard curves were generated by serial 
dilution of MT-ND1 and B2M (or MT-CO3 and RNAseP) (Figure 2.1). These PCR 
products were generated by a standard PCR technique and extracted from agarose gel and 
quantified as described in Section 2.3.5. Primer pairs used to generate the templates are 
shown in Table 2.2. This DNA concentration was then used to calculate the DNA copy 
number from the formula: 
Copies/µl = !"#. A 
Where C is the concentration g/ µl, Mw is the molecular weight given by product length in 
bp x 2 x 330 and A is Avogadro’s constant (6.02 x1023 mol-1). 
Each DNA sample for quantification was initially diluted to produce a starting 
concentration of 10 ng/µL. A 20 µL reaction mix was set up as follows: 0.6 µL of each 
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primer (MT-ND1/B2M or MT-CO3/RNAseP forward and reverse primers), 0.4 µL of each 
probe (MT-ND1-HEX, B2M-FAM or MT-CO3-FAM, RNAseP-HEX), 10 µL iTaq 
SuperMix reaction buffer (Bio-Rad), 1 µL of sample DNA and 4.2 µL nuclease free water. 
Primer pairs for the qPCR reaction are shown in Table 2.2. Cycling conditions were as 
follows: 95ºC for 3 minutes, then 40 cycles of 62.5ºC for 1 minute and 95ºC for 10 
seconds and then followed by 95ºC for 1 minute. For each DNA sample the Ct values of 
each gene were assayed in triplicate and a mean was calculated (Figure 2.1). A maximum 
of 0.5 Ct value was set as the acceptable threshold difference between replicates. Relative 
mtDNA copy number values were calculated with the delta Ct method where: 
Delta Ct = Ct MT-ND1 – Ct B2M 
Or 
Delta Ct = Ct MT-CO3 – Ct RNAseP 
and 




Table 2.2. Details of primer pairs used in qPCR analysis of mtDNA copy number 
Template Forward Sequence Reverse Sequence Size 
MT-ND1 AGGAACTCGGCAAATCTTACC GTCATGTGAGAAGAAGCAGG 1092 bp 
B2M CGCAATCTCCAGTGACAGAA GCAGAATAGGCTGCTGTTCC 1040 bp 
 
qPCR Dye Forward Sequence Reverse Sequence Probe 
MT-ND1 HEX ACGCCATAAAACTCTTCA CCAAAG GGGTTCATAGTAGAAGAGCGATGG CCGTGGAACCATGTGACTTTGTC 
MT-CO3 FAM ATGACCCACCAATCACATG ATCACATGGCTAGGCCGGAG ACCCAGCCCATGACCCCTAAC 
MT-CYB HEX ATGACCCCAATACGCAAAA CGAAGTTTCATCATGCGGAG CATTCATCGACCTCCCCACCC 
B2M FAM CACTGAAAAAGATGAGTA TGCC AACATTCCCTGACAATCCC ACCCGCCACATCTACCATCACCCTC 




Figure 2.1. Analysis of quantitative PCR data. (A) Standard curve and  
(B) amplification plots generated by CFX Manager Software using serial dilutions of MT-ND1 
template (E= Reaction efficiency, R2 = coefficient of determination) 
2.3.10! Gene expression analysis 
2.3.10.1! RNA isolation from cultured cells 
RNA was isolated from fibroblast cells using RNeasy Mini Kit (Qiagen). All buffers were 
supplied with the kit. Cells were harvested from culture flasks and pelleted as described in 
Section 2.1.2. Approximately 1 × 106 cells were lysed in 350 µl of Buffer RLT containing 
0.1% β- mercaptoethanol (Sigma). This mixture was then transferred into an Eppendorf 
microcentrifuge tube and rotated on a tube rotator for 5 minutes. Following this 350 µl of 
70% ethanol was added and the mixture was transferred to an RNeasy spin column in a 2 




discarded and 700 µl of Buffer RW1 was added. This mixture was centrifuged for 15 
seconds at 8000 × g and the flow through was discarded and 500 µl of Buffer RPE was 
added and the column centrifuged for 2 minutes. The spin column was then placed in a 
fresh 1.5 ml collection tube and 45 µl of RNAse free water was used to elute the sample by 
centrifugation at 8000 × g for 1 minute. The RNA concentration was ascertained using the 
NanoDrop 2000 spectrophotometer (UVP) and the sample was then stored at -80ºC for 
further analysis. 
2.3.10.2! Complementary DNA (cDNA) synthesis 
cDNA was synthesised from RNA isolated from fibroblast cell lines as described in 
Section 2.3.10.1 using High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). All reagents were supplied with the kit. To denature the RNA 1.8 µg of 
sample was made to 14.2 µl with water and combined with 2 µl 10X RT buffer, 0.8 µl 25X 
dNTP mix (100 mM), 2ul 10X RT Random Primers, 1 µl MultiScribe Reverse 
Transcriptase and briefly centrifuged. All reactions were performed on ice in a total 
volume of 20 µl. The samples were then incubated at 25oC for 10 minutes, 37ºC for 120 
minutes and 85ºC for 5 minutes in a Veriti® 96-well Thermal Cycler. The samples were 
then stored for future analysis as described in Section 2.3.10.1. 
2.3.10.3! Quantitative Real Time PCR for gene expression 
Quantification of the expression of specific genes was carried out with qPCR using the 
TaqMan gene Expression Assay (Applied Biosystems) as described in Section 2.3.9. The 
assay was performed on the 7500 Fast Real Time PCR System (Thermo Fisher Scientific) 
using the following mix: 10 µL 2 x TaqMan Gene Expression Master Mix, 1 µL 20 X 
Taqman Gene Expression assay (Table 2.3), 7 µL RNase free water and 2 µL cDNA. The 
reaction cycling conditions were as follows, initial incubation at 50ºC for 2 minutes, 
denaturing at 95ºC for 20 seconds and 40 cycles annealing at 60ºC for 30 seconds and 
95ºC for 3 seconds. Serial 1:10 dilutions of cDNA in RNase free water were used to ensure 
linearity and efficiency of the reaction and for standard curve quantification. Each sample 
was measured in triplicate and a cDNA negative control was used to exclude 
contamination of reagents. The relative amount of cDNA for each target gene was 
calculated by comparison with a housekeeping gene (GAPDH) whereby: 
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Delta Ct = Ct Target Gene – Ct GAPDH 
Relative RNA transcription = 2-delta Ct 
Table 2.3. Details of the Taqman Gene Expression Assays used in qPCR for gene 
expression analysis 
Gene Assay ID Amplicon length (bp) 
SSBP1 Hs00995376_g1 80 
MT-CYB Hs02596867_s1 151 
GAPDH Hs02758991_g1 63 
 
2.3.11! Pyrosequencing 
Pyrosequencing of extracted DNA was performed to quantify mtDNA heteroplasmy levels 
at m.1555. Pyrosequencing enables real time DNA sequencing based on the detection of 
pyrophosphate released during DNA elongation. A specific pair of PCR primers is used to 
generate a locus specific amplicon (approximately 200 bp) where the reverse primer is 
biotin labelled. A sequencing primer is then used to amplify the region of interest and 
quantity heteroplasmy levels. 
The procedure firstly converts the double stranded PCR products into single stranded 
fragments. The biotin labelled strand is then used as the template for Pyrosequencing by 
the addition of a sequencing primer with specific nucleotide dispensed to a known order. 
Pyrophosphate molecules are released when the nucleotide is incorporated into the 
elongating strand and converted by ATP-sulfurylase into ATP. This is used to drive a 
luciferase dependent light response that can be detected using a charged couple device 
(CCD) camera. The output is represented in the form of a pyrogram peak providing 
information on the percentage level of A and G present at the m.1555 nucleotide location. 
Apyrase eliminates excess nucleotides that would otherwise interfere with subsequent 
reactions. The cycle was repeated for each dNTP type at each DNA-strand nucleotide. 
2.3.11.1! Pyrosequencing assay design 
PCR and sequencing primers for the assay were designed using PyroMark Assay Design 
Software 2.0 (Qiagen). The MT-RNR1 sequence was visualised in Ensembl 
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(htttp://www.ensembl.org) and 400 bp surrounding the variant of interest was entered into 
the software. The Allele Quantification mode was selected and the base change A/G was 
inserted at the appropriate position. The primers are given a ranking of 0 to 100 based on 
predicted fidelity of PCR. The highest scoring primer pair was selected. The reverse 
primer was biotinylated for product identification. The software generated the dispensation 
order of nucleotides for sequencing (Table 2.4). 
Table 2.4. Details of the primers used in Pyrosequencing analysis 
Primer Sequence 5’-3’ 
Forward GACATTTAACTAAAACCCCTACGC 
Reverse (5’biotin—3’) TTTGGCTAAGGTTGTCTGGTAGTA 
Sequencing CCCTACGCATTTATATAGAG 
Sequence to analyse GAGA/GCAAGTCGTAACATGGTAAGTGTACT 
 
2.3.11.2! Pyrosequencing procedure 
Amplification of the primary PCR product was performed by standard PCR as described in 
Section 2.3.4. The cycling conditions were as follows: denaturation at 95ºC for 10 
minutes, followed by 30 cycles of 96ºC for 30 seconds, annealing at 60ºC for 30 seconds 
and extension at 72ºC for 30 seconds, followed by 72ºC for 10 minutes. An aliquot of the 
PCR product was electrophoresed on an agarose gel to check product size as described in 
Section 2.3.5. 
Pyrosequencing was performed using a Pyromark Q24 Instrument (Qiagen). To start the 
assay 10 µl PCR sample was added into an 8 tube PCR strip (Starlab). This was made to 
80 µl with 28 µl dH20, 40 µl PyroMark Binding Buffer (Qiagen) and 2 µl Streptavidin 
Sepharose High Performance beads (GE Healthcare, Amersham, UK). The sepharose 
beads bind to the biotin labelled strand by shaking the plate for 15 minutes on a microplate 
agitator (Bioshake IQ, Quantifoil Instruments, GmbH, Germany). Once the samples had 
been agitated they were transferred to the PyroMark Q24 Workstation (Qiagen). The 
workstation consists of 6 reservoirs that are filled to the marked line. The reservoirs are as 
follows: 70% ethanol, PyroMark Denaturation Solution (Qiagen), PyroMark 1X washing 
buffer (Qiagen), parking (unfilled reservoir) and two dH20 reservoirs. 
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The samples were taken up by the Workstation vacuum pump tool, to which the sepharose 
beads adhered. The vacuum pump was then placed in 70% ethanol for 10 seconds with the 
vacuum pump turned on to remove any contaminants. The vacuum pump was next placed 
in Denaturation Solution for 5 seconds whilst turned on. This removes the opposite DNA 
strand leaving only the attached single-stranded DNA with biotin label. The vacuum pump 
was then placed in Wash Buffer for 10 seconds. After this the pump was switched off and 
held vertically to remove excess liquid. The pump was then placed into a 24-Well 
PyroMark Q24 Plate (Qiagen), with each well containing 2.5 µl PyroMark Sequencing 
Primers (Qiagen) and 22.25 µl PyroMark Annealing Buffer (Qiagen), to allow the single-
stranded DNA to enter the mixture. 
The plate was incubated at 80ºC for 2 minutes on a hot block (Digital Dry bath, 
Accublock, Labnet, NJ, USA) then cooled to room temperature to allow primer binding. 
The plate was then placed into the Pyromark Q24 Instrument (Qiagen). The PyroMark 
Q24 Software (Qiagen) was used to create a plate map by loading the designed assay as 
described in Section 2.3.11.1. This generates a pre-run information sheet detailing the 
volumes of reagents (PyroMark Gold reagents, Qiagen) to be used. The generated run file 
is saved to a USB drive for use in the Pyrosequencer. 
The sequencing cartridge was loaded with the pre-determined volumes of Pyromark 
Enzyme Mixture (containing DNA polymerase, ATP-sulfurylase, luciferase, and apyrase), 
PyroMark Substrate Mixture (containing adenosine 5’ phosphosulfate and luciferin), and 
nucleotides (dATP, dTTP, dGTP, and dCTP) (PyroMark Gold reagents, Qiagen) as 
determined by the Pyromark Q24 Software. Typical loaded volumes were as follows: 116 
µl enzyme, 116 µl Substrate Mixture and 57 µl of the 4 separate dNTPs. 
The reaction was performed and the sequencing cartridge and reservoirs were thoroughly 
cleaned. Data, in the form of representative pyrograms were analysed using PyroMark Q24 
Software (Figure 2.2). 
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Figure 2.2. Pyrosequencing for allelic quantification. A representative pyrogram from a 
Pyrosequencing reaction for the allelic quantification of m.1555 using a wild type control (100% A 
at m.1555). 
2.3.11.3! Generation of assay standard curve 
In order to assess the accuracy of the Pyrosequencing reaction a standard curve of 
m.1555A>G heteroplasmy levels was constructed by proportional dilution of a known 
100% m.1555 G sample with wild type DNA (100% A at m.1555). The dilutions were as 
follows: 100% G, 90% G, 75% G, 50% G, 25% G, 10% G and 0% G. The data was plotted 
as observed to expected heteroplasmy level and represented in Figure 2.3. 
 
Figure 2.3. Pyrosequencing standard curve. The observed compared to expected 
heteroplasmy levels at m.1555 are compared by construction of a standard curve (Coefficient of 
determination R2=0.997) 





















2.3.12! Analysis of mitochondrial 7S DNA 
2.3.12.1! Smash and grab extraction of total cellular DNA 
Total cellular DNA was isolated by two sequential phenol-chloroform extractions with 
subsequent precipitation. Phenol-chloroform extraction is a liquid-liquid based extraction 
method based on the differing solubilities of compounds in two different immiscible 
liquids. Proteins segregate into the denser organic phase whereas nucleic acids remain in 
the less dense aqueous phase. Culture vessels of confluent fibroblast cells were harvested 
as described in Section 2.1.2 and lysed using 16 ml of ‘Smash and Grab’ lysis buffer 
(75mM NaCl, 50mM acid EDTA pH 8, 20mM HEPES pH 7.8, 0.5% (w/v) sodium 
dodecyl sulphate (SDS), 0.2 mg/ml Proteinase K at 37ºC, all Thermo Fisher Scientific). To 
this 16 ml of phenol (Sigma-Aldrich) was added and the mixture was agitated for 15 
minutes at room temperature. The mixture was then centrifuged at 5200 × g for 15 minutes 
at room temperature and the aqueous phase isolated. This was then mixed with an equal 
volume of chloroform/isoamylalcohol (24:1) (Sigma-Aldrich), and agitated for 15 minutes 
at room temperature followed by centrifugation at 5200 × g for 15 minutes at 4ºC. The 
aqueous phase was again isolated and a final concentration of 100 mM NaCl was added 
(using a stock solution of 175 mM NaCl) to precipitate the DNA. This was followed by 
addition of an equal volume of isopropanol and centrifugation at 5200 × g for 10 minutes 
at 4ºC to pellet the DNA. The pellet was washed with 1 ml of 70% ethanol, transferred to 
an Eppendorf microcentrifuge tube and centrifuged at 21000 × g for 5 minutes at 4ºC. The 
pellet was air-dried and re-suspended in 415 µl TE buffer (10mM Tris-HCl pH 7.4, 1mM 
EDTA) overnight. Following this, 7.5 µl of 5 M NaCl, 50 µl of 0.5 M EDTA, 5 µl of 20 
mg/ml proteinase K, 12.5 µl of 20 % sodium lauroyl sarcosinate (Sigma-Aldrich) and 10 
µl of 1 M HEPES-NaOH pH 7.8 (Thermo Fisher Scientific). The mixture was incubated at 
4ºC for 30 minutes followed by an addition of an equal volume of phenol before 
centrifugation at 21000 × g for 5 minutes at room temperature. The aqueous phase was 
isolated and mixed with an equal volume of chloroform/isoamylalcohol (24:1). This was 
then centrifuged at 21000 × g for 5 minutes at 4ºC. The aqueous phase was isolated and a 
final concentration of 100 mM NaCl was added (using a stock solution of 175 mM NaCl) 
followed by an equal volume of isopropanol with gentle mixing. The mixture was 
incubated at 4ºC for 10 minutes and then centrifuged at 21000 × g for 10 minutes at 4ºC. 
The pellet of DNA was air-dried and re-suspended in 150 µl TE buffer. The concentration 
and quality of the DNA were determined as described in Section 2.3.1. 
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2.3.12.2! DNA restriction enzyme digestions 
Five µg of total DNA was restricted in 25 µl reactions using 10 units of PvuII restriction 
enzyme (New England Biolabs, MA, USA) and 10X NeBuffer 3.1 (New England Biolabs) 
for 2.5 hours at 37ºC. Each sample was combined with 2.5 µl of 10X DNA loading dye 
(0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol, 40% (v/v) glycerol, all 
Thermo Fisher Scientific) and loaded on to a 0.6% agarose gel as described in Section 
2.3.5. 
2.3.12.3! Southern blotting 
Following the separation of restricted DNA fragments by electrophoresis the agarose gel 
was depurinated in 0.25N HCL (Thermo Fisher Scientific) for 20 minutes with gentle 
agitation. The gel was then denatured by twice incubating in a buffer consisting of 0.5 M 
NaOH (Sigma-Aldrich) and 1.5 M NaCl for 10 minutes. This was followed by twice 
incubating in a buffer consisting of 5M Tris-HCl pH 7.4 and 1.5 M NaCl for 10 minutes. 
The gel was then dry blotted overnight using weights on to a nylon membrane and then 
cross-linked by UV exposure (254 nm, 120 mJ/cm2). 
2.3.12.4! Preparation of radiolabelled probes 
Probes were PCR amplified from total HeLa cell DNA using Taq polymerase with specific 
primers (Table 2.5) and purified using a PCR purification kit (performed by Dr Payam 
Gammage, Mitochondrial Biology Unit, Cambridge, UK). OLB buffer A (2 M HEPES pH 
6.6) and OLB buffer B (1.25 M Tris-HCl pH 8, 125 mM MgCl2 (Thermo Fisher 
Scientific), 250 mM β-mercaptoethanol (Sigma-Aldrich), 0.5 mM dATP, dGTP and dTTP 
(Promega, WI, USA)) were mixed in a 5:2 ratio to make 1X OLB buffer. Fifty ng of PCR 
product was heated at 95ºC for 5 minutes and labelled by adding 10 µl 1X OLB buffer, 5 
U Klenow polymerase (New England Biolabs), 2 µl 1 mg/ml BSA (Sigma-Aldrich), 1 µl 
of 50 mM random hexamers (Thermo Fisher Scientific), 13 µl nuclease-free water 
(Thermo Fisher Scientific) and 3 µl of α-32P dCTP (111 TBq/mmol, Perkin Elmer, 
Beaconsfield, UK), at 37ºC for 1 hour. The probe was then further purified by adding it to 
a Sephadex® size exclusion spin column (Sigma-Aldrich) and centrifuging at 8000 × g for 
5 minutes to remove excess 32P. The purified probe was then heated at 95 ºC for 5 minutes. 
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Table 2.5. Primer sequences for preparation of radiolabelled dsDNA probes 
Probe  Sequence 5’-3’ mtDNA position 
A Forward CTAGGATACCAACAAACCTACCC 16270 - 16292 
A Reverse CTGTTAGGCTGGTGTTAGGG 389 – 369 
28S Forward GCCTAGCAGCCGACTTAGAACTGG - 
28S Reverse GAGGTGTAGAATAAGTGGGAGGCC - 
 
2.3.12.5! Hybridisation with radiolabelled probes 
The membrane was blocked by incubation in 25 ml Church’s Buffer (0.25 M phosphate 
buffer, 7% (w/v) SDS) for 1 hour at 65ºC in a hybridisation tube. The buffer was then 
replaced with 15 ml of Church’s buffer that included the labelled probe and heated at 65ºC 
for 12 hours. The probe was then removed and stored for future use. The membrane was 
washed in 50 ml 1X saline-sodium-citrate (SSC) (150 mM NaCl, 15 mM sodium citrate 
pH 7 (Sigma-Aldrich)) three times for 30 minutes. 
2.3.12.6! Imaging of radiolabelled blots 
The labelled membrane was exposed to a BAS Storage Phosphor screen (GE Healthcare) 
for 72 hours, scanned on a Typhoon 9410 scanner (GE Healthcare) and quantified using 
ImageJ software (National Institutes for Health, Maryland, USA). 
2.3.13! Mitochondrial repopulation assay 
The mitochondrial repopulation assay determines the rate of mtDNA repopulation after 
depletion using the intercalating agent ethidium bromide (EtBr). 
2.3.13.1! Optimisation of experimental protocol 
Fibroblast cells were seeded in T25 flasks at 1.7 × 104 cells per flask in supplemented high 
glucose DMEM with the addition of uridine to avoid selection against respiratory 
incompetent cells due to loss of functional dihydroorotate dehydrogenase occurring in 
mitochondria lacking mtDNA. Alternatively, cells were grown in glucose free DMEM 
supplemented with 5 mM galactose (Sigma-Aldrich), 2 mM L-glutamine, 1 mM sodium 
pyruvate, 10% FCS and 50 µg/ml uridine. Mitochondrial DNA depletion was undertaken 
by supplementing the medium with 50 ng/ml EtBr for 15 days. At this point the cells were 
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switched to grow in supplemented high glucose DMEM cell culture medium without EtBr 
for a further 21 days. For each cell line, EtBr treated cells were grown in parallel with 
untreated controls. At day 0, 3, 6, 15, 23, 29 and 36, treated and untreated cells were 
pelleted individually and used for independent technical replicates or to reseed T25 flasks 
in order to continue the experiment (Figure 2.4). Genomic DNA isolation from individual 
pellets was performed as described in Section 2.3.1. The mtDNA copy number was 
determined by performing the MT-ND1/B2M qPCR assay as described in Section 2.3.9. 
 
 
Figure 2.4. Mitochondrial repopulation optimisation experiment. (A) Fibroblast cells 
treated with EtBr to cause depopulation of mtDNA in parallel with untreated cells were grown in 
T25 flasks. At each time point indicated in (B) cells were harvested for mtDNA copy number 
determination. 
2.3.13.2! Calculation of mtDNA repopulation level 
The repopulation level (RL) was determined at each time point as a ratio of mtDNA copy 
number of treated cells to mtDNA copy number of untreated cells as follows: 




2.3.13.3! Mitochondrial repopulation assay with shorter depletion phase 
Cells were seeded at 3 × 104 cells per well in 6 well plates in either (i) supplemented high 
glucose DMEM or (ii) glucose free DMEM with 5 mM galactose (Sigma-Aldrich) 
supplemented as described in Section 2.3.13.1. mtDNA depletion was undertaken by 
supplementation with EtBr at a concentration of 50 ng/ml for 4 days. At this point, the cells 
were switched to growth in supplemented high glucose DMEM without EtBr for a further 6 
days. For each cell line in a 6 well plate, 3 wells of EtBr treated cells were grown in parallel 
with 3 wells of untreated controls. At day 0, 4, 6, 8 and 10 cells were pelleted individually 
and used for independent technical replicates or to reseed six well plates in order to 
continue the experiment as described in Section 2.3.13.1 (Figure 2.5). Genomic DNA 
isolation from individual pellets was performed as described in Section 2.3.1. The mtDNA 
copy number was determined by performing the MT-ND1/B2M qPCR assay as described in 
Section 2.3.9. RL for each time point was determined as described in Section 2.3.13.1. 
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Figure 2.5. Modified mitochondrial repopulation experiment with shorter depopulation 
phase. (A) Fibroblast cells treated with ethidium bromide to cause depopulation of mtDNA in parallel 
with untreated cells were grown in six well plates. At each time point indicated in (B) cells were 
harvested for mtDNA copy number determination. 
2.3.14! Generation of Whole Exome Sequencing data 
One µg total cellular DNA was fragmented and enriched by TruSeq™ DNA Sample 
Preparation Kit and TruSeq™ 62 Mb Exome Enrichment Kit (Illumina, CA, USA). 
Sequencing was performed on an Illumina HiSeq 2000 Sequencing System (Illumina) with 
100 bp paired-end reads by AROS (AROS Applied Biotechnology A/S, Aarhus, Denmark) 
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2.3.14.1! Bioinformatic analysis 
Read alignment, variant calling and annotation was undertaken by Dr Helen Griffin 
(Newcastle University, UK). FASTQ files were initially checked for quality control using 
FASTQC (Babraham Bioinformatics, UK), a java application that quantifies data quality 
by analysing a number of parameters including GC content and per base Phred scores 
quantifying the probability that a nucleotide base is called correctly. 
Reads were aligned to UCSC hg19 (https://genome.ucsc.edu) using Burrows-Wheeler 
Aligner (BWA) (Li and Durbin 2010). Subsequently, duplicate DNA sequencing reads were 
removed with Picard v1.85 (Broad Institute, MA, USA). GATK (Genome Analysis Toolkit) 
was used to detect single nucleotide variants (SNVs) and insertion/deletions (INDEL) using 
standard filtering parameters according to GATK Best Practice Recommendations for 
detection of somatic SNPs in exomes (DePristo, Banks et al. 2011). GATK performs SNV 
and INDEL calling by comparing the aligned read file against the reference genome 
producing a Variant Call Format (VCF) file. A single multi-sample VCF, containing data 
from all sequenced exomes, was created using VCFtools (http://vcftools.sourceforge.net/). 
Read depth and exome coverage was computed using SAMTools (Li, Handsaker et al. 2009). 
Interrogation of mtDNA variants was performed using MITOMASTER, an online 
bioinformatic tool that performs automatic evaluation of inputted mtDNA sequence 
variation through comparisons against data sets encompassing information such as 
common mtDNA pathogenic mutations and known haplogroups polymorphisms (Brandon, 
Ruiz-Pesini et al. 2009). mtDNA variants were subsequently manually cross-referenced 
using Phylotree (www.phylotree.org), a comprehensive phylogenetic tree of global 




Figure 2.6. A schematic of the bioinformatic pipeline used to analyse exome sequencing data. Bioinformatic programmes as described in Section 
2.3.14.1 and 2.3.14.2. 
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2.3.14.2! Ingenuity Variant Analysis and in silico prediction tools 
Ingenuity Variant Analysis (IVA) is a cloud-based application that allows the iterative 
filtering of variants to a manageable number of candidates that can be then prioritised for 
further analysis. The platform supports the upload of a multi-sample VCF file (e.g. 
containing cases and controls) before annotation with relevant metadata from the 
‘Ingenuity Knowledge Base’. Four levels of variant filtration are automatically applied to 
the data. Firstly, the ‘Confidence filter’ considers only variants with a Phred score of 20 in 
at least one case or control and a read depth of 10 to remain within the dataset. The 
Frequency filter removes variants on the basis of a specified minor allele frequency e.g. 
>1% in ExAc, 1000 Genomes Project and NHLBIESP (National Heart Lung and Blood 
Institute Exome Sequencing Project) (Genomes Project, Auton et al. 2015, Lek, 
Karczewski et al. 2016). Following this, the ‘Predicted Deleterious’ filter keeps only 
variants deemed Pathogenic, Likely Pathogenic of Uncertain Significance in accordance 
with the American College of Medical Genetics guidelines (ACMG). IVA computationally 
implements these guidelines in conjunction with clinical evidence from the Ingenuity 
Knowledge Bank to automatically provide ACMG classifications. This filter also 
highlights variants that are associated with a gain or loss of function. Loss of function 
variants includes missense, frameshift, in-frame indel, change to start/stop codon or splice 
site change. IVA integrates external pathogenicity prediction tools SIFT (Kumar, Henikoff 
et al. 2009) and PolyPhen-2 (Adzhubei, Jordan et al. 2013). These in-silico prediction tools 
estimate potential pathogenicity on the degree of sequence homology and the degree of 
conservation across evolutionarily diverse species. 
The Genetic Filter allows filtration by zygosity depending on the suspected mode of 
inheritance e.g. heterozygous changes for autosomal dominant conditions, homozygous or 
compound heterozygous changes for autosomal recessive conditions. The final gene list 
can then be prioritised by gene function by either manually searching through the linked 
Gene Ontology and OMIM Gene Descriptions or by using the in-built Biological Context 
Filter. This filter highlights genes involved in relevant diseases, processes, pathways or 
phenotype. 
Further pathogenicity prediction was undertaken using MutationTaster (Schwarz, Rodelsperger 
et al. 2010) and LRT (Chun and Fay 2009). Open reading frame (ORF) prediction was 
undertaken using ORF Finder (http://www.bioinformatics.org/sms2/orf_find.html). Multiple 
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sequence alignments were undertaken using the Clustal Omega bioinformatic tool 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). 
2.4! Protein analysis methodology 
2.4.1! Preparation of cell lysates 
Cells were harvested from culture vessels by first washing in PBS followed by 
trypsinisation and pelleting as described in Section 2.1.2. Lysis of the cell pellet was 
performed either using a lysis buffer (50 mM Tris HCL pH 7.5, 130 mM NaCl, 2 mM 
magnesium chloride, 0.1% Triton X, all Sigma-Aldrich) and supplemented with a Protease 
inhibitor (Roche) or a Cell Extraction buffer (FNN0011, Thermo Fisher Scientific) (1 ml 
per 1 × 108 cells) supplemented with 1 mM phenylmethylsulphonyl fluoride (PMSF) 
designed to minimise cellular phosphatases. On ice, 50 µl lysis buffer was added to the cell 
pellet for 30 minutes, vortexing every 10 minutes. The extract was then centrifuged at 
8000 × g for 10 minutes. The supernatant was then aliquoted into fresh microcentrifuge 
tubes and stored at -80ºC. 
2.4.2! Quantification of protein 
The Bradford assay was used to quantify protein concentration (Bradford 1976). The assay 
is based on a shift in the maximum absorbance at 595 nm detected by the 
spectrophotometer when an acidic solution of Coomassie Brilliant Blue G-250 dye binds 
to proteins within the sample. Samples were diluted depending on amount of starting 
cellular material. A standard curve was established each time an assay was performed 
using 0.05 µg, 0.1 µg, 0.2 µg, 0.3 µg, 0.4 µg and 0.5 µg Bovine Serum Albumin (BSA, 
Sigma-Aldrich) per µl solution. Ten µl of the BSA standards and diluted samples were 
loaded in triplicate on to a 96 well microplate (Thermo Fisher Scientific). A blank was also 
used to correct for background absorbance. To each of the standards and diluted samples, 
200 µL of 1:5 dilution (in dH20) of Bradford solution (BioRad) was added and absorbance 
was determined by the Multiskan! Ascent Plate Reader (MTX Lab Systems, FL, USA). 
The concentration of the test sample was determined relative to its absorbance by 




Figure 2.7. Bradford assay for protein quantification. Standard curve with linear regression 
of protein concentration against absorbance (measured at 595 nm). Coefficient of determination 
(r2) >0.99. 
2.4.3! Sample preparation 
A 20 µL sample volume was made by adding 2 µL 10X Sample Reducing Agent, 5 µL 4X 
LDS Sample Buffer (both Novex®, Thermo Fisher Scientific), the appropriate volume of 
sample lysate based on the protein concentration as determined by the Bradford assay and 
the remaining volume was made with dH20. The samples were boiled at 70ºC for 5 
minutes in a dry bath incubator and then cooled on ice to allow protein denaturation. 
Samples were then vortexed and centrifuged at 8000 × g for 1 minute. 
2.4.4! Polyacrylamide gel electrophoresis (SDS-PAGE) 
Samples were loaded on to 4-12% polyacrylamide gel (NuPAGE® Bis-Tris Precast Gels, 
Thermo Fisher Scientific) in an XCell SureLock electrophoresis system (Thermo Fisher 
Scientific). Gels were run for 2 hours at 150 V in 1x MES buffer with 500 µL antioxidant 
(both NuPAGE®, Thermo Fisher Scientific) until the molecular weight dye (SeeBlue Plus 
2, Thermo Fisher Scientific) reached the bottom of the gel. 
2.4.5! Western blotting 
Transfer to a polyvinylidene difluoride (PVDF) membrane was undertaken using the iBlot 
2 Semi Dry Transfer System (Thermo Fisher Scientific). The gel was removed from its 
casing using a plastering spatula and soaked in Tris Buffer Saline with Tween 20 ® (TBST 
buffer, consisting of 20mM Tris hydrochloride pH 7 (Sigma-Aldrich), 0.5mM NaCl 




















y = 1.442x + 0.001
r2=0.995
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(VWR, Lutterworth, UK) and 0.1% Tween 20 (Sigma-Aldrich) for 1 minute. IBlot 2 
Transfer Stacks were used as instructed by the manufacturer. The supplied filter paper was 
soaked in dH2O and the stack assembled as follows; stack-membrane-gel-filter paper-
stack. The P0 protocol for mixed molecular weight was used for 7 minutes at a constant 
1.3 A. 
The membrane was then washed with TBST buffer and then blocked with 5% (w/v) milk 
in TBST. Following this, the membrane was incubated with the primary antibody at 4ºC 
under the conditions indicated in Table 2.6. The membrane was then washed three times 
for 5 minutes in TBST and incubated with secondary antibody for 2 hours at room 
temperature. After washing three times for 5 minutes in TBST, protein signal was detected 
by developing with Clarity Western ECL Western Blotting substrate (Bio-Rad) for 5 
minutes in the dark. The membrane was then imaged using the Amersham Imager 600 (GE 
Healthcare). Densitometric analysis was performed using ImageQuant TL 8.1 software 
(GE Healthcare). GAPDH, a constitutively expressed protein, was used to normalize the 
results and the protein of interest : GAPDH ratio was calculated. To facilitate re-probing of 
membranes with additional primary antibodies, membrane stripping was undertaken by 
incubating with 20 ml Restore™ Western Blot Stripping Buffer (Thermo Fisher Scientific) 
for 30 minutes at 37ºC. Following this, the membrane was incubated with the appropriate 
secondary antibody and developed to ensure there was no detectable signal before 




Table 2.6. Primary and secondary antibodies used in Western blotting. 
Antibody Company Product ID Host Size Conditions 
Anti-AMPK alpha Cell signalling 2532 Rabbit 63kD 1:1000 in TBST and 5% BSA 
Anti-pT172 AMPK alpha Cell signalling 40H9 Rabbit 63kD 1:200-1000 in TBST and 5% BSA 
Anti-S6K Cell signalling 9202 Rabbit 70kD 1:1000 in TBST and 5% BSA 
Anti-pT389 S6K Cell signalling 9205 Rabbit 70kD 1:1000 in TBST and 5% BSA 
Anti-MTCO1 Abcam ab14705 Mouse 40kD 1:1000 in 5% milk 
Anti-SDHA Abcam ab14715 Mouse 70kD 1:5000 in 5% milk 
Anti-MTCO2 Abcam 12C4F12 Mouse 26kD 1:1000 in 5% milk 
Anti-TFAM Source Biosci. LS-C143233 Mouse 25kD 1:5000 in 5% milk 
Anti-HSP60 Gene Tex GTX110089 Rabbit 61kD 1:5000 in 5% milk 
Anti-OXPHOS cocktail MitoSciences MS604 Mouse 55kD 1:250 in 5% milk 
Anti-BiP Abnova PAB2462 Rabbit 78kD 1:4000 in 5% milk 
Anti-HSP70 Abcam ab182844 Rabbit 70kD 1:5000 in 5% milk 
Anti-GPx1 Genetex GTX116040 Rabbit 22kD 1:1000 in 5% milk 
Anti-OPA1 Abcam ab42364 Rabbit 93kD 1:2000 in 5% milk 
Anti-TOMM20 Abcam ab56783 Mouse 16kD 1:1000 in 5% milk 
Anti-SSBP1 Proteintech 12212-1-AP Rabbit 17kD 1:1000 in 5% milk 
Anti-DRP1 Cell Signalling D6C7 Rabbit 82 kD 1:1000 in TBST and 5% BSA 
Anti-MFN2 Abcam ab56889 Mouse 86 kD 1:2000 in 5% milk 
Anti-GAPDH Santa Cruz sc-25778 Rabbit 38kD 1:1000 in 5% milk 
Swine anti-rabbit HRP DAKO P0399 Swine 63kD 1:1000 in 5% milk 
Rabbit anti-mouse HRP DAKO P0260 Rabbit 63kD 1:1000 in 5% milk 
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2.4.6! AMPK-Alpha 1 ELISA 
Total cellular AMPK–alpha 1 was measured using an in vitro SimpleStep ELISA 
(Enzyme-linked immunosorbent assay) (Abcam, MA, USA. Product, ab181422). This 
assay uses an affinity tag labelled capture antibody with a reporter conjugated detector 
antibody that can immune-capture the sample analyte (AMPK-alpha1) in solution. This 
complex is then immobilized by an anti-tag antibody that coats the well of the ELISA 
plate. The assay was performed following the manufacturer’s instructions. Cell lysates 
were diluted 1:10 with 1X cell extraction buffer and a total of 5 µg of total protein was 
loaded for each sample. A standard curve was constructed by reconstitution of the 
provided AMPK-alpha 1 standard sample. Absorbance was measured at 450 nm using the 
MultiSkan Ascent plate reader. The concentration of AMPK–alpha 1 (ng/ml) in the sample 
was calculated by interpolating the blank subtracted absorbance values against the 
standard curve and multiplying by the dilution factor (10X) (Figure 2.8). 
 
Figure 2.8. Typical standard curve of AMPK-A SimpleStep ELISA 
2.4.7! Phospho-AMPK pT172 ELISA 
Phosphorylation of AMPK Threonine-172 was measured by the Phospho-AMPK (pT172) 
ELISA Kit (Thermo Fisher). This assay is a solid phase sandwich ELISA where an 
AMPK-alpha 1 specific monoclonal anybody is immobilized in the wells of an ELISA 
plate. Samples are pipetted into the wells of the ELISA plate and incubated allowing the 
AMPK-alpha 1 antigen to bind the immobilized (capture) antibody. After washing a 
detection antibody specific for AMPK-alpha 1 phosphorylated at Threonine 172 is added 














followed by a horseradish peroxidase (HRP) labelled Anti-Rabbit IgG. The assay was 
performed in accordance with the manufacturer’s guidelines. A standard curve was 
constructed by reconstitution of the provided phosphorylated recombinant AMPK-alpha 1 
phosphorylated standard. Absorbance was read at 450 nm using the MultiSkan! Ascent 
plate reader. The activity of Phospho-AMPK (pT172) (AMPK-P) in the sample was 
calculated by interpolating the blank subtracted absorbance values against the standard 
curve and expressed as AMPK-P activity units/ml (Figure 2.9). 
 
Figure 2.9. Typical standard curve of Phospho-AMPK (pT172) ELISA Kit 
2.4.8! Optimisation of AMPK pT172 ELISA assay 
Cell extraction from control fibroblasts was performed according to the manufacturer’s 
instructions. To determine the amount of total protein to load into the assay, a standard 
curve was constructed by loading known quantities of this protein into the ELISA assay. 
The optimum amount of protein (40 µg) was chosen as the least amount of protein that lay 
on the linear part of the standard curve (Figure 2.10). 















Figure 2.10. Optimisation of Phospho-AMPK (pT172) ELISA 
2.4.9! Heat shock response assay 
Fibroblast cells were plated in T25 culture vessels at a density of 3 × 105 cells per flask in 
supplemented high glucose DMEM. For each cell line, cells were either maintained at 
37ºC or treated with heat shock at 42ºC for 1 hour and allowed to recover at 37ºC for 4 
hours. Cells were then harvested by pelleting as described in Section 2.1.2. Cell lysates 
were prepared as described in Section 2.4.1. Samples were then loaded on to 4-12% 
polyacrylamide gel and Western blot analysis was performed as described in Section 2.4.5 
using antibodies to HSP60, HSP70 and BiP (Table 2.6). 
2.4.10! In vivo mitochondrial translation assay 
Fibroblast cells were plated at a density of 3 × 105 cells/well in six well dishes (Corning 
Costar®, Sigma-Aldrich) and allowed to adhere for 24 hours. Following this, cells were 
washed twice in supplemented high glucose DMEM medium without methionine and 
cysteine (Gibco, Thermo Fisher Scientific) for 10 minutes at 37ºC. In order to block 
cytosolic translation the cells were incubated in DMEM without methionine and cysteine 
supplemented with 10% dialysed FCS, 2 mM L-glutamine, 1 mM sodium pyruvate and a 
final concentration 100 µg/ml emetine dihydrochloride (Sigma-Aldrich) for 20 minutes at 
37ºC. Following this, 100 µCi EasyTag™ 35S L-methionine (Perkin Elmer) was added to 
each well and incubated at 37ºC for 1 hour after which the labelling mix was removed. The 
cells were harvested with 0.05% trypsin/PBS, collected and centrifuged at 500 × g for 5 
minutes. Cell pellets were further washed in PBS, re-pelleted and frozen at -80ºC. Prior to 






















electrophoresis, samples were thawed and combined with 100 µl PBS and incubated on ice 
for 20 minutes with 50 units Benzonase Nuclease (Novagen, WI, USA) and 0.1% n-
Dodecyl β-D-maltoside (Sigma-Aldrich). The protein was then quantified as described in 
Section 2.4.2. For gel loading, 40 µg protein was combined with 1X loading buffer and 
separated on a 4-12% (w/v) SDS-PAGE as described in Section 2.3.5. Sample loading was 
assessed by Western blot using TOMM20 as described in Section 2.4.5. Gels were then 
de-stained for 1 hour using de-stain solution (20% methanol, 7% acetic acid, Sigma-
Aldrich). Gels were then dried at 80ºC for 1 hour using a Bio Rad 583 Electrophoresis Gel 
Dryer (Bio Rad). Visualisation of proteins was performed as described in Section 2.3.12.6. 
2.5! Immunocytochemistry 
2.5.1! Mitochondrial network analysis 
For each fibroblast cell line 1 × 105 cells were seeded in supplemented high glucose 
DMEM on a glass bottom dish (Willco, Amsterdam, Netherlands) and incubated for 24 
hours to allow attachment. Medium was then aspirated and the cells were washed twice in 
PBS. The medium was replaced with medium containing 75 nM Mitotracker Red 
CMXRos (Thermo Fisher Scientific). Cells were incubated at 37ºC, 5% CO2 for 30 
minutes. The cells were then washed twice in PBS and placed in 1 ml MEM medium 
without phenol red and supplemented with 25 mM HEPES (Sigma-Aldrich). 
2.5.2! Imaging 
The mitochondrial network was analysed using live-cell imaging. Individual images were 
acquired at room temperature with an inverted Nikon A1R confocal microscope (Nikon, 
Tokyo, Japan) using a 60×, 1.40 numerical aperture oil immersion objective. Images were 
acquired along the Z-axis using a piezo Z stage (69 Z-stacks of 0.12 µm). These images 
were then reconstructed to model the mitochondrial network within each individual cell. 
2.5.3! Image processing 
Raw data files were converted into tagged image file format (TIFF) by NIS elements 
software (Nikon). A 3-Dimensional reconstruction of the mitochondrial network was then 
created using ImageJ to stack the 69 image planes acquired from each cell. 
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2.5.4! Huygens Essential Software analysis 
The images were subsequently deconvolved with Huygens Essentials software (SVI, 
Hilversum, Netherlands) using the batch processor. Huygens Object Analyzer (SVI) was 
used to analyse the mitochondrial network of individually imaged fibroblasts for each cell 
line. The software uses a seed-threshold method to label specific objects whilst removing 
objects with a size below a set ‘garbage’ volume. The parameters were set as follows: 
threshold automatically determined, 0% seed and 60 voxels garbage volume. For each 
fibroblast, the following parameters were analysed: (i) the average length of mitochondrial 
fragments, and (ii) the total number of mitochondrial fragments. Average values were then 
generated for each individual cell line and the merged control dataset. The distribution of 
mitochondrial fragment lengths was determined by sorting mitochondrial fragments into 
bins defined by their length as follows: <2 µm, 2 to 5 µm, 5 to10 µM and >10 µM. 
2.5.5! Confocal microscopy imaging of mitochondrial nucleoids 
Fibroblast cells were plated on to FisherBrand™ Borosilicate Glass Circle Coverslips 
(Thermo Fisher Scientific) and placed in 6 well tissue culture dish (Corning Costar®, 
Sigma-Aldrich) and incubated at 37ºC, 5% CO2 overnight. The cover slips were removed 
from the 6 well plate and rinsed once with 2 ml 1X PBS. Cells were then fixed by adding 1 
ml 4% paraformaldehyde (Sigma-Aldrich) in PBS for 15 minutes at 37ºC. This was 
followed by a further three washes with 2 ml PBS for 5 minutes. Cells were then 
permeabilized with the addition of 1% Triton X-100 (Sigma-Aldrich) in PBS for 5 minutes 
at room temperature. Cells were then washed again three times with 1 ml PBS for 5 
minutes. Cells were then blocked by incubation with 1 ml 5% FCS in PBS at room 
temperature for 30 minutes. The blocking solution was removed and the cells were rinsed 
in 2 ml of PBS. The cells were then incubated at 4ºC overnight with the primary 
antibodies, TOMM20 1:300 (Abcam, ab56783) and Anti-DNA 1:150 (Progen Biotechnik 
GmbH, Heidelberg, Germany) in PBS with 5% FCS. The cells were then washed with 2 
ml PBS with 5% FCS for 5 minutes three times. The cells were then incubated with 1:1000 
dilution of Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 647 goat anti-rabbit IgG 
(both Thermo Fisher Scientific) in the dark for 1 hour at room temperature. Following this, 
the cells were washed three times for 5 minutes with 2ml PBS. To visualise the cells 10 µl 
of ProLong Gold Anti Fade Mountant with DAPI (Thermo Fisher Scientific) was applied 
to a microscope slide (VWR) and the cover slip was placed cell side down on to the 
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mountant. The slide was left to dry overnight. Slides were then imaged with the Zeiss Axio 
Imager (Carl Zeiss, Oberkochen, Germany). 
2.6! Biochemical methodology 
2.6.1! Measurement of cellular reactive oxygen species (ROS) 
Cellular ROS were measured using the fluorescent cell permeant dye 2’, 7’-
dichlorofluorescin diacetate (H2DCFDA). H2DCFDA diffuses into the cell where it is 
deacetylated by cellular esterases to dichlorofluorescein (DCFH), a non-fluorescent 
compound that can be oxidized by cellular ROS including hydroxyl radicals, hydrogen 
peroxide and peroxynitrite to the highly fluorescent compound DCF. 
Fibroblast cells were seeded at 3 × 104 cells/well in Nunc ™ Microwell 96- well optical 
bottom plates (Thermo Fisher Scientific) and allowed to adhere for 24 hours. Cells were 
then washed twice with PBS and incubated with H2DCFDA (20 µM, Thermo Fisher 
Scientific) in 100 µl PBS for 30 minutes at 37ºC. Following this, the cells were washed 
twice with PBS and fluorescence was measured on a Fluoroskan Ascent (Thermo Fisher 
Scientific) by excitation 485 nm followed by emission at 535 nm. The fluorescence signal 
was normalised to the amount of protein quantified by the Bradford assay as described in 
Section 2.4.2. 
2.6.2! Oxidative DNA damage analysis 
The Oxiselect TM Oxidative DNA Damage kit (Cell Biolabs, CA, USA) measures 8-OHdG 
DNA modification by a competitive ELISA. Firstly, a microplate is conjugated with 8-
OHdG/BSA by adding 8-OHdG conjugate overnight at 4oC. DNA was extracted from cell 
pellets using DNeasy Blood & Tissue Kit (Qiagen) and quantified as described in Section 
2.3.1. To perform the assay 2.5 µg of extracted DNA was converted to single-stranded 
DNA by boiling at 95ºC. DNA was digested using 6 units of nuclease P1 (Sigma-Aldrich) 
for 2 hours at 37ºC in a final concentration of 20 mM sodium acetate pH 5.2 (Sigma-
Aldrich). This was then treated with 8 units alkaline phosphatase (Sigma-Aldrich) for 1 
hour at 37ºC in a final concentration of 100 mM Tris pH 7.5 (Sigma-Aldrich). This 
mixture was then centrifuged for 5 minutes at 6000 × g and the supernatant was used for 
the ELISA performed in accordance with the manufacturer’s instructions. Absorbance was 
measured at 450 nm on the MultiSkan Ascent plate reader and normalised to µg of DNA. 
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2.6.3! Protein carbonylation analysis 
Oxyblot™ Protein Oxidation Detection Kit (MerckMillipore, Darmstadt, Germany) was 
used to detect oxidative modification of the cellular proteome as directed by the 
manufacturer’s instructions. Protein carbonyl groups are common forms of protein 
oxidation by reactive oxygen species. Cells were trypsinsed, pelleted and lysed as 
described in (Section 2.1.2 and Section 2.4.2). Detection of protein carbonyl groups in the 
cell lysates was performed by derivatization of the carbonyl group to 2,4-
dinitrophenylhydrazone using dinitrophenylhydrazine (DNPH). Then 7-9 µg was subjected 
to electrophoresis and transferred to a PVDF membrane. Following this, immunoblotting 
with an anti-DNP antibody and HRP-linked secondary antibody (provided with the kit) 
was performed according to the manufacturer’s protocol. For each cellular lysate a second 
corresponding aliquot was treated with 1X Derivatization-Control Solution that acted as an 
untreated negative control. GAPDH protein levels in the corresponding negative control 
lane of the same gel were used as a loading control. 
2.6.4! Assay of cellular respiration by Seahorse XF96e Extracellular Flux Analyser 
Cellular respiration was assessed with the Seahorse XF96e extracellular flux analyser 
(Agilent Technologies, CA, USA). The Seahorse analyser measures real time oxygen 
consumption and extracellular acidification rate in intact live cells (OCR and ECAR 
respectively). A transient microchamber is created above a monolayer of cells plated in a 
Seahorse 96 well plate. A solid-state sensor probe is then used to measure the rate of 
change of dissolved oxygen. Different aspects of cellular respiration can be assessed by the 
use of a variety of chemical inhibitors of respiration. Oligomycin (1 µM, Sigma-Aldrich) 
blocks ATP synthase (Complex V) and enables determination of the proton leak through 
the mitochondrial membrane. Carbonyl cyanide 4-trifluoromethoxy phenylhydrazone 
(FCCP) (0.5 µM/1 µM, Sigma-Aldrich) is an uncoupling agent allowing protons to leak 
across the mitochondrial membrane. This enables determination of the maximal oxygen 
consumption and spare respiratory capacity. Rotenone and Antimycin A (1 µM, both 
Sigma-Aldrich) inhibit Complex I and III to abolish mitochondrial respiration and enable 
the determination of non-mitochondrial respiration. 
Firstly, the sensor cartridge was pre-hydrated in a calibration plate containing 200 µl per 
well of XF Calibrant Solution at 37oC without CO2 for 12 hours prior to the start of the 
assay. Fibroblasts were seeded into a 96 well microplate (Thermo Fisher Scientific) at 3 
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×104 cells per well in 175 µl of XF Mito Stress Test Assay Medium containing MEM, 11.1 
mM D-Glucose (Sigma-Aldrich) and 2 mM L-Glutamine (Thermo Fisher Scientific) 
adjusted to pH 7. The plate was then incubated for 1 hour in the non-CO2 incubator. The 
chemical inhibitor drugs were then prepared in assay medium and loaded into the 4 
injection ports in the sensor cartridge. The calibration plate was then replaced with assay 
plate containing the plated primary fibroblasts and the assay was started. Sequential 
addition of the chemical inhibitors allowed the following aspects of cellular respiration to 
be measured: endogenous respiration, maximal respiration and proton leak respiration. 
These were determined as follows: endogenous respiration is the difference between basal 
OCR and non-mitochondrial OCR; maximal respiration is the difference between maximal 
OCR and non-mitochondrial OCR; proton leak respiration is the difference between post-
oligomycin OCR and non-mitochondrial respiration. The recorded OCR data was then 
normalised to the total protein content per well by using the Bradford assay as described in 
Section 2.4.2. 
2.7! Statistical analysis 
All data was collected in Microsoft Excel 2013 (Microsoft, Washington, USA). Tests of 
significance between proportions (Fisher’s exact test), calculation of confidence intervals 
and independent t-tests or one-way analysis of variance (ANOVA) with Tukey’s post hoc 
analysis were performed as appropriate to the data set using Graphpad v7 (Graphpad 





A survey of the frequency of the m.1555A>G variant in UK 
patients with suspected mitochondrial deafness 
3.1! Introduction 
The m.1555A>G variant in the mitochondrial 12S rRNA gene, MT-RNR1, is a recognised 
cause of both maternally transmitted aminoglycoside ototoxicity and maternally inherited 
non-syndromic deafness (Prezant, Agapian et al. 1993). The background frequency of the 
variant is estimated at 0.21% in the population (95% confidence interval (CI), 0.08–0.46, 
6/2856 positive tests) (Vandebona, Mitchell et al. 2009) but the majority of carriers have 
been shown to have normal hearing well into adult life (Rahman, Ecob et al. 2012). The 
major modifiable risk for the manifestation of hearing impairment associated with the 
m.1555A>G mutation is the administration of aminoglycoside antibiotics, as the variant is 
thought to alter the secondary structure of the 12S rRNA molecule to more closely 
resemble that of susceptible bacteria (Hobbie, Akshay et al. 2008). This evidence, along 
with genetic linkage studies in hearing impaired families carrying the m.1555A>G variant 
unexposed to aminoglycosides suggests hearing loss in carriers depends on both the 
nuclear genetic background and environmental insults (Bykhovskaya, Estivill et al. 2000). 
Together, this suggests the variant is a necessary but not sufficient cause of maternally 
inherited deafness (Guan, Fischel-Ghodsian et al. 2001, Rahman, Ecob et al. 2012). 
In the UK, testing for the m.1555A>G variant is performed both in the diagnostic work-up 
of hearing loss of unknown origin and in cases of prospective aminoglycoside use, for 
example in the treatment of cystic fibrosis (Veenstra, Harris et al. 2007). Targeted 
mutation analysis of m.1555A>G in the UK is provided by the UK Genetic Testing 
Network (UKGTN) in five accredited laboratories: Oxford (Oxford Medical Genetics 
Laboratories, Oxford University Hospitals NHS Trust), Birmingham (West Midlands 
Inherited Metabolic Disease unit), London (University College London Hospitals Queen 
Square, UCLH, and Great Ormond Street Hospital, GOSH) and Newcastle upon Tyne 
(NHS Highly Specialised Mitochondrial Service). The whole mitochondrial genome, 
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encompassing the MT-RNR1 gene, is also sequenced in the diagnosis of suspected 
mitochondrial disease by the laboratories in Newcastle and UCLH. 
3.2! Materials and Methods 
3.2.1! Survey methodology 
Each of the five laboratories was contacted by e-mail or telephone and asked to provide 
information on the total number of genetic diagnostic tests performed for the m.1555A>G 
variant in the previous 5 years (period: November 2009-November 2014). This included 
both targeted variant tests and whole mitochondrial genome sequencing where appropriate. 
Each laboratory also supplied information on the clinical indications for each test. 
3.2.2! Statistical analysis 
Tests of significance between proportions (Fisher’s exact test) and confidence intervals 
were calculated using Graphpad Prism v7 (Graphpad Software, La Jolla, USA). A p-value 
of less than 0.05 was considered statistically significant. 
3.3! Results 
A total of 3979 m.1555A>G specific test requests and 1336 complete mitochondrial 
genomes (including the MT-RNR1 gene, total=5315 tests) were recorded at the five testing 
laboratories in the study period. A review of clinical referral data revealed that this 
included testing in patients with hearing loss of unknown origin, patients for prospective 
aminoglycoside treatment and patients with undetermined neurological phenotypes 
suspected to result from a pathogenic mtDNA mutation (Table 3.1). 
In total 20 positive test results within the 5-year survey period were recorded (20/5315, 
0.37%, 95% CI=0.21-0.53). Mitochondrial genome sequencing in patients with suspected 
mtDNA disease (e.g. neonatal leukodystrophy and lactic acidosis and hence not 
specifically for hearing impairment) detected 4 positive diagnoses (4/1336, 0.3% 95% 
CI=0.1-0.59) consistent with the background population frequency (Fisher’s exact 
p=0.735) (Vandebona, Mitchell et al. 2009). 
Of the specific tests for m.1555A>G the number of positive tests (16/3979, 0.4% 95% 
CI=0.2-0.6) appears to be higher than the published background population incidence for 
the variant within the population, but was not statistically different (Fisher’s exact p=0.19) 
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(Vandebona, Mitchell et al. 2009). All but one of the positive results in the hearing loss 
group was detected at GOSH (n=12) and the number of positive tests in this group 
(12/2147, 0.56%, 95% CI=0.24-0.88) was also not significantly higher than the 
background population frequency (Fisher exact p=0.06). Additionally, it was noteworthy 
that 15/20 (75%) of the positive tests were recorded at GOSH, although this was not 
significantly different from the detection rate at other centres (GOSH 15/2957 positive 
tests vs. other centres 5/2358 positive tests, Fisher’s exact p=0.113). 
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Oxford 270 83 353 0 0 0 0 0 
Newcastle 212 226 438 1 0 713 3 4 
London (UCLH) 35 0 35 0 0 623 1 1 
London (GOSH) 1434 1523 2957 11 4 0 0 15 
Birmingham 196 0 196 0 0 0 0 0 




We surveyed the 5 laboratories in the UK providing either specific genetic testing for 
m.1555A>G or whole mitochondrial genome sequencing that incorporates the MT-RNR1 
gene. As expected, the frequency of the variant in patients undergoing mitochondrial 
genome sequencing i.e. a group not selected on the basis of hearing loss, was no different 
to the background frequency reported in a previous study (Vandebona, Mitchell et al. 
2009). Surprisingly, however, the m.1555A>G variant was not found at a frequency higher 
than in the background population in patients referred with hearing loss (i.e. a selected 
group with a relatively greater risk for the variant). 
Although there was no statistically significant difference, our results also demonstrate an 
apparent geographical bias in the detection of m.1555A>G, with the majority of positive 
tests found at GOSH. It is possible that this is a result of the ethnic heterogeneity of the 
UK population, reflecting the worldwide variation in the frequency of m.1555A>G in 
published studies (Estivill, Govea et al. 1998, Usami, Abe et al. 2000, Bitner-Glindzicz, 
Pembrey et al. 2009). Alternatively, this may reflect the diagnosis of m.1555A>G in 
numerous individuals within families. 
On the basis of our results, we conclude that the m.1555A>G variant is not significantly 
associated with hearing loss in the UK population. It is therefore possible that m.1555A>G 
testing could be potentially misleading in patients with hearing loss of unknown origin 
without a maternal family history or documented aminoglycoside usage. Moreover, our 
findings are further evidence that the m.1555A>G variant does not confer a strong effect 
size, but requires the presence of an additional factor either environmental e.g. 
aminoglycosides or a permissive nuclear background, to cause hearing loss. In view of 
this, we designed an exome sequencing strategy to identify nuclear genetic modifiers of 




The identification of a nuclear genetic modifier 
in carriers of m.1555A>G 
4.1! Introduction 
The use of aminoglycosides is a known modifier factor for the hearing loss associated with 
the m.1555A>G variant. However, their use cannot account for all hearing impaired 
carriers in multi-generational pedigrees (Hakli, Luotonen et al. 2013). Moreover, the 
severity and age of onset of hearing loss is highly variable amongst individuals in these 
families carrying the m.1555A>G variant, independent of aminoglycoside usage (Estivill, 
Govea et al. 1998). Together, this evidence suggests the manifestation of m.1555A>G 
associated hearing loss may be dependent on additional co-segregating nuclear genetic 
factors (Bykhovskaya, Shohat et al. 1998, Guan, Yan et al. 2006, Meng, Cang et al. 2017). 
Given the suggestion that nuclear modifiers may modulate the risk for hearing loss we 
aimed to determine protein coding risk factors that may confer this function. Carriers of 
the m.1555A>G variant were identified from (i) a multigenerational family living in 
northern Finland by Professor Kari Majamaa (Oulu University, Finland) and (ii) 9 sporadic 
cases from north-eastern Spain by Professor Julio Montoya (University of Zaragoza, 
Spain). To address the hypothesis that a nuclear variant accounted for the variable hearing 
loss associated with m.1555A>G, exome sequencing was undertaken in selected Finnish 
familial (n=5) and Spanish sporadic cases (n=4). 
4.2! Materials and Methods 
4.2.1! A multi-generational Finnish family 
A large multi-generational family transmitting the m.1555A>G variant along the maternal 
lineage was previously identified and characterised by Professor Kari Majamaa, Oulu 
University, Finland (Lehtonen, Uimonen et al. 2000). The family consists of 46 individuals 
(21 female: 25 male, Figure 4.1). Full audiological history and phenotyping of individuals 
in generation IV has been described previously (Hakli, Luotonen et al. 2013). In this study, 
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Hakli et al, undertook prospective audiological phenotyping with a combination of 
TEOAEs and sound field audiometry, with pure tone audiometry when age appropriate. 
Pure tone thresholds were measured at 0.125, 0.25, 0.5, 1, 2, 3, 4, 6 and 8 kHz. On the 
basis of these pure tone thresholds, individuals were categorised as having (i) normal 
hearing, (ii) high frequency hearing loss (iii) moderate progressive pan-frequency hearing 
loss or (iv) profound pan-frequency hearing loss. There was no documented history of 
aminoglycoside usage in any family member (Hakli, Luotonen et al. 2013) and 
neurological examination of all individuals was otherwise normal (Professor Kari 
Majamaa, personal communication). 
Generation IV consists of 19 individuals (9 female: 10 male) forming three families – Family 
A (n=6), Family B (n=9) and Family C (n=4). Individuals were categorised based on the 
results of audiological investigations as having normal hearing (n=9) or hearing loss (n=10, 
either high frequency (n=3), moderate progressive pan-frequency (n=6) or profound pan-
frequency hearing loss (n=1)). The mean age of diagnosis of hearing loss was 3.7 years (range 
1.6 – 5.4 years) although 13 of the children had passed universal neonatal hearing screening 
(Table 4.1). Phenotypic information, where available, for individuals in generation II and III 
was provided by personal communication from Professor Kari Majamaa (Table 4.2). We 
subsequently also identified the children of fathers in generation III (Family D, n=9; and 
Family E, n=6) (discussed in Section 4.3.2.1.3, Table 4.3) 
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Table 4.1. Clinical characteristics of the 19 children in generation IV. n.a = not 
applicable. P = profound pan-frequency hearing loss, HF = high frequency hearing loss,  
M = moderate progressive pan-frequency hearing loss, N = normal hearing Adapted from Hakli, 








Age at last 
examination 
(years) 
Hearing phenotype Genomic DNA available (Yes/No) 
Family A 
IV-1 (A) F n.a 8.8 N Yes 
IV-2 (A) F 5.4 9.3 HF Yes 
IV-3 (A) F n.a 6.5 N Yes 
IV-4 (A) M 2.9 7.2 M Yes 
IV-5 (A) M 2.3 5.5 HF Yes 
IV-6 (A) M 3.5 3.5 HF Yes 
Family B 
IV-1 (B) M n.a 8 N Yes 
IV-2 (B) F 4.8 13.2 P Yes 
IV-3 (B) M 5.2 10.9 M Yes 
IV-4 (B) M 4.7 10.3 M Yes 
IV-5 (B) M n.a 6.2 N No 
IV-6 (B) M 3.8 7.0 M Yes 
IV-7 (B) M 3.0 5.3 M Yes 
IV-8 (B) F n.a 3.6 N Yes 
IV-9 (B) M 1.6 2.1 M Yes 
Family C 
IV-1 (C) F n.a 7.9 N Yes 
IV-2 (C) F n.a 5.3 N Yes 
IV-3 (C) F n.a 3.9 N Yes 
IV-4 (C) F n.a 2.1 N Yes 
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Table 4.2. Clinical characteristics and availability of genomic DNA of individuals in 
generation II and III. n.a = not applicable, -= unknown P = profound pan-frequency hearing loss, 





Age at diagnosis 
(years) Hearing phenotype 
Genomic DNA available 
(Yes/No) 
II-1 F n.a N Yes 
II-2 M 20 HF No 
II-3 M n.a N No 
II-4 F n.a N No 
II-5 F n.a N No 
II-6 M n.a N No 
II-7 F n.a N Yes 
II-8 F 42 HF Yes 
II-9 F n.a N Yes 
III-1 F n.a N Yes 
III-2 M - P No 
III-3 F n.a N Yes 
III-4 M n.a N No 
III-5 F 8 HF Yes 
III-6 M 4 P Yes 
III-7 M n.a N No 
III-8 F 7 HF Yes 
III-9 F 21 HF Yes 
III-10 M 5 P Yes 
III-11 M - HF No 
III-12 M - N No 
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Table 4.3. Clinical characteristics and availability of genomic DNA of children of fathers 
in generation III. As discussed in Section 4.3.2.1.3. N = normal hearing 




III-6 IV-1 (D) M 19 N Yes 
III-6 IV-2 (D) F 15 N Yes 
III-6 IV-3 (D) M 13 N Yes 
III-6 IV-4 (D) F 10 N Yes 
III-6 IV-5 (D) F 7 N Yes 
III-6 IV-6 (D) F 17 N Yes 
III-6 IV-7 (D) F 4 N Yes 
III-6 IV-8 (D) F 12 N Yes 
III-6 IV-9 (D) F 1 N Yes 
Family E 
III-10 IV-1 (E) F 14 N Yes 
III-10 IV-2 (E) M 13 N Yes 
III-10 IV-3 (E) F 11 N Yes 
III-10 IV-4 (E) M 6 N Yes 
III-10 IV-5 (E) M 3 N Yes 




Figure 4.1. Pedigree of Finnish family transmitting the m.1555A>G variant in 4 
generations. Individuals numbered sequentially (generation II – green, generation III – red, 
generation IV- black). Fathers in families A, B, C marked as FIV-A, FIV-B and FIV-C 
respectively, father of generation III is denoted FIII. Symbols are as follows: yellow filled- high 
frequency hearing loss; grey filled- moderate progressive pan-frequency hearing loss; black filled- 
profound pan-frequency hearing loss; unfilled- normal hearing; red star- exome sequenced 
individual (II-8, III-6, III-10, IV-4 (A), IV-2 (B)). 
4.2.2! Sporadic cases 
A second cohort of patients was also identified to determine if a conserved genetic 
mechanism accounted for hearing loss in m.1555A>G carriers. Nine sporadic carriers of 
m.1555A>G were identified during diagnostic workup for hearing impairment by 
Professor Julio Montoya (Universidad Zaragoza, Spain). Phenotypic data consisted only of 
the presence of hearing loss with no additional available information. All patients had 
received antibiotics in infancy; however, whether this included the administration of 
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Table 4.4. Demographic information for nine sporadic Spanish carriers of m.1555A>G 
Patient I.D Sex (M/F) Age (Years) 
DF40 M 51 
DF95 F 44 
DF39 F 45 
DF178 M 8 
DF56 F 70 
DF195 F 64 
DF36 M 48 
DF38 M 52 
DF206 M 42 
 
4.2.3! Samples 
Genomic DNA was extracted from peripheral blood lymphocytes by standard procedures 
in the laboratories of Professor Kari Majamaa (Finnish samples) and Professor Julio 
Montoya (Spanish samples). Detection of the m.1555A>G mutation was performed by 
restriction fragment polymorphism analysis or a direct sequencing approach (Hakli, 
Luotonen et al. 2013). Genomic DNA was available from 44 Finnish individuals (29 
individuals from generations II – IV and 15 individuals from Family D and E) and 9 
individuals from the cohort of sporadic Spanish cases (see Table 4.1, 4.2, 4.3 and 4.4). 
4.2.4! Allelic quantification of m.1555A>G by Pyrosequencing 
Pyrosequencing was undertaken to quantify the A: G nucleotide composition at m.1555 
(determined between 100% A for wild type to 100% G for homoplasmic mutant) as 
described in Section 2.3.11. 
4.2.5! Exome sequencing 
Exome sequencing of 1 µg of extracted DNA was undertaken using a Illumina HiSeq 2000 
Sequencing System (Illumina, CA, USA) with 100 bp paired-end reads by AROS (AROS 
Applied Biotechnology A/S, Aarhus, Denmark) as described in Section 2.3.14. The 
following affected patients from the Finnish family were chosen for exome sequencing: II-
8, III-6, III-10, IV-4 (A) and IV-2 (B) and selected based upon the maximum number of 
meioses between the individuals. Individuals III-6, III-10, IV-4 (A), IV-2 (B) had profound 
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pan-frequency hearing loss, individual II-8 had high frequency hearing loss. In addition, 
four sporadic cases from the Spanish cohort were selected for exome sequencing: DF95, 
DF178, DF40, DF39. 
4.2.5.1! Exome sequencing bioinformatics analysis 
Read alignment, variant calling and annotation were undertaken by Dr Helen Griffin 
(Newcastle University, UK) as described in Section 2.3.14.1. Variant filtering and 
prioritisation were performed using IVA as described in Section 2.3.14.2. Determination 
of mitochondrial haplogroups was performed using MITOMASTER and Phylotree as 
described in Section 2.3.14.2. 
4.2.6! Analysis of known hearing loss genes 
In accordance with the recommendations for the interrogation of putative pathogenic 
variants in human disease, initial analysis focussed on genes that have been previously 
linked to hearing loss (MacArthur, Manolio et al. 2014). The Hereditary Hearing Loss 
Homepage (www.herediaryhearingloss.org) gives an up to date list of all known genes 
identified to be causative for both syndromic and non-syndromic monogenic hearing 
impairment. Non-syndromic hearing loss can be further classified based on the respective 
models of inheritance as; AD, AR and X-linked based. Genes in these lists were screened 
for putative pathogenic variants that could account for the hearing loss in the patients 
(Table 4.5, Table 4.6 and Hypothesis 1, Section 4.3.2.1.1). Similarly, nuclear genes 
associated with mitochondrial disorders of which deafness is a component were also 
prioritised for assessment (Table 4.7). 
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Table 4.5. Established genes known to cause monogenic non-syndromic hearing loss 
classified by inheritance model. Information obtained from Hereditary Hearing Loss Homepage 
(October 2016) (www.herediaryhearingloss.org) 
Autosomal dominant Autosomal recessive X-linked 
CEACAM16 ACTG1 GJB2 BSND PRPS1 
GJB3 SLC17A8 GJB6 TECTA POU3F4 
GJB2 GRHL2 MYO7A OTOA SMPX 
GJB6 OSBPL2 MYO15A PCDH15 COL4A6 
MYH14 HOMER2 SLC26A4 RDX  
DFNA5 MCM2 TMIE GRXCR1  
WFS1 KITLG2 TMC1 TRIOBP  
TECTA COL11A2 MYO15A CLDN14  
COCH  SLC22A4 MYO3A  
POU4F3  TMICE WHRN  
MYH9  TMC1 ESRRB  
MYO6  TMPRSS3 ESPN  
SIX1  OTOF MYO6  
TMC1  CDH23 HGF  
P2RX2  GIPC3 ILDR1  
CCDC50  STRC ADCY1  
MIRN96  USH1C CIB2  
TJP2  OTOG MARVELD2  
TNC  BDP1 CABP2  
SMAC/DIABLO  MSRB3 MET  
TBC1D24  BSND TSPEAR  
CD164  OTOGL GRXCR2  
CRYM  TBC1D24 EPS8  
DIAPH1  ELMOD3 CLIC5  
EYA4  KARS CDC14A  
MYO7A  SERPINB6 FAM65B  
  EPS8L2   
  PJVK   
  DCDC2   
  PNPT1   
  COL11A2   
  COMT   
  LHFPL5   
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Table 4.6. Established genes known to cause non-mitochondrial multisystem phenotypes 
of which hearing loss is a component. Information obtained from Hereditary Hearing Loss 
Homepage (October 2016) (www.herediaryhearingloss.org) 
Genes associated with syndromic hearing loss 
COL4A5 SEMA3E FOXI1 COL9A2 CDH23 
COL4A3 CHD7 KCNJ10 TCOF1 PCDH15 
COL4A4 KCNQ1 COL2A1 POLR1D SANS 
EYA1 KCNE1 COL11A1 POLR1C CIB2 
SIX5 NDP1 COL11A2 MYO7A USH2A 
SIX1 SLC26A4 COL9A1 USH1C VLGR1 
Table 4.7. Nuclear genes associated with mitochondrial disorders of which deafness is a 
component. Adapted and updated from Luo, Hou et al. 2013. 









4.2.7! Analysis of genes previously suggested as modifiers of the m.1555A>G 
phenotype 
A number of nuclear genes encoding mitochondrial proteins have previously been 
described as possible modifiers of the m.1555A>G variant specifically; TRMU (Meng, 
Cang et al. 2017), GTPBP3 (Bykhovskaya, Mengesha et al. 2004), MTO1 (Li, Li et al. 
2002), TFB1M (Bykhovskaya, Mengesha et al. 2004) and MRPS12 (Emperador, Pacheu-
Grau et al. 2014) (Table 4.8). The studies deriving the association between m.1555A>G 
and deafness are described in Section 1.14.7. 
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Table 4.8. Genes previously suggested as modifiers of m.1555A>G hearing loss 
Putative nuclear gene modifiers 
GTPBP3 (Bykhovskaya, Mengesha et al. 2004) MTO1 (Li and Guan 2002) 
TRMU (Guan, Yan et al. 2006, Meng, Cang et al. 2017) TFB1M (Bykhovskaya, Mengesha et al. 2004) 
MRPS12 (Emperador, Pacheu-Grau et al. 2014)  
 
4.2.8! Analysis of genes associated with mitochondrial replication 
To determine whether a conserved mechanism accounted for the phenotype in the familial 
and sporadic cases, genes coding for proteins known to be involved in mtDNA replication 
were assessed in the sporadic cohort. A list of current known genes associated with 
mtDNA replication was obtained by performing a Gene Ontology annotation search of 
MitoCarta, a compendium of all known mitochondrial proteins, via the MitoMiner v3.1 
interface (Table 4.9) (Calvo, Clauser et al. 2016, Smith and Robinson 2016). 
Table 4.9. Known genes coding for proteins involved in mitochondrial DNA replication. 
Information obtained from Mitocarta via Mitominer v3.1 (October 2016). 
Genes coding for proteins involved in mitochondrial DNA replication 
DNAJA3 DNA2 SLC25A33 POLG2 
SSBP1 PIF1 RNASEH1  
C10ORF2 POLG TEFM  
TFAM TK2 TOP1MT  
MGME1 DUT NT5M  
 
4.2.9! Genomic amplification and Sanger sequencing validation of candidate genes 
Total genomic DNA was amplified using the REPLI-g Ultrafast Mini Kit (Qiagen) when 
required for sequencing reactions as described in Section 2.3.3. Confirmation of variants 
identified by exome sequencing as putative disease modifiers of the m.1555A>G mutation 
was performed by Sanger sequencing as described in Section 2.3.7. Each putative 
candidate variant was sequenced in 5 affected and 5 unaffected individuals within the 
family in order to determine whether putative pathogenic mutations segregated with the 
phenotype. All primer pairs were designed with Primer3 (http://primer3.ut.ee/) and primer 
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specificity was determined using Primer-Blast (Ye, Coulouris et al. 2012). Details of 
primer pairs are shown in Table 4.10. 
4.2.10! Sanger sequencing of SSBP1 
All coding regions (exons 2–9) including at least 10 bp overlap of the exon-intron 
boundaries of SSBP1 were Sanger sequenced in DF40, DF95, DF39, DF178, DF56, 
DF195, DF36, DF38 and DF206 as described in Section 2.3.7. Primer pairs for each exon 
are shown in Table 4.11. 
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Table 4.10. Primer sequences, annealing temperatures and amplicon sizes for candidate genes prioritised from exome sequencing of m.1555A>G 
carriers. 
Gene Forward primer sequence 5’-3’ Reverse primer sequence 5’-3’ Anneal temp (˚C) PCR product size (bp) 
MYO6 GGTGCTGAGATCTTGCCAAG ACAAATTCACCAAAAGCCGTG 58 289 
LOXHD1 ACCTAAGCTGGAGAAAACACC TGGGGTAGCCACTGTCTAAC 58 221 
SSBP1 TGGTGAGTTGTACTTTTGCCA AGGTCTTTTGCCCCTGTAGT 58 226 
ITIH4 GAGGCTCAGGGACAAAGAGG CGGGAGAAACATGGAGCAGT 58 240 
SMG7 AGCTCTCCTCCAACACACAA CACCCATGGCTAAGGGATGA 58 247 
CCDC136 GGCTGCTTCTCAACTTGACT GGGGAGTGCAGAGCCTCT 58 500 
TRMU CGCAGAAGAAGAGCAGTGAG TCCGAACCAAAGTCAGAGGA 58 542 
MGAM GACTCCCTGCTGTTGAATTCC AAGGGAACAGGCGATGCTTA 58 344 
GBP5 CTTTGGTGCCATCCCATACC AGTACTCTGATCACCCCACT 58 384 
VPS33B ACCCCACCTCTAAATGCCAT CCCCAGTAACAGGCTCTCC 58 230 




Table 4.11. Primer sequences, annealing temperatures and amplicon sizes for all SSBP1 coding regions 
Exon Forward primer sequence 5’-3’ Reverse primer sequence 5’-3’ Anneal temp (˚C) PCR product size (bp) 
2 GGTGCTGAGATCTTGCCAAG ACAAATTCACCAAAAGCCGTG 60 300 
3 ACCTAAGCTGGAGAAAACACC TGGGGTAGCCACTGTCTAAC 60 275 
4+5 TGGTGAGTTGTACTTTTGCCA AGGTCTTTTGCCCCTGTAGT 60 557 
6 GAGGCTCAGGGACAAAGAGG CGGGAGAAACATGGAGCAGT 60 243 




Allelic quantification of the m.1555 base was undertaken in all available DNA samples 
reported to possess the m.1555A>G variant by Pyrosequencing as described in Section 
2.3.11. The Pyrosequencing assay was performed on the following samples from the 
Finnish family in duplicate: II-2, II-7, II-8, II-9, III-1, III-3, III-5, III-6, III-8, III-9, III-10, 
and all individuals from generation IV except IV-5 (B) where no DNA was available. 
Pyrosequencing was also performed in duplicate on genomic DNA from the sporadic 
Spanish cases: DF40, DF95, DF39, DF178, DF56, DF195, DF36, DF38 and DF206. Given 
the known limit of sensitivity of detection of the Pyrosequencing assay (approximately 
5%, Qiagen Knowledge Resource) all samples were confirmed to be homoplasmic at 
m.1555A>G (range 98-100%, see Figure 4.2). 
 
Figure 4.2. Representative pyrograms generated from Pyrosequencing. (A) Pyrogram of 
positive control demonstrating 100% A at m.1555 and (B) Pyrogram of individual IV-1(B) showing 
99% G at m.1555 and hence classified as homoplasmic. 
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4.3.1! Coverage analysis of consensus coding sequence (CCDS) bases and known 
hearing loss genes 
Read coverage and depth for all CCDS bases for all nine exome sequenced individuals 
across (a) the whole exome, (b) within known hearing loss genes (Table 4.12, 4.13) was 
performed by Dr Helen Griffin (Newcastle University, UK) using SAMtools (Li, 
Handsaker et al. 2009). Custom Perl scripts were then used to calculate mean base depth 
across the exome and within the genes of interest together with the percentage of bases 
covered above a depth of 30, 10, 5 and 1 read depth. 
The mean target base coverage of all CCDS bases for all 9 individuals was 55.2-fold 
(SD=8.8). On average, 69.0% of all CCDS bases were covered above 30-fold depth, 
93.0% of all CCDS bases were covered at greater than 10-fold depth, and 99.4% of all 
CCDS bases were covered at greater than 5-fold (Table 4.12). The mean target base 
coverage for the CCDS regions within of known hearing loss genes in this study was 42.3-
fold (SD=6.6). Within these genes, 59.1% of bases were covered 30-fold, 88.7% of bases 
were covered 10-fold and 94.9% of bases were covered 5-fold (Table 4.13). These metrics 
indicated that there was adequate coverage of the whole exome and the specific hearing 
loss genes examined in Hypothesis 1, Section 4.3.2.1.1. 
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Table 4.12. Coverage and depth statistics calculated for all Consensus Coding Sequence (CCDS) bases. Target bases as defined by Illumina Truseq 
62Mb enrichment kit. 

































IV-4 (A) 31935069 62.5 23870817 74.7 30159703 94.4 31218112 97.8 31798034 99.6 
IV-2 (B) 31935069 65.5 24470472 76.6 30296467 94.9 31243217 97.8 31789289 99.5 
II-9 31935069 61.7 23798526 74.5 30146737 94.4 31191978 97.7 31782896 99.5 
III-6 31935069 42.2 18206224 57.0 28614409 89.6 30606737 95.8 31711023 99.3 
III-10 31935069 56.1 22669349 71.0 30018674 94.0 31187756 97.7 31804326 99.6 
DF95 31935069 50.1 21342809 66.8 29703723 93.0 30977233 97.0 31714121 99.3 
DF178 31935069 42.2 18513570 58.0 28829490 90.3 30613101 95.9 31652856 99.1 
DF40 31935069 53.5 21748658 68.1 29528268 92.5 30964339 97.0 31770530 99.5 
DF39 31935069 62.8 23736845 74.3 29915314 93.7 31065601 97.3 31755972 99.4 
Mean 31935069 55.2 22039697 69.0 29690309 93.0 31007564 97.1 31753227 99.4 




Table 4.13. Coverage and depth statistics calculated for known genes associated with hearing loss in Table 4.5, 4.6 and 4.7 

































IV-4 (A) 29287 47.7 19497 66.6 26433 90.3 28014 95.7 28750 98.2 
IV-2 (B) 29287 49.4 19564 66.8 26825 91.6 28076 95.9 28671 97.9 
II-9 29287 46.6 18863 64.4 26448 90.3 28038 95.7 28559 97.5 
III-6 29287 32.1 13413 45.8 24473 83.6 27170 92.8 28644 97.8 
III-10 29287 42.9 17557 59.9 26057 89.0 27981 95.5 28666 97.9 
DF95 29287 38.2 16918 57.8 26288 89.8 27890 95.2 28648 97.8 
DF178 29287 32.9 14053 48.0 25108 85.7 27504 93.9 28663 97.9 
DF40 29287 41.9 16840 57.5 25974 88.7 27896 95.3 28658 97.9 
DF39 29287 48.8 19150 65.4 26120 89.2 27690 94.5 28732 98.1 
Mean 29287 42.3 17317 59.1 21840 88.7 27806 94.9 28665 97.9 
SD 0 6.6 2288 7.8 1502 2.5 301 1.02 54.5 0.18 
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4.3.2! Filtering for putative variants acting as modifiers of the m.1555A>G phenotype 
A multi-sample VCF file containing data from all sequenced exomes (n=5 Finnish family, 
n=4 Spanish cohort) was uploaded into IVA together with 8 age-matched control 
individuals. The controls were derived from a cohort of patients investigated for cerebral 
vascular malformations and did not have any hearing impairment after extensive 
neurological examinations (personal communication, Dr Michael Keogh, Mitochondrial 
Biology Unit, Cambridge, UK). All controls were processed on the same exome 
sequencing run on a Hi-Seq 2000, and were selected to remove run-specific sequencing 
errors. A total of 120411 variants in 16293 genes were identified in the 9 exomes and 
further classified by translational impact (see Table 4.14). 
Table 4.14. Summary of variants from all sequenced exomes (n=9) irrespective of MAF in 
the population or functional impact. 
Translation impact No. Variants 
Non-coding  66346 
Synonymous  27017 
Missense  25473 
In-frame 774 
Frameshift 345 





4.3.2.1! Filtering strategies 
Iterative filtering using IVA was used to address four specific hypotheses of the cause of 
hearing loss within both the Finnish familial and Spanish sporadic cases. 
4.3.2.1.1! Hypothesis 1 
(1a) A single rare pathogenic variant in a known hearing loss gene (n=141 genes, Table 
4.5, 4.6 and 4.7), or in a previously suggested putative nuclear modifier gene of the 
m.1555A>G variant (n=5 genes, Table 4.8) segregates with the phenotype in the Finnish 
family. 
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(1b) A single rare pathogenic variant(s) in known hearing loss gene(s) or in a putative 
nuclear modifier gene causes the phenotype in the Spanish sporadic cases. 
Four filters were applied to the complete set of identified variants in the familial and 
sporadic cases, specifically; (i) confidence filter, (ii) frequency filter, (iii) predicted 
deleterious filter, (iv) a user defined list of known hearing loss genes (compiled from genes 
in Table 4.5, 4.6 and 4.7 and see Figure 4.3). The confidence and predicted deleterious 
filters were used as described in Section 2.3.14.2. The frequency filter was set to remove 
variants with a MAF >3% in the 1000 Genome Project or ExAC databases. This threshold 
was selected in order to capture potential monogenic cases of hearing loss (caused by 
alleles with a MAF of <0.1% (Shearer, Eppsteiner et al. 2014), and also to include alleles 
that may act as putative risk factors for common diseases (Manolio, Collins et al. 2009). 
The final stage of the filtering process involved the manual cross-referencing of the 
remaining variants with a list of genes known to be associated with hearing loss, see 
Section 4.2.6. For hearing loss genes that cause disease through AD inheritance, only 
heterozygous changes shared between affected individuals were retained. For hearing loss 
genes associated with AR inheritance only compound heterozygous or homozygous 
variants were considered. 
We first considered genes known to cause disease in a recessive manner, by initially 
aiming to detect homozygous or compound heterozygous variants in an established hearing 
loss gene present in all individuals within the Finnish family. No homozygous, compound 
heterozygous or heterozygous alleles were detected. Relaxing our filtering to detect 
variants shared by only 4 of the 5 individuals (to account for potential false negatives with 
variant calling due to poor coverage or pipeline calling error), we again detected no 
homozygous or compound heterozygous variants shared between individuals, as also 
expected by the multigenerational phenotype seen within the family. We subsequently 
therefore considered a dominant model, detecting a heterozygous variant in MYO6 
(c.3755A>G, p.1252C) in 4 of 5 individuals in the family (Table 4.15). This variant was 
then sequenced by Sanger sequencing in affected and unaffected individuals from the 
Finnish family, but did not segregate with disease (3 affected individuals, IV-7 (B), IV-2 
(B) and IV-2 (A), were confirmed have the wild-type allele, Table 4.15, 4.17, 4.18 and see 
Figure 4.4). On this basis, it was concluded that there was no established rare genetically 
determined form of deafness causing disease within the family. 
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Figure 4.3. Hypothesis 1; variant filtering workflow. All variants were iteratively filtered 
using defined criteria as discussed in the text above to attempt to identify rare, deleterious variants 
shared by at least 4 of 5 familial cases in known autosomal recessive (AR) hearing loss genes (ii) 
variants shared by at least 4 of 5 familial cases in known autosomal dominant (AD) hearing loss 
genes (iii) variants in known AR hearing loss genes in discrete sporadic cases (iv) variants in 
known AD hearing loss genes in discrete sporadic cases. 
Hypothesis (1b) sought to determine whether any of the sporadic cases also had a 
previously established genetically determined cause of deafness. Each of the Spanish cases 
was considered as a discrete case and examined for deleterious heterozygous or 
homozygous/compound heterozygous variants for AD and AR hearing loss genes 
respectively. No variants passing the iterative filtering steps were found in genes 
associated with autosomal dominant hearing loss. In contrast, when assessing genes 
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associated with an AR inheritance model, one individual (DF40) possessed a compound 
heterozygous variant LOXHD1 c.1894 G>T, p.G632C, and LOXHD1 c.1876G>T 
p.G626C, Table 4.15 and Figure 4.4. However, on closer analysis these variants were 
considered ‘likely benign’ under ACMG guidelines due to an allele frequency greater than 
is expected for the associated hearing loss (ExAC frequency = 2.512% for both variants). 
In addition, LOXHD1 variants have only been reported to be causally linked to hearing 
loss in 4 families worldwide (Grillet, Schwander et al. 2009, Edvardson, Jalas et al. 2011, 
Mori, Moteki et al. 2015) and have not been detected as a cause of deafness in several 
other large studies (Bademci, Foster Ii et al. 2016, Jung, Lee et al. 2017). 
When taken together, these data are consistent with the conclusion that the sporadic cases, 




Table 4.15. Annotation for variants identified in known hearing loss genes in familial and sporadic cases after iterative filtering as shown in 
Figure 4.3. Ch = chromosome, SIFT, PolyPhen2, 1000 genomes project, ExAC – as discussed in Section 2.3.14. 
Familial cases 













































1 44157764 C A LOXHD1 c.1894G>T p.G632C Missense - Probably 
Damaging 
1.238 2.512 






Figure 4.4. Confirmatory Sanger sequencing electropherograms of LOXHD1 and MYO6 
variants. (i) LOXHD1 variants present in individual DF40 and (ii) MYO6 c.3755A>G variant, that 
did not segregate with the phenotype in the Finnish family (sequencing result of individual III-9 
(left panel) and IV-4A (right panel) representing variant and wild type sequence respectively). 
An additional analysis to screen the five genes that have previously been suggested as 
modifiers of the m.1555A>G phenotype (Table 4.8) was also undertaken using filters (i)-
(iii) as previously defined, followed by manual cross-referencing of the remaining variants 
using a gene list compiled from genes in Table 4.8. This revealed that there were no 
shared rare, deleterious variants in these genes in either the familial or sporadic cases. 
Of note, we specifically searched for a recently characterised variant in TRMU c.28G>T 
p.A10S, that occurs at a MAF significantly in excess of our threshold (ExAC frequency= 
19.7%) (Meng, Cang et al. 2017). This allele was present in 2 of 5 exomes from the 
Finnish family (IV-4 (A) and IV-2 (B), Table 4.16 (i)) and one of the exome sequenced 
Spanish individuals (DF95) but also 2/8 normal hearing controls, consistent with the MAF 
in reference databases. Further Sanger sequencing of affected and unaffected individuals 
from the Finnish family confirmed the variant was found in both hearing impaired (4/10, 
40%) and normal hearing (2/5, 40%) individuals in the Finnish family and hence cannot 
account for the variable penetrance of m.1555A>G in our patients (Table 4.16 (ii)). 
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Table 4.16. Results of TRMU c.28G>T sequencing. (i) Exome sequencing and confirmatory 
Sanger sequencing (ii) segregation analysis by Sanger sequencing in affected and unaffected 
individuals in the Finnish family. 
(i) 
 Exome sequencing Sanger sequencing 








TRMU wt wt wt het het wt wt wt het het 
(ii) 
 Affected Unaffected 


















TRMU wt het wt wt het het wt wt het wt 
 
4.3.2.1.2! Hypothesis 2 
A single, rare, nuclear variant within the exome segregates with the phenotype in the 
Finnish family. 
Between all individuals within the Finnish family (n=5), 110875 variants in 15883 genes 
were detected across the whole exome. Four filters were subsequently applied to this data 
(i) confidence filter (ii) frequency filter (iii) predicted deleterious filter (iv) genetic filter. 
The confidence and predicted deleterious filters were used as described in Section 
2.3.14.2, and variants with a MAF <1% in the 1000 Genome Project or the ExAC 
databases were selected. 
The genetic filter was used to further filter variants on the suspected mode of inheritance, 
assumed to be AD based on the segregation of hearing impairment across multiple 
generations within the family. We also considered an X-linked dominant model due to the 
absence of any male-male transmission in the pedigree. Subsequently, only heterozygous 
or hemizygous variants present in at least 4 of the 5 patients and absent in control cases 
(n=8) were included in further analysis. After this filtering strategy, 10 variants in 10 genes 
were present in all affected individuals in the Finnish family; see Figure 4.5 and Table 
4.17. Confirmatory Sanger sequencing was then performed on all variants and the results 
for each exome sequenced individual are shown in Table 4.18. 
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Figure 4.5. Hypothesis 2; variant filtering workflow. All variants were iteratively filtered 
using defined criteria as discussed above to attempt to identify rare, deleterious variants shared by 
at least 4 of 5 familial cases. 
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Table 4.17. Annotation of all variants seen that were shared between at least 4 of the 5 individuals within the Finnish cohort. Iterative filtering was 
performed as shown in Figure 4.5. Ch = chromosome, freq = frequency, SIFT, PolyPhen2, 1000 genomes project, ExAC – as discussed in Section 2.3.14. 














freq ExAc freq 
1 89733172 A T GBP5 c.356C>T p.A119V Missense Damaging Possibly 
Damaging 
0.1 0.36 
1 98144726 T C DPYD c.775A>G p.K259E Missense Damaging Benign 0.439 1.022 
3 52860854 C T ITIH4 c.472G>A p.E158K Missense Damaging Probably 
Damaging 
0.02 0.017 
7 141438969 G A SSBP1 c.3G>A p.M1? Start Loss Damaging Benign - 0.003 
7 141736753 C T MGAM c.2207C>T p.T736M Missense Damaging Probably 
Damaging 
- 0.007 
14 23313633 G A MMP14 c.1065G>A p.M355I Missense Damaging Benign 0.559 1.811 
























Missense - Probably 
Damaging 
0.359 0.535 













Table 4.18. Exome sequencing and confirmatory Sanger sequencing results of all patients 
possessing one of the variants listed in Table 4.17. het = heterozygous, wt = wild type. 
 Exome sequencing Sanger sequencing 
Gene II-8 III-6 III-10 IV-4 (A) 
IV-2 





GBP5 het het het het wt het het het het wt 
DPYD het het het het wt het het het het wt 
ITIH4 het het het wt het het het het wt het 
SSBP1 wt het het het het wt het het het het 
MGAM wt het het het het wt het het het het 
MMP14 het het het het het het het het het het 
CCDC13 wt het het het het wt het het het het 
VPS33B wt het het het het wt het het het het 
MYO6 het het het het wt het het het het wt 
SMG7 het het het het wt het het het het wt 
Table 4.19. Results of segregation analysis by Sanger sequencing. SSBP1 and MGAM 
(highlighted in purple) were heterozygous in those affecteds (except II-8, discussed below) and 
wild type in all those unaffected. n.d = not determined. 
 Affected Unaffected 

















GBP5 wt het het wt wt wt wt het het wt 
DPYD wt wt het het het het het wt wt wt 
ITIH4 het wt wt het wt het wt het wt het 
SSBP1 het het het het het wt wt wt wt wt 
MGAM het het het het het wt wt wt wt wt 
MMP14 het wt wt wt het wt het wt het wt 
CCDC136 wt wt het wt het het het wt wt het 
VPS33B het wt wt het wt wt wt n.d wt het 
MYO6 het wt wt het het wt wt het het n.d 
SMG7 het n.d wt n.d wt n.d het het n.d wt 
 
Sanger sequencing confirmed all 50 (100%) of the exome sequence results of the 10 variants 
of interest (Table 4.18) indicating there were no false positives and no false negatives due to 
missing coverage. To confirm segregation of the variants with hearing loss in the Finnish 
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family, an additional 5 affected and unaffected individuals were selected and Sanger 
sequencing of the variants was performed. This revealed that the c.3G>A SSBP1 and 
c.2207C>T MGAM variants segregated with the phenotype, being heterozygous in the affected 
individuals (n=5) and wild type in all unaffected individuals (n=5) (Table 4.19). The number 
of correctly attributed variants (either heterozygous for affected individuals or wild type for 
unaffected individuals, maximum = 10 correct) is represented for each gene in Figure 4.6. 
 
Figure 4.6. Bar graph representing the number of correctly attributed variants in the 
segregation analysis. c.3G>A SSBP1 and c.2207C>T MGAM variants were correctly attributed 
with the phenotype in 10/10 Sanger sequenced individuals. 
Of the variants in the two genes that segregated with the phenotype, the SSBP1 variant was 
considered the more likely candidate as a modifier variant and therefore the MGAM 
variant was not further analysed, but is discussed in Section 4.4. 
Given that the c.3G>A SSBP1 variant segregated with the phenotype in the 10 selected 
cases, further sequencing was performed for all individuals in generations II-IV where 
DNA was available (n=29). This revealed that the variant segregated with the phenotype 
within the whole family. As such, 15 of 16 affected individuals (93.8%) were confirmed to 
be heterozygous for the mutation, and 13/13 unaffected individuals, (100%) were wild 
type (Figure 4.7). Individual II-8 was the only case where the variant was not correctly 
attributed to the phenotype. Importantly, however, hearing loss in II-8 was diagnosed aged 
42 years whereas the remainder of the family were diagnosed with hearing loss in 











































hearing loss diagnosis in II-8 is >2 SD greater than mean of rest of family. This individual 




Figure 4.7. Segregation analysis of c.3G>A SSBP1 variant within the Finnish family. (A) 
Confirmatory Sanger sequencing electropherograms of SSBP1 variant. Sequencing of the SSBP1 
variant reveals segregation with the phenotype in the Finnish family (sequencing result of III-9, 
affected, and IV-3 (A), unaffected, reveals c.3G>A variant and wild type sequence respectively. (B) 
Finnish pedigree, sequencing result noted below each individual: G/G represents wild type alleles, 
A/G represents heterozygous variant. Symbols are as follows: yellow filled-, high frequency hearing 
loss; grey filled-, moderate progressive pan-frequency hearing loss; black filled profound pan-
frequency hearing loss; unfilled-, normal hearing, red star- exome sequenced individual (II-8, III-6, 
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4.3.2.1.3! Sanger sequencing of SSBP1 c.3G>A in children of fathers in generation III 
The members of the multi-generational Finnish family were originally identified and 
characterised by Professor Kari Majamaa, Oulu University, Finland (Lehtonen, Uimonen et 
al. 2000). As a clinical mitochondrial diagnosis, the initial phenotyping study focussed solely 
on the maternal lineage. Having identified the SSBP1 c.3G>A variant, we hypothesised that 
the children of the fathers in generation III would not carry m.1555A>G, given the strict 
maternal inheritance of mtDNA, but may carry the SSBP1 variant inherited from their fathers. 
Sanger sequencing of the SSBP1 in the children of III-6 (n=9, 2 male: 7 female) and of III-10 
(n= 6, 4 male: 2 female) revealed 10/15, (66.7%) were carriers of the SSBP1 c.3G>A variant 
but all carried the wild- type m.1555A allele (Figure 4.8). An investigation into the clinical 
history of these children revealed that school hearing tests indicated normal hearing in all 
individuals (personal communication, Dr Sanna Hakli, Oulu University, Finland). 
 
Figure 4.8. Sanger sequencing analysis of the c.3G>A SSBP1 variant in the children of 
III-6 (Family D) and III-10 (Family D). Sequencing results noted below each individual: G/G 
represents wild type alleles, A/G represents heterozygous variant. Symbols are as follows: black 
filled- profound pan-frequency hearing loss; unfilled-, normal hearing. 
4.3.2.1.4! Hypothesis 3 
There is a conserved genetic mechanism identified in the Finnish family that also causes 
disease in the sporadic Spanish cohort. 
Having identified the SSBP1 variant segregating with the phenotype in the Finnish family 
the read coverage and depth for all CCDS bases in SSBP1 was performed by Dr Helen 
Griffin (Newcastle University, UK) using SAMtools (Li, Handsaker et al. 2009). Custom 
Perl scripts were then used to calculate mean base depth across the exome and within the 
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genes of interest together with the percentage of bases covered above a depth of 30, 10, 5 
and 1 read depth. This revealed that the 100% of CCDS bases in SSBP1 were covered at 
10-fold read depth in all exome sequenced individuals (familial cases n=5, sporadic cases 
n=4), implying that pathogenic variants within this gene were unlikely to be missed as 
false negatives. Nevertheless, all coding exons of the SSBP1 gene (exon 2-7) were also 
Sanger sequenced in the 9 individuals in the Spanish cohort, confirming that no variants 
were present in any individual. 
Whilst no variants in SSBP1 were therefore seen in the sporadic cases, we subsequently 
sought to identify if a single rare, deleterious variant in another established mitochondrial 
replication protein (Table 4.9) was shared between all individuals. Further analysis of 16 
genes from the exome sequencing data of these individuals revealed there were no shared 
variants between all 4 or even 3 individuals within these genes, suggesting that no shared 
allele within mitochondrial DNA replication proteins was responsible for disease in the 
sporadic cases. 
4.3.2.1.5! Hypothesis 4 
A novel genetic variant(s) are responsible for disease within the Spanish sporadic cases. 
Having excluded the possibility of either a single variant, or multiple variants in an 
established hearing loss gene cause disease in the sporadic Spanish cases (Hypothesis 1b), we 
sought to determine whether a single mutation was present between all four individuals in a 
novel disease gene, which would be consistent with the hypothesis of a possible conserved 
single allele causing disease in all four individuals. The same filtering strategy as was used in 
Hypothesis 2 was employed. However, we did not find any rare, non-synonymous alleles 
with predicted pathogenicity that were shared between all four, or even three of the Spanish 
cases suggesting that was no shared genetic variant causing disease (Figure 4.10). 
An alternative hypothesis that a ‘burden’ of rare variants in a novel gene was responsible 
for the phenotype in the Spanish cases was also considered. Restricting the analysis to rare 
heterozygous mutations revealed no genes in which rare, deleterious variants were shared 
between more than 2 individuals (Figure 4.9). In order to generate some power 
calculations for the number of cases we would therefore require to detect a novel gene that 
may be associated with deafness in m.1555A>G carriers, we determined that we would 
require 42 carriers of m.1555A>G (assuming 50% carry a variant) and 42 controls to have 
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95% power to detect a 100% difference in allele frequency, or 287 affected and unaffected 
individuals to have a 95% power to detect a 50% difference in allele frequency (Faul, 
Erdfelder et al. 2009). Given that these cohorts are significantly larger than the samples 
available in this study, further investigations for a burden of mutations in sporadic cases 
was not undertaken, but is discussed in Section 4.4. 
 
Figure 4.9. Hypothesis 4 variant filtering workflow. All variants were iteratively filtered 
using defined criteria as discussed above to attempt to identify rare, deleterious variants shared by 
at least 3 of 4 Spanish sporadic cases. 
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4.3.3! Mitochondrial variants mediating disease risk 
An alternative mechanism by which the m.1555A>G variant may be associated with 
hearing loss in these individuals is through the co-association of a separate mtDNA variant 
acting with m.1555A>G in a synergistic or additive manner. In this instance it is also 
possible that the m.1555A>G variant is simply an ‘innocent bystander’, and the phenotype 
is dependent on the other mtDNA variant (Swalwell, Blakely et al. 2008). We deemed that 
this possibility was however unlikely, as patients were selected from 2 international 
collaborators that had screened for mitochondrial causes of deafness within their 
respective clinical laboratories. In both cases whole mitochondrial genome sequencing was 
performed, and m.1555A>G considered the only candidate for causing hearing loss 
(personal communication, Professor Julio Montoya and Professor Kari Majamaa). 
Table 4.20. mtDNA haplogroups of all exome sequenced individuals as determined by 
MITOMASTER and Phylotree analysis. SNP = single nucleotide polymorphism. 
Individual Haplogroup Haplogroup defining SNP 
Finnish family 
II-8 J1c m.295C>T, m.12612A>G, m.14798T>C 
III-6 J1c m.295C>T, m.12612A>G, m.14798T>C 
III-9 J1c m.295C>T, m.12612A>G, m.14798T>C 
IV-2 J1c m.295C>T, m.12612A>G, m.14798T>C 
Spanish cohort 
DF95 H1b m.12705T>C, m.14766T>C, m.10454 T>C 
DF178 U5b m.12308A>G, m.7768A>G 
DF40 H3q m.12705T>C, m.14766T>C, m.12236G>A 
DF39 U8a m.12308A>G, m.282T>C, m.6392T>C 
 
In order to determine whether the mtDNA haplogroup background may modify disease 
risk caused by the m.1555A>G variant, we used ‘off target’ mtDNA reads from each 
exome sequenced individual to assign the appropriate haplogroups using the 
MITOMASTER bioinformatic tool manually cross-referenced by Phylotree 
(www.phylotree.org) (Brandon, Ruiz-Pesini et al. 2009, van Oven and Kayser 2009). This 
confirmed all individuals were from European mtDNA haplogroups (Table 4.20). The 
Spanish cases were assigned to either Haplogroup H or U, haplogroups commonly found 
in the Iberian peninsula (Torroni, Huoponen et al. 1996). The Finnish family were 
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assigned to Haplogroup J1c, a haplogroup that has previously been suggested to modify 
the disease penetrance of the LHON mutation m.14484A>G (Hudson, Carelli et al. 2007). 
Although an interesting finding, given the haplogroup is shared between affected and 
unaffected family members it cannot be a causative factor in the variable penetrance of the 
phenotype in our patients. 
4.4! Discussion 
By exome sequencing of 5 individuals in a multi-generational Finnish family that 
transmitted the m.1555A>G variant along the maternal lineage but manifested a variable 
penetrance of hearing loss, we identified the heterozygous variant c.3G>A SSBP1. Exome 
sequencing results were confirmed by Sanger sequencing in each of these individuals and 
a further segregation analysis in the family determined the variant was correctly attributed 
to the phenotype in 28 of 29 individuals. SSBP1 encodes a mitochondrial protein; single 
stranded binding protein (SSBP1) that forms a core component of the mtDNA replisome 
machinery. Given the important role of SSBP1 in mitochondrial metabolism as discussed 
in Section 1.8.2.3 it was considered as the primary candidate to take forward for further 
analysis (presented in Chapter 5). 
Given that 28 individuals were found to segregate the SSBP1 variant with the phenotype, 
the odds that this mutation segregates with disease by chance are therefore <1x10-6 
(binomial test). Additionally, 10/15 of the children of III-6 and III-10 carry the SSBP1 
variant without the m.1555A>G variant and have normal hearing. Together, this evidence 
adds substantial weight to the conclusion that the SSBP1 variant is a strong candidate for a 
nuclear genetic modifier of the phenotype associated with the m.1555A>G variant but in 
isolation is not pathogenic. 
Incidentally, the c.2207C>T variant in MGAM was also found to segregate with the 
phenotype in the Finnish family. This gene encodes maltase-glucoamylase, a brush border 
membrane enzyme that functions in the digestion of starch (Sim, Quezada-Calvillo et al. 
2008). In keeping with its biological function, the protein is primarily expressed in the 
small intestine with low expression in the central nervous system (Genecards 2017). To 
date there are no reports in the literature linking MGAM variants and hearing loss, nor is it 
possible to envisage a potential mechanism whereby MGAM variants could cause hearing 
loss or modulate mitochondrial function. Given that SSBP1 and MGAM are separated by 
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297 Kb on chromosome 7, it is likely that the MGAM variant is a non-pathogenic SNP in 
linkage disequilibrium with the SSBP1 variant and that the two are inherited together 
within the family. Taken together, this evidence strongly suggests the SSBP1 variant is the 
more likely candidate modifier gene within the family. 
There was one individual, II-8, in whom the SSBP1 variant was found incorrectly 
attributed to the phenotype (II-8 is affected by hearing loss but carries the wild-type 
allele). However, in this individual, hearing loss was not diagnosed until 42 years of age 
and significantly, this individual was known to have experienced recurrent childhood ear 
infections (personal communication, Dr Sanna Hakli, Oulu University, Finland). While we 
accept that heterogeneity exists in mitochondrial deafness (Uimonen, Moilanen et al. 
2001), the significant difference in the age of onset of hearing loss in this individual 
compared to the rest of the family combined with the history of infections raises enough 
doubt that we consider alternative forms of deafness to be highly likely in this woman who 
was therefore removed from further analysis. This highlights the importance of ‘deep 
phenotyping’, the practice of precisely defining phenotypes to minimise the confounding 
effect of phenotypic heterogeneity in genetic studies to (Robinson 2012). 
A number of factors may account for the inability of our experimental strategy to identify 
causes of the hearing loss in the Spanish sporadic cases. Importantly, it is possible that 
there is no genetic cause to be found in the Spanish individuals whose hearing loss may be 
environmentally determined. Specifically, aminoglycosides are a recognised cause of 
hearing loss in carriers of m.1555A>G and remain widely used in Spain (Fernandez-
Martinez, Miro et al. 2015). We were unable to ascertain whether any of the Spanish 
cohort had been exposed to aminoglycosides and therefore we could not eliminate this as a 
potential confounding factor. 
Initially, we felt it important to exclude potential monogenic cases of hearing loss that may 
confound the lack of observed replication in the Spanish cases. Using established clinical 
gene lists we found no evidence that any individual in the Spanish cohort was likely to 
have an alternative, established genetically mediated form of deafness. However, we 
cannot exclude the possibility that the hearing loss in these individuals resulted from 
variants in hitherto uncharacterised genes physiologically linked to hearing. 
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Similarly, we aimed to identify whether a conserved pathological mechanism underpinned 
the hearing loss in both the Finnish and Spanish individuals. To this effect, we screened 
known genes coding for mtDNA replication proteins; however, we were unable to identify 
rare, deleterious shared variants in these genes. With this established, we aimed to detect 
the presence of causative variants in novel genes with only 4 samples, limited by power 
and reliant on a ‘founder mutation’. This was not the case. 
The c.3G>A SSBP1 variant is found in 4/120610 sequenced alleles in the ExAC database 
(3/6610 Finnish, 1/66404 European non-Finnish and 0/47596 non-European alleles) 
possibly indicating a founder effect within the Finnish population. Hence, given its rarity 
in the general population, it is unsurprising that the variant was specific to the Finnish 
family and we were therefore unable to detect this variant in the Spanish cohort. Given that 
the Spanish individuals are derived from a more genetically diverse population than the 
Finnish family, it is less likely that founder mutations will be identified in selected 
unrelated individuals as in our cohort. The identification of recurring alleles in an outbred 
population would therefore require a far larger sample size. 
Exome sequencing has a number of technical limitations to be considered in the context of 
the failure to identify a cause for the hearing loss in the Spanish cohort. Firstly, by 
definition, exome sequencing interrogates only the exonic component of the genome, and 
hence only covers ~ 2% of the genome (64 million / 3 billion bases) (Ng, Turner et al. 
2009). Although the vast majority of variants causing Mendelian disease are found in 
protein-coding sequences (Stenson, Mort et al. 2017), non-coding variants and epigenetic 
modifications are now realised to be causative for a number of diseases and hence may 
account for the hearing loss in some or all of the Spanish individuals (Spielmann and 
Mundlos 2016).  
Secondly, as only 1-2% of the human genome is comprised of protein coding sequences, 
exon-targeting capture is a necessary step in exome sequencing. The exon-capture probes 
are designed based on sequences in gene annotation databases. This creates an inherent 
bias, as exons which anneal well to capture probes are often easy to sequence in 
comparison to those with poor probe specificity, leading to the possibility of false negative 
variant calls. Thirdly, there is heterogeneity in the coverage of sequenced exons due to 
differences in base composition, for example GC-poor and GC-rich sequences may show 
biased PCR amplification compromising genome assembly (Chen, Liu et al. 2013). It is 
 140 
therefore possible that causative variants lie within regions that are not adequately covered 
by our exome sequencing. Additionally, we are unable to exclude the possibility that 
structural variation including copy number variations (CNVs) or chromosomal 
rearrangements may account for the hearing loss in a proportion of Spanish individuals. 
This class of genomic alterations has recently been shown to be causative for some forms 
of non-syndromic hearing loss (Shearer, Kolbe et al. 2014); however, detection of these 
changes by exome sequencing remains technically challenging (Hong, Singh et al. 2016). 
There are also a number of factors that may confound the analysis and filtering of exome 
data leading to the exclusion of causative variants. Firstly, disease-causing variants may 
have been incorrectly filtered, as pathogenic mutations are known to be included in public 
databases such as 1000 genomes, dbSNP and ExAC (Arthur, Cheung et al. 2015). 
Secondly, prediction of variant pathogenicity is reliant on the use of computational 
algorithms. There are numerous reports of the successful utilisation of in silico prediction 
programs to isolate causative pathogenic variants (Macia, Halbritter et al. 2017, Srour, 
Shimokawa et al. 2017); but their results also frequently disagree due to differences in 
their underlying algorithms (Leong, Stuckey et al. 2015). It is therefore recommended that 
pathogenicity prediction results should always be interpreted cautiously (Walters-Sen, 
Hashimoto et al. 2015). Interestingly, the c.3G>A variant in SSBP1 identified segregating 
in the Finnish family was defined as ‘pathogenic’ by SIFT but ‘benign’ by PolyPhen2. 
Further analysis of this variant using the alternate in silico prediction tools, MutationTaster 
(Schwarz, Rodelsperger et al. 2010) and LRT (Chun and Fay 2009), both suggested this 
variant was indeed pathogenic. This disparity between prediction tools is important as it 
highlights the converse possibility that causative variants may have been discarded in our 
analysis based on incorrect assignment as benign. 
Causative variants may also have been excluded if they occurred at a MAF above our cut-
off threshold. Setting a higher MAF threshold increases the number of variants remaining 
after iterative filtering, often producing an unmanageably large list of variants that cannot 
be further analysed and ultimately which must be classified variants of unknown 
significance. The setting of a MAF threshold is arbitrary, hence, MAFs may vary between 
databases (Manolio, Collins et al. 2009). This can lead to potential difficulties filtering 
variants predicated on a defined MAF threshold. 
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Another possibility is that each discrete Spanish individual carries a different disease 
causing nuclear variant, analogous to focussing our analysis on a single member of the 
Finnish family without the ability to perform segregation analysis. Furthermore, assigning 
pathogenicity to variants isolated in singleton cases is fraught with difficulty considering it 
has been estimated that the average healthy individual carries >400 damaging variants 
(Xue, Chen et al. 2012). 
It is possible that the individuals in the Spanish cohort carry different pathological variants 
in the same gene, a so-called ‘genetic burden’. However, obtaining the statistical power to 
ascertain whether there is an enrichment of causative variants in certain genes in cases 
versus controls requires large cohorts of carriers. As the cost of NGS technologies 
decreases it becomes increasingly feasible to construct large genetically and 
phenotypically characterised patient databases. One such database, The NIHR Bioresource 
(https://bioresource.nihr.ac.uk/) could potentially be used to find carriers of m.1555A>G 
both with and without hearing loss. Analysis of the exomes and whole genomes of these 
patients could potentially provide a powerful approach to define novel genetic modifier 
genes. 
In conclusion, the work presented in this chapter has demonstrated that exome sequencing 
coupled with segregation analysis is a powerful technique to identify nuclear genetic 
modifiers of mitochondrial diseases. Through our analysis we established the c.3G>A 
variant in SSBP1, that encodes a core component of the mitochondrial DNA replisome 
machinery, as a strong candidate accounting for the variable penetrance of hearing loss in 
the Finnish family. However, we were not able to demonstrate a conserved mechanism of 
hearing loss in the Spanish sporadic cases implying divergent mechanisms account for 
hearing loss in m.1555A>G carriers. The functional characterisation of the SSBP1 variant 




Characterising the functional effect of the SSBP1 variant 
5.1! Introduction 
The work presented in Chapter 4 detailed the use of exome sequencing in familial and 
sporadic carriers of the m.1555A>G variant in the 12S rRNA gene, MT-RNR1. This 
approach addressed the hypothesis that a nuclear genetic modifier accounted for the 
variable manifestation of hearing loss in carriers of this mtDNA variant. Our strategy 
identified the heterozygous variant c.3G>A in SSBP1 that segregated with hearing loss in a 
multi-generational Finnish family. To further elucidate the underlying pathological 
mechanism we studied primary and immortalised fibroblasts derived from (i) two 
individuals from the Finnish family carrying both the SSBP1 and m.1555A>G variants, (ii) 
a patient carrying m.1555A>G without any known nuclear genetic modifier of 
m.1555A>G and (iii) established laboratory controls from non-hearing impaired patients 
who do not carry the m.1555A>G variant. Our investigations centred on the determining 
whether the SSBP1 and m.1555A>G variants compromised their primary biological 
functions, specifically mtDNA maintenance and mitochondrial translation respectively. 
We also characterised the effect on mitochondrial respiration (OXPHOS), mitochondrial 
dynamics, oxidative stress and mitochondrial retrograde signalling pathways in our model, 
attempting to further clarify the downstream consequences of these variants. Additionally, 
we studied myoblasts and skeletal muscle biopsies derived from familial cases and age 
matched controls to gain insight into the mechanisms underpinning the tissue specific 
disease observations in our patients. 
5.2! Materials and methods 
5.2.1! Cell lines and skeletal muscle 
Primary fibroblast cell lines were established from (i) two individuals from the Finnish 
family (III-6, P1 and III-5, P2) carrying the c.3G>A SSBP1 and m.1555A>G variants, (ii) 
an unrelated individual carrying m.1555A>G alone (P3) identified from the Newcastle 
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Academic Health Partners Bioresource (Newcastle University, UK) (Table 5.1) and (iii) 
three control lines (C1–C3) (Table 5.2). Primary myoblast cell lines were established from 
III-6, (P1m) and III-5, (P2m). Immortalised fibroblast cell lines were established from III-
6 (P1i) and III-5 (P2i), P3 (P3i) and from C1 and C2 (C1i, C2i) as described in Section 
2.1.5 (Table 5.1 and Table 5.2). Skeletal muscle biopsies from individuals III-10 (P4) and 
III-8 (P5) were collected by Professor Kari Majamaa (Oulu University, Finland) (Table 
5.3). 
When presenting the results of the following experiments the term ‘patients’ refers to a 
group consisting of P1, P2 and P3. The results of individual cell lines are specified using 
the nomenclature presented in Table 5.1 and Table 5.2. 
For clarity, ‘SSBP1’ used in the text as an identifier refers to grouped P1 and P2 
fibroblasts/myoblasts or P4 and P5 skeletal muscle tissue, although it should be noted that 
these cells also carry the m.1555A>G variant. When appropriate, ‘m.1555A>G’ used as an 
identifier refers to P3 fibroblasts. 
Table 5.1. Clinical and genetic features of the patient derived fibroblast cell lines. I.D. = 














P1 P1i III-6 37 M P m.1555A>G SSBP1 c.3G>A 
P2 P2i III-5 36 F HF m.1555A>G SSBP1 c.3G>A 
P3 P3i n.a 28 M N m.1555A>G 
Table 5.2. Details of the control fibroblasts. ID. = identifier. Laboratory I.D denotes 
identifiers of established cell lines used in Professor Chinnery’s group; n.a = not applicable, -= 
unknown. 
Primary 
fibroblast I.D Laboratory I.D 
Immortalised 
fibroblast I.D Age (years) Sex (M/F) 
C1 F253 C1i - - 
C2 F153 C2i 23 F 
C3 F152 n.a 27 F 
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Table 5.3. Clinical and genetic details of skeletal muscle biopsies. P = profound pan-
frequency hearing loss, HF = high frequency hearing loss. 
Patient ID. Pedigree code Age (years) Sex (M/F) Clinical features Variant 
P4 III-10 38 M P 
m.1555A>G 
SSBP1 c.3G>A 




5.2.2! Genomic DNA extraction and Sanger sequencing 
Total genomic DNA was extracted from cultured fibroblasts, myoblast cells or skeletal 
muscle using the DNeasy® Blood & Tissue Kit (Qiagen) as described in Sections 2.3.1 
and 2.3.2. Sequencing of the c.3G>A SSBP1 variant was performed as described in 
Section 2.3.7 using primer pairs as shown in Table 4.11. Further bioinformatic analysis 
was undertaken using NCBI ORF Finder and Clustal Omega as described in Section 
2.3.14.2. Confirmation of the m.1555 A>G variant was performed by Sanger sequencing 
as described in Section 2.3.7. The primer pairs are detailed in Table 5.4. The sequencing 
results were analysed using SeqScape v2.6 comparing against the rCRS reference 
sequence (NCBI accession number NC_012920). 
Table 5.4. Primer sequences, annealing temperatures and mtDNA nucleotide position 














5.2.3! Protein analysis 
Western blot analysis was performed on 40 µg protein from total cell lysate extracted from 
harvested fibroblasts as described in Section 2.4.5. Specific proteins were detected using 
primary and secondary antibodies as detailed in Table 2.6. Normalisation of the 
densitometric quantification of a protein of interest was performed using GAPDH as 
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described in Section 2.4.5. Analysis of phosphorylated and total proteins by Western blot 
was undertaken by first probing with the antibody to the phosphorylated protein, stripping 
the membrane as described in Section 2.4.5, and then re-probing with the antibody specific 
to the total protein. Intra-mitochondrial de novo protein synthesis was measured by the in 
vivo mitochondrial translation assay as described in Section 2.4.9. The AMPK alpha 
SimpleStep ELISA and Phospho-AMPK-pT172 ELISA Kit were used to quantify total 
AMPK-A and phosphorylated AMPK-pT172 respectively as described in Sections 2.4.6 
and 2.4.7. These results were used to generate a ratio of Phospho-AMPK-pT172: total 
AMPK-A (AMPK-P:AMPK-A) as a marker of AMPK signalling activity. 
5.2.4! Skeletal muscle analysis 
Biopsy samples were snap frozen in liquid nitrogen and maintained at -80oC. Tissue 
preparation, sectioning and staining for (i) H&E and (ii) combined COX/SDH was 
performed as detailed in Section 2.2.1 Age matched control skeletal muscle biopsy 
samples were obtained from the Cambridge BioResource, Cambridge, UK. 
5.2.5! Long range polymerase chain reaction 
For the investigation of mtDNA deletions a fragment of approximately 16 kB (see Table 
2.1 for PCR product sizes) that encompasses almost the entire mitochondrial genome was 
amplified by long range PCR and visualised by agarose gel electrophoresis as described in 
Section 2.3.5. 
5.2.6! Analysis of mitochondrial 7S DNA 
Total cellular DNA was extracted by two sequential phenol-chloroform extractions with 
subsequent precipitation from fibroblast cell lines as described in Section 2.3.12.1. Five µg 
of total DNA was restricted using PvuII and run on a 0.6% agarose gel. Southern blotting 
using specific radiolabelled probes to 7S DNA (Probe A) and 28S was performed as 
described in Section 2.3.12.5. 
5.2.7! Mitochondrial repopulation assay 
The mitochondrial repopulation assay was undertaken as described in Section 2.3.13.1. 
Genomic DNA was isolated from individual fibroblast pellets was performed as described 
in Section 2.3.1. The mtDNA copy number was determined by performing the MT-
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ND1/B2M qPCR assay as described in Section 2.3.9. RLs were calculated as described in 
Section 2.3.13.2. The repopulation rate of each cell line was calculated by taking the 
gradient of a linear regression line of mtDNA copy number ratio treated:untreated (RL) in 
the repopulation phase. 
5.2.8! Quantitative real time polymerase chain reaction 
Relative mtDNA copy number was determined using the CFX96 C1000 Touch 
Thermocycler using either MT-ND1 (mitochondrial reference gene) and B2M (nuclear 
reference gene) or MT-CO3 (mitochondrial reference gene) and RNAseP (nuclear 
reference gene) as described in Section 2.3.9. Quantification of the expression of specific 
genes was carried out with qPCR using the TaqMan gene Expression Assay using cDNA 
synthesised from RNA extracted from primary fibroblasts as described in Section 2.3.10. 
Details of the Taqman Gene Expression Assays used in qPCR for gene expression analysis 
are shown in Tables 2.2 and 2.3. 
5.2.9! Analysis of mitochondrial bioenergetics and oxidative stress 
Cellular ROS were measured using the fluorescent cell permeant dye H2DCFDA. The 
Oxiselect TM Oxidative DNA Damage kit was used to measure 8-OHdG DNA 
modifications. Oxyblot™ Protein Oxidation Detection Kit was used to detected oxidative 
modification of the cellular proteome. Cellular respiration was assessed with the Seahorse 
XF96e extracellular flux analyser. Detailed methodology for these assays is described in 
Section 2.6. Cell growth was assessed by growing fibroblast cells with high glucose 
medium vs glucose-free medium supplemented with 5mM galactose using IncuCyte® Live 
Cell imager as described in Section 2.1.6. Cell doubling times were calculated by 
nonlinear regression using an exponential growth equation in Graphpad v7 (Graphpad 
statistical software). 
5.2.10! Mitochondrial network and nucleoid analysis 
The mitochondrial network was analysed using live cell imaging as described in Section 
2.5.1. Images were processed with Image J and further morphological analysis was 
undertaken with Huygens Essentials software as described in Section 2.5.2. Mitochondrial 
nucleoids were analysed by immunocytochemistry and confocal microscopy as described 
in Section 2.5.5 
 148 
5.2.11! Heat shock response assay 
For the heat shock response assay primary fibroblasts were either maintained at 37ºC or 
treated with heat shock at 42ºC for 1 hour and allowed to recover at 37ºC for 4 hours. 
Western blot analysis was then performed using antibodies to HSP60, HSP70 and BiP as 
described in Section 2.4.8. The densitometric quantification of HSP60, HSP70 and BiP at 
steady state (pS) and after heat shock (pHS) was used to calculate a protein induction fold 
change defined as pS:pHS. 
5.3! Results 
5.3.1! Confirmatory Sanger sequencing of SSBP1 and m.1555A>G variants 
Sanger sequencing of DNA extracted from primary and immortalised fibroblasts from P1 
and P2 confirmed the presence of the heterozygous c.3G>A SSBP1 and m.1555A>G 
variants which were absent in control cells (Figure 5.1). Sanger sequencing of DNA 
extracted from primary and immortalised fibroblasts from P3 confirmed the presence of 
m.1555A>G and wild type SSBP1 (Figure 5.1). 
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Figure 5.1. Confirmatory Sanger sequencing electropherograms of m.1555A>G and 
SSBP1 variants. Sequencing traces are representative of results from DNA extracted from primary 
and immortalised patient and control fibroblasts. 
5.3.2! Genetic effect of the c.3G>A SSBP1 variant 
The c.3G>A variant is situated in the first coding exon (exon 2) of the SSBP1 gene. The 
variant is predicted to cause a loss of the third base of the primary start codon ATG coding 
for methionine and result in the loss of protein translation from one allele (Figure 5.2 A). 
Consistent with the critical role the start site methionine plays in translation initiation, an 
evolutionary analysis demonstrated complete invariance of the residue across species 
(Figure 5.2 B). Using the NCBI ORF Finder tool, a single alternative out of frame 
translation start site is found downstream of the canonical start site at codon 16. Activation 
of this downstream start codon creates a new reading frame and introduces a stop codon at 
codon 30. This is predicted to produce a truncated protein of 14 amino acids lacking the 




Figure 5.2. Genomic structure of SSBP1 gene and multiple sequence alignment of the 
SSBP1 protein.  (A) SSBP1 exons marked 1–7, exon 1 is a non-coding exon. Location of c.3G>A 
variant in exon 2 causing translation start loss mutation marked and resulting in an effective null 
allele. The wild-type allele (represented as the maternal allele) is unaffected and produces a normal 
protein product. MTS = mitochondrial targeting sequence, SSB domain = single stranded binding 
domain. (B) Multiple sequence alignment of SSBP1 across evolutionarily diverse species 













5.3.3! SSBP1 protein expression in fibroblasts 
On the basis on the evidence presented in Section 5.3.2 we evaluated the effect of the 
SSBP1 variant on SSBP1 protein expression by Western blot analysis in primary and 
immortalised fibroblasts from patient and control fibroblasts. This revealed the SSBP1 
protein was reduced to approximately 20% of control levels in P1 and P2 fibroblasts 
whereas there was no significant difference in the expression of SSBP1 between P3 and 
controls (Figure 5.3). 
 
Figure 5.3. SSBP1 protein analysis in patient and control fibroblasts. (A) Western blot 
analysis of SSBP1 in primary patient (P1–P3) and control fibroblast cell lines (C1–3). Image 
representative of 3 independent experiments. Western blot analysis results were comparable in 
immortalised fibroblasts. (B) Densitometric quantification of SSBP1 normalised to GAPDH for 
primary fibroblasts. P1=0.24±0.23, P2=0.22±0.1, P3=0.66±0.09, Controls=1.0±0.30. Data 
represents mean normalised SSBP1±SD of 3 independent experiments, **p<0.01 (one way 
ANOVA with post hoc Tukey test). 
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5.3.4! SSBP1 gene expression in fibroblasts 
To determine whether the SSBP1 variant affected gene transcription, the levels of mRNA 
expression of SSBP1 in patient (P1–P3) and control (C1–C3) primary fibroblasts was 
measured using the Taqman® Gene Expression Assay, observing no significant difference 
between patient and control cells (Figure 5.4). 
 
Figure 5.4. SSBP1 mRNA expression in patient and control fibroblasts. mRNA expression 
of SSBP1 in patient (P1–P3) and control (C1–C3) primary fibroblasts measured by the Taqman® 
Gene Expression Assay. For data normalisation GAPDH was used as an endogenous housekeeping 
gene. Normalisation of Ct values and determination of gene expression was calculated using the 
2−deltaCt (2−ΔCt) method. P1=0.005±0.0005, P2=0.006±0.003, P3=0.008±0.004, 
Controls=0.006±0.002. Data represents mean 2−ΔCt ±SD of 3 biological replicates. No results were 















5.3.5! Analysis of SSBP1 skeletal muscle biopsy 
5.3.5.1! Muscle Histochemistry 
Mutations in mtDNA or nuclear genes encoding mitochondrial proteins often present with 
deficiencies of the respiratory chain (Gorman, Chinnery et al. 2016). Mitochondrial 
histochemistry provides a reliable method to detect the resulting OXPHOS dysfunction in 
tissue biopsies (Section 2.2.1) (Taylor, Schaefer et al. 2004). H&E staining of skeletal 
muscle sections from P5 were unremarkable with no evidence of necrosis, centralised 
nuclei or inflammatory infiltrates. Sequential COX/SDH staining, however, revealed 
evidence of a respiratory chain deficiency with a low number of COX-negative and COX 
intermediate fibres estimated at 5/174 fibres (3.4%, Figure 5.5). 
 
 
Figure 5.5. Mitochondrial histochemistry of SSBP1 skeletal muscle biopsy (patient P5). 
Sequential COX/SDH staining reveals the presence of COX negative fibres (blue fibres marked by 
yellow arrows) and COX intermediate fibres (partially blue fibre marked by blue arrow). H&E 
staining reveals fibre size variation within normal limits. Scale bars=100 µm. 
  
 154 
5.3.5.2! Long-range PCR analysis SSBP1 skeletal muscle DNA 
Mutations in mtDNA maintenance genes are typically associated with mtDNA deletions 
and copy number depletion (Viscomi and Zeviani 2017). Long-range PCR amplification of 
total genomic DNA obtained from SSBP1 skeletal muscle homogenate revealed the 




Figure 5.6. Long-range PCR analysis for mtDNA deletions in SSBP1 and control skeletal 
muscle biopsies. Agarose gel (0.7%) revealing mtDNA deletions in total genomic DNA isolated 
from skeletal muscle homogenate of P4 and P5. Lane 1 = GeneRuler 1Kb DNA Ladder, Lane 2 = 
P4, Lane 3 = P5, Lane 4 = age-matched control. 
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5.3.5.3! Analysis of mtDNA copy number in SSBP1 muscle DNA 
Given the critical role of SSBP1 in mtDNA replication, we determined mtDNA copy 
number from SSBP1 and control skeletal muscle DNA using real time PCR Taqman® 
assays targeting MT-CO3 and RNAseP. This revealed muscle mtDNA copy number was 
reduced in P4 and P5 to approximately 40% of age-matched control level (Figure 5.7). 
 
Figure 5.7. mtDNA copy number analysis in SSBP1 and control skeletal muscle. mtDNA 
copy number as determined by qPCR targeting MT-CO3 and RNAseP in P4, P5 and controls. 
P4=35.8±4, P5=36.5±13.3 % of age-matched controls (n=2). Data represents mean mtDNA copy 
number±SD of 2 independent determinations, *p <0.05 (one way ANOVA with post hoc Tukey test). 
5.3.6! Analysis of mtDNA copy number analysis in fibroblasts 
The mtDNA copy number was determined from patient (P1–P3) and control (C1–C3) 
primary fibroblast cell DNA using real time PCR Taqman® assays targeting MT-ND1 and 
B2M. This revealed no significant difference between any of the cell lines (Figure 5.8 A). 
Western blot analysis of patient (P1–P3) and control (C1–C3) fibroblasts revealed no 
difference in steady state TFAM expression, consistent with the lack of difference in the 



















Figure 5.8. mtDNA copy number analysis in patient and control fibroblasts. (A) Total 
mtDNA copy number of patient (P1–P3) and control (C1–C3) primary fibroblasts analysed by MT-
ND1/B2M singleplex Taqman real time PCR. P1=158.3±11.9, P2=164.7±8.5, P3=128±18.3, 
Controls=185.8±73.6 Data represents mean mtDNA copy number±SD of 3 biological replicates. No 
results were significantly different (one way ANOVA). (B) Western blot analysis of TFAM in 
primary fibroblasts shows no difference in patients (P1–P3) and controls (C1–C3). Image 
representative of 2 independent experiments. 
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5.3.7! Analysis of mtDNA copy number analysis in blood 
The mtDNA copy number was determined from total blood DNA in individuals carrying 
the SSBP1 variant (n=8) and wild type SSBP1 (n=9) from the Finnish family, using real 
time PCR Taqman® assays targeting MT-ND1 and B2M. This revealed no significant 
difference between the two groups (Figure 5.9). 
 
Figure 5.9. mtDNA copy number analysis in blood from individuals in the Finnish family. 
Carriers of SSBP1 variant (SSBP+/-) and carriers of wild type SSBP1 (SSBP1+/+) are compared. 
SSBP1+/-=62.4±13.7, SSBP1+/+=70.4±13.4. Data represents mean mtDNA copy number±SD with 




























5.3.8! Long-range PCR analysis of myoblast and fibroblast DNA 
Long-range PCR amplification of total genomic DNA revealed no mtDNA deletions in 
patient myoblasts (P1m, P2m) or fibroblasts (P1–P3) (Figure 5.10). 
 
 
Figure 5.10. Agarose gel of long-range PCR amplified total genomic DNA from myoblasts 
and fibroblasts. (A) Myoblasts from patients (P1m, P2m) and a (+) positive deletion control. (B) 
Fibroblasts from patients (P1–P3) and controls (C1–C3) and a (+) positive deletion control. In both 
gels (-) represents a negative DNA control and L represents GeneRuler 1 Kb ladder. No evidence 
of mtDNA deletions in patients or controls was detected in either cell type. Primer pairs as 
indicated: 16F and 16R, D2F and D1R. 
5.3.9! Analysis of 7S DNA in fibroblasts 
Given the role of SSBP1 in the synthesis and regulation of the mitochondrial D-loop, we 
investigated the effect of the SSBP1 variant on the abundance of the D-loop third strand, 
7S DNA, using Southern blotting in immortalised patient (P1i–Pi3) and control (C1i) 
fibroblasts (Takamatsu, Umeda et al. 2002). A radiolabeled probe was used that detected 
both a 6.4 kb fragment of mtDNA including the complete NCR and 7S DNA (Figure 
5.11). 7S DNA levels normalised to full-length mtDNA were significantly reduced in P1i 
and P2i compared to P3i and control. There was no difference in the level of full-length 
mtDNA relative to nuclear 28S DNA, indicating a lack of difference in mtDNA copy 
number in P1i, P2i and P3i fibroblasts compared to controls (Figure 5.12). 
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Figure 5.11. Southern blot analysis of 7S and total mtDNA in patient and control 
fibroblasts. 3µg total DNA from patient (P1i–P3i) and control (C1i) fibroblasts was digested with 
PvuII and analysed by one dimensional Southern blot. Hybridisation was performed with Probe A 
which detects both genomic mtDNA and 7S DNA. Hybridisation of probe to the 28S DNA was 
used as a loading control. Image representative of 3 independent experiments. 
 
Figure 5.12. Quantification of 7S and total mtDNA in patient and control fibroblasts. (A) 
7S DNA levels normalised to genomic mtDNA levels, P1=49.1±16.7, P2=41.6±8.1, P3=90.6±10.8. 
Data represents mean % of control±SD of 3 independent experiments *p<0.05, **p<0.01 (one way 
ANOVA with post hoc Tukey test) (B) Full length mtDNA normalized to 28S DNA levels. 
mtDNA levels P1=88.72±18, P2=106.3.6±30.8, P3=90.3±19.7. Data represents mean % of 
control±SD of 3 independent experiments, no significant difference detected between groups (one 
way ANOVA). 
5.3.10! Mitochondrial repopulation assay 
A mitochondrial repopulation assay was undertaken in order to determine the effect of the 
SSBP1 and m.1555A>G variants on the efficiency of mtDNA replication. Fibroblasts from 
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allowed to repopulate their mtDNA copy number by removal of EtBr from the culture 
medium. EtBr has been shown to interfere with mtDNA replication reducing superhelical 
density as well as inhibiting mitochondrial protein and RNA synthesis without affecting 
nuclear DNA (Leibowitz 1971). The effect of EtBr is reversible and hence on removal of 
the compound, mtDNA replication reactivates and copy number increases. The rate of 
mtDNA copy number repopulation is thus an indicator of mtDNA replication efficiency. 
In parallel, each cell line was also cultured in medium without EtBr to control for 
fluctuations in copy number during cell culture. 
5.3.10.1! Optimisation of protocol for mitochondrial repopulation assay 
Optimisation of the mitochondrial repopulation assay was undertaken to determine (i) the 
duration of EtBr exposure required by fibroblasts to depopulate mtDNA copy number and 
(ii) to gain further insight into the subsequent repopulation kinetics. The mtDNA depletion 
and repopulation curves are constructed from the RLs calculated at each time point 
(Figure 5.13). After commencing treatment with EtBr (day 0) there was a decrease in 
mtDNA copy number in all fibroblast cell lines by Day 6. EtBr was then withdrawn from 
the medium at day 15. Following this, mtDNA copy number remained depleted in all cell 
lines until day 29. Continued repopulation was only seen in P1 cell line at day 36, with all 
other cell lines showing a decrease in mtDNA copy number. It was noticed that addition of 
EtBr to the medium progressively decreased cell viability over the course of depopulation 
phase and hence continuation of the experiment after day 36 was not possible. 
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Figure 5.13. Optimisation of mitochondrial repopulation assay. Fibroblasts from patient (P1, 
P2) and control (C1, C2) were grown in supplemented high glucose DMEM medium and were 
depleted of mtDNA by treatment with EtBr for 15 days then allowed to repopulate. Each data point 
represents the mtDNA copy number treated:untreated from the single optimisation experiment. 
Error bars represent SDs of triplicate qPCR measurement. RLs for each time point are presented in 
Appendix 2. 
5.3.10.2! Modified protocol for mitochondrial repopulation assay 
Given that 15 days’ of exposure to EtBr reduced cell viability, it was not possible to 
observe sustained mtDNA repopulation in any of the cell lines. Therefore, we employed a 
modified protocol using 4 days’ exposure to EtBr followed by a 6-day period of 
repopulation. The mtDNA repopulation curves of the individual cell lines are presented in 
Figure 5.14. Each individual cell line was then compared to control cell lines (mean of C1, 
C2), presented in Figure 5.15, Figure 5.16 and Figure 5.17. 
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This revealed patient cells (P1–P3) had a trend towards higher RLs at each time point in 
the repopulation phase, although this difference only reached statistical significant at day 8 
in P1 and P3. A closer analysis was performed by calculation of a repopulation rate 
defined as the gradient of a regression line of RLs plotted against time in the repopulation 
phase (day 6 to day 10). This revealed that repopulation rate of P1 and P2 was 
approximately double that of P3 and controls (Figure 5.18). 
Attempting to perform the modified protocol using glucose-free medium supplemented 
with 5 mM galactose resulted in massive cell death of P1 and P2 cell lines and less marked 
death of P3 and control cells. Given the reduction in cell viability under these conditions it 
was not possible to continue with this experimental paradigm. 
 
 
Figure 5.14. Modified mitochondrial repopulation assay. mtDNA repopulation curves for 
individual patient (P1 –P3) and control lines (C1, C2). Data points represent the mean mtDNA 
copy number treated:untreated (RL)±SD from 3 independent experiments. The RLs of individual 
cell lines are presented in Appendix 2. 



































Figure 5.15. mtDNA repopulation curve for P1 and control. The data points represent the 
mean mtDNA copy number treated:untreated (RL)±SD from 3 independent experiments. No 
difference was detected between P1 and control at any time point except day 8, day 8 RL 
P1=1.11±0.03 vs Control= 0.538±0.05 p <0.01 (unpaired t-test, p-value uncorrected). The RLs of 





Figure 5.16. mtDNA repopulation curve for P2 and control. The data points represent the 
mean copy number treated:untreated (RL)±SD from 3 independent experiments. The difference 
between P2 and control was not significant at any time point (unpaired t-tests). The RLs of 




Figure 5.17. mtDNA repopulation curve for P3 and control. The data points represent the 
mean copy number treated:untreated (RL)±SD from 3 independent experiments. The difference 
between P3 and control was not significant at any time point except day 8; day 8 RL 
P3=1.106±0.113 vs Control= 0.538±0.05, p <0.0001 (unpaired t-test, p-value uncorrected). The 





Figure 5.18. Calculation of mtDNA repopulation rate. (A) Representative analysis of the 
mtDNA repopulation rate. The repopulation rate was calculated by taking the gradient of 
regression line of mtDNA copy number ratio treated:untreated (RL) in the repopulation phase (day 
6 to day 10). (B) Repopulation rates of patient (P1–P3) and control cell lines (purple symbols 
represent C1, grey symbols represent C2). Each data point represents the calculated repopulation 
rate from 1 of 3 independent experiments. Data reveal a trend towards an increased repopulation 
rate of P1 and P2 compared to P3 and controls, P1=2.06±0.09, P2=2.34±1.29, P3=1.37±0.72, fold 
change of mean repopulation rate±SD vs control from 3 independent experiments. Difference 
between groups not significant (one way ANOVA). 
5.3.11! Analysis of mitochondrial respiration in fibroblasts 
It was next important to determine whether the SSBP1 and m.1555A>G variants 
compromised the mitochondrial respiratory chain function in fibroblasts concordant with 
their effect in skeletal muscle. To this effect, the OCR was measured in patient (P1–P3) 




Analyzer (Figure 5.19). OCR was determined at basal state and after the addition of 
mitochondrial inhibitors enabling the determination of (i) endogenous respiration (ii) 
maximal respiration and (iii) proton leak respiration. There was no significant difference in 
these parameters between patient cells and control cells, however patient fibroblasts 
showed a trend towards decreased maximal respiration, although this did not reach 
statistical significance (Figure 5.20). 
 
Figure 5.19. Example of Seahorse analysis of mitochondrial respiration in patient and 
control fibroblasts. Mitochondrial respiration was assayed in fibroblasts from patients (P1–P3) 
and controls (C1–C3, mean of 3 controls shown) by measuring OCR (pmol O2/min/mg protein) 
























































Figure 5.20. Determination of key parameters of mitochondrial respiration in patient and 
control fibroblasts by Seahorse analysis. Different aspects of mitochondrial respiration were 
measured using the Seahorse XF96e extracellular flux analyser by determination of the OCR after 
sequential addition of metabolic inhibitors. (A) Endogenous respiration = basal OCR – non 
mitochondrial OCR P1=39.5±10.0, P2=49.5±11.9, P3=43.8±10.5, Controls=43.5±13.0 (B) 
Maximal respiration = maximal OCR – non mitochondrial OCR P1=51.6±19.9, P2=59.2±13.9, 
P3=54.9±25.6, Controls=75.6±28.0. (C) Proton leak respiration = post oligomycin OCR – non 
mitochondrial respiration P1=7.3±4.0, P2=9.9±7.0, P3=5.0±2.3, Controls=6.4±5.2. Data 
represents mean pmol oxygen/min/mg protein±SD of 4 independent experiments. There was no 
statistical difference in any aspect of mitochondrial respiration between the groups (one-way 
ANOVA). 
5.3.12! Analysis of fibroblast cell growth 
A functioning mitochondrial respiratory chain is a prerequisite for efficient cellular 
proliferation (Birsoy, Wang et al. 2015). Cellular growth rates were therefore determined 
in immortalised fibroblasts from patients (P1i-Pi3) and controls (C1i and C2i) grown in 
glucose and glucose-free medium supplemented with 5 mM galactose. Culture medium 
containing galactose as the major carbon source does not facilitate anaerobic glycolysis 












































































et al. 1992). Under these conditions of enhanced mitochondrial metabolism, P1i, P2i and 
P3i cells had significantly greater doubling times than controls (Figure 5.21 and Figure 
5.22). 
 
Figure 5.21. Cellular growth curve analysis of patient and control immortalised 
fibroblasts. Cellular growth curves of patient (P1i–P3i) and control fibroblasts (C1i and C2i; C1i 
shown as representative of both control lines) on glucose (green line) and glucose free medium 
supplemented with 5 mM galactose (red line). Graphs represent cell confluency (%) vs time 
(hours). Data representative of 3 independent experiments. 
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Figure 5.22. Quantification of doubling time (DT) of patient and control immortalised 
fibroblasts. DT of patient (P1i–P3i) and controls (C1i and C2i) in galactose medium normalized to 
growth on glucose medium. P1i=2.16±0.31, P2i=1.99±0.41, P3i=1.95±0.199, Controls=1.15±0.2, 
mean DT±SD of 3 independent experiments, **p<0.01 (one way ANOVA with post hoc Tukey 
test). 
5.3.13! Analysis of intra-mitochondrial translation in fibroblasts 
The m.1555A>G variant is predicted to cause mitochondrial mRNA misreading leading to 
a reduction in translation efficiency (Hobbie, Bruell et al. 2008). To determine whether the 
m.1555A>G variant affected de novo mitochondrial protein synthesis, and whether this 
effect was compounded by the SSBP1 variant, an intra-mitochondrial translation assay was 
performed by the incorporation of 35S radiolabelled methionine. This revealed markedly 
reduced global mitochondrial protein synthesis in fibroblasts from patients (P1–P3) 


























Figure 5.23. Mitochondrial protein translation analysis in patient and control fibroblasts. 
Mitochondrial protein translation measured by incorporation of 35S methionine reveals a clear 
reduction of mitochondrial protein synthesis in patient fibroblasts (P1–P3) compared to controls 
(C1, C2). The characteristic bands of mitochondrial encoded proteins are annotated (ND2, ND6: 
NADH dehydrogenase subunit 2,6; CO1, CO2: mitochondrially encoded cytochrome c oxidase, I, 
II; CYB: mitochondrially encoded cytochrome b. Loading determined by TOMM20 Western blot. 
Image representative of 2 independent experiments. 
5.3.14! Analysis of steady state mitochondrial encoded proteins in fibroblasts 
Given the reduction in de novo protein synthesis, Western blot analysis of primary 
fibroblasts from patients (P1–P3) and controls (C1–C3) was used to determine the effect of 
the SSBP1 and m.1555A>G variants on the steady state expression of the mitochondrially 
encoded complex IV proteins, MT-CO1 and MT-CO2. There was a statistically significant 
reduction in MT-CO2 expression in P1, P2 and P3 compared to controls. Similarly, there 
was a trend towards a reduction in MT-CO1 expression in P1, P2 compared to P3 and 
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Figure 5.24. Western blot analysis of mitochondrial encoded proteins in patient and 
control fibroblasts. (A) Western blot analysis of mitochondrial encoded MT-CO1 and MT-CO2 
proteins in primary fibroblasts from patients (P1–P3) and controls (C1–C3). Images representative 
of 3 independent experiments (B) Densitometric quantification of MT-CO1 and MT-CO2 
normalised to GAPDH. MT-CO2 (P1=0.19±0.13, P2=0.18±0.02, P3=0.37±0.07, 
Controls=1.02±0.31, MT-CO1 (P1=0.92±0.53, P2=1.2±0.33, P3=1.9±0.9, Controls=2.1±0.82). 
Data represents mean normalised MT-CO1 or MT-CO2 levels±SD of 3 independent experiments, 
**p<0.01 (one way ANOVA with post hoc Tukey test). 
5.3.15! Analysis of steady state nuclear encoded mitochondrial proteins in fibroblasts 
Western blot analysis of primary fibroblasts from patients (P1–P3) and controls (C1–C3) 
was used to determine the effect of the SSBP1 and m.1555A>G variants on the steady state 
expression of nuclear encoded mitochondrial proteins. This revealed no statistically 
significant difference in the expression of ATP5A (F1F0 ATP synthase, Complex V 
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subunit) or SDHA (succinate dehydrogenase, Complex II subunit) in P1, P2 and P3 
compared to controls (Figure 5.25). 
 
Figure 5.25. Western blot analysis of nuclear encoded mitochondrial proteins in patient 
and control fibroblasts. (A) Western blot analysis of nuclear encoded ATP5A and SDHA 
proteins shows no significant difference in primary fibroblasts from patients (P1–P3) and controls 
(C1–C3). Images representative of 3 independent experiments. 
5.3.16! Analysis of mitochondrial gene expression in fibroblasts 
We next set out to determine whether the reduction in steady state levels of mitochondrial 
proteins could result from a reduction in mitochondrial transcription in addition to the 
demonstrated defect in mitochondrial translation. Therefore, the mRNA expression of the 
mitochondrial gene MT-CYB was measured in patient (P1–P3) and control (C1–C3) 
fibroblasts using TaqMan® Gene Expression Assay. This revealed no significant 
difference between groups (Figure 5.26). 
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Figure 5.26. Analysis of mitochondrial gene expression in patient and control fibroblasts. 
Expression of MT-CYB was measured in patient (P1–P3) and control (C1–C3) primary fibroblasts. 
For data normalisation GAPDH was used as an endogenous housekeeping gene. Normalisation of 
Ct values and determination of gene expression was calculated using the 2−ΔCt method. 
P1=0.86±0.46, P2=0.88±0.29, P3=0.9±0.44, Controls=0.64±0.22. Data represents mean 2−ΔCt ±SD 
of 3 biological replicates. No results were significantly different (one-way ANOVA). 
5.3.17! Analysis of the mitochondrial network in fibroblasts 
Mitochondria exist in highly dynamic reticular networks that both drive and respond to 
changes in cellular conditions by morphological alterations (Picard, Wallace et al. 2016). 
Maintenance of these networks is critical for both mitochondrial and cellular function 
(Lackner 2014, Hoitzing, Johnston et al. 2015). The effect of the and SSBP1 and 
m.1555A>G variants on mitochondrial network morphology was investigated using 
Huygens Essential Software to quantify the average mitochondrial fragment length and 
average number of fragments within 3D-reconstructions of the mitochondrial networks in 
patient (P1–P3) and control (C1, C2) fibroblasts (Figure 5.27). The average length of 
mitochondrial fragments in P1 was significantly lower than in controls (Figure 5.28 A). 
Similarly, the total number of mitochondrial fragments was significantly increased in P1 















Figure 5.27. Mitochondrial networks in patient and control fibroblasts. Representative 
images of mitochondrial networks in primary fibroblasts from patient and controls. (A) P1 (B) P2 (C) 
P3 (D) Control (C1 and C2; C2 shown as representative of both control lines) (E) Example of 3D 
reconstructed mitochondrial networks analysed by Huygens Essential Software (C2, control shown). 
Scale bars = 20 µm 
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Figure 5.28. The average length and average number of mitochondrial fragments in 
patient and control fibroblasts. (A) The average length of mitochondrial fragments in patient 
(P1–P3) and control (C1, C2) primary fibroblasts. P1=3.03±0.17 (n=26 cells), P2=3.72± 0.93 
(n=16 cells), P3=4.21± 1.15 (n=18 cells) and Controls=4.27±1.1(C1, C2, n=63 cells). (B) The 
average number of fragments in patient (P1–P3) and control (C1, C2) primary fibroblasts. 
P1=180.8±101.9 (n=26 cells), P2=102.4± 42.5 (n=16 cells), P3=128.7±82.1 (n=18 cells) 
Controls=102.5±56.6 (C1, C2, n=63 cells). Data are mean length (µm)±SD n= ≥16 *** p=<0.0001 
(two tailed unpaired t test). 
The distribution of mitochondrial fragment lengths within the mitochondrial network of 
patient fibroblasts (P1–P3) and controls (C1, C2) was also assessed. Adapting the 
methodology of Bannwarth et al a frequency distribution of mitochondrial fragment length 
was created by sorting individual fragments into bins of <1µm, 1 to 2µm, 2 to 5µm, 5 to 














































and P2 had a significantly higher frequency of smaller fragment mitochondria (fragment 
length ≤1 to 5 µm) with significantly reduced larger fragments (fragment length 5 to >10 
µm) compared to controls although this was more markedly apparent in P1, corresponding 
with the significantly decreased average mitochondrial fragment length (Figure 5.29 A 
and Figure 5.29 B). Fragment length distribution was more comparable to control in P3 
although again there was a significant increase in smaller mitochondrial fragments 
(fragment length 1 to 2 µm) and a significant decrease in larger fragments (fragment 
length 5 to10 µm) (Figure 5.29 C). 
 
Figure 5.29. Distribution of mitochondrial fragment lengths. (A) P1 (B) P2 (C) P3 compared 
to control fibroblasts (mean of C1,C2). Data are relative frequency±SD n= ≥16 **p<0.01 *** 
p<0.0001 (two tailed unpaired t test) (see Appendix 1 for relative frequency distributions in each cell 
line). 
5.3.18! Analysis of mitochondrial dynamics proteins in fibroblasts 
Western blot analysis of patient (P1–P3) and control (C1–C3) fibroblasts was undertaken 
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by changes in steady state levels of proteins known to control mitochondrial dynamics. 
This demonstrated a trend towards increased steady state levels of the OPA1 in P1 and P2 
fibroblasts compared to P3 and controls. Conversely, there were no significant differences 
in the mitochondrial fission proteins MFN2 and DRP1 between patients and controls 
(Figure 5.30 and Figure 5.31). 
 
Figure 5.30. Western blot analysis of mitochondrial dynamics proteins in patient and 
control fibroblasts. Western blot of OPA1, MFN2 and DRP1 in patient (P1–P3) and control (C1–

































Figure 5.31. Quantification of OPA1 levels in patient and control fibroblasts. Densitometric 
quantification of OPA1 normalised to GAPDH P1=2.06±0.73, P2=2.10±1.01, P3=1.51±0.7, 
Controls=1.66±0.84. Data represents mean normalised OPA1±SD of 3 independent experiments. 
No significant difference detected between groups (one way ANOVA). 
5.3.19! Analysis of mitochondrial nucleoids in fibroblasts 
SSBP1 is a core component of mitochondrial nucleoids, the DNA-protein assemblies that 
package the mtDNA (Gilkerson, Bravo et al. 2013). To profile the effect of the SSBP1 
variant on the organisation of mitochondrial nucleoids, patient (P1–P3) and control (C1, C2) 
fibroblasts were investigated by immunocytochemical staining of mtDNA with anti-DNA 
and the mitochondrial network with anti-TOMM20. This revealed that mitochondrial 
nucleoids were dispersed throughout the mitochondrial network in all cell lines as evidenced 
by co-localisation of anti-DNA and TOMM20 staining in merged images. There was no 
gross alteration in nucleoid content or nucleoid morphology comparing the patient and 

































Figure 5.32. Analysis of mitochondrial nucleoids in patient and control fibroblasts.  
Representative confocal microscopy images of patient (P1–P3) and control (C1 shown as 
representative of C1 and C2) displaying DAPI staining for the nucleus (first column, blue), Anti-
TOM20 for the mitochondrial network (second column, red), Anti-DNA for mitochondrial DNA 
(third column, green) and a merge image produced by overlaying the nuclear, mitochondrial 
network and mtDNA images. Approximately 10 cells per cell line were examined in 2 independent 
experiments. Scale bars=10 µm. 
5.3.20! Analysis of oxidative stress 
Mitochondria are the major source of intracellular ROS, important cell signalling 
molecules that in excess result in oxidative stress (Murphy 2009). Dysfunctional OXPHOS 













cellular ROS levels (Hayashi and Cortopassi 2015). Moreover, ROS have previously been 
implicated as an important mediator in m.1555A>G pathogenesis (Section 1.13.4) 
(Raimundo, Song et al. 2012). We therefore determined oxidative stress levels in patient 
and control fibroblasts by assaying cellular ROS levels in conjunction with biomarkers of 
DNA and protein damage (Stark 2005, Jena 2012). 
5.3.20.1! Analysis of ROS levels in fibroblasts 
Cellular ROS levels were measured in fibroblasts from patients (P1–P3) and controls (C1, 
C2) using the cell permeant dye H2DCFDA that fluoresces when oxidized, functioning as a 
marker of generalised oxidative stress. No significant difference was detected between 
patient and control cell lines (Figure 5.33). 
 
Figure 5.33. Measurement of cellular ROS levels in patient and control fibroblasts.  ROS 
levels in patient (P1–P3) and control (C1, C2) fibroblasts were assessed using the H2DCFDA 
assay, (P1=5.78±1.01, P2=4.5±0.45 P3=5.23±1.22, Controls=5.18±0.36) Data represents mean 
RFU/mg protein±SD of three independent experiments. No significant difference between groups 
was detected (one-way ANOVA). 
5.3.20.2! 8-OHdG DNA Damage ELISA in fibroblasts 
DNA is considered a major target of oxidative damage within the cell and the formation of 
8-hydroxydeoxyguanosine (8-OHdG) is a common marker of oxidative stress. The 
formation of 8-OHDG DNA adducts levels were quantified by 8-OHdG ELISA, however, 
no significant difference in 8-OHDG DNA adduct levels was detected between patient 




















Figure 5.34. Quantification of 8-hydroxydeoxyguanosine in patient and control fibroblast 
DNA. 8-OHdG levels as quantified by 8-OHdG ELISA in patient (P1–P3) and control cells (C1–
C3), P1=0.057±0.007, P2=0.059±0.01, P3=0.058±0.006, Controls=0.059±0.004. Data represents 
mean OD 450nm/µg DNA±SD of 2 independent experiments. No significant difference between 
groups was detected (one-way ANOVA). 
5.3.20.3! Analysis of steady state glutathione peroxidase in fibroblasts 
To further investigate the cellular oxidative stress response, the steady state level of the 
antioxidant glutathione peroxidase 1 (GPx1) was analysed by Western blot. There was a 
trend towards decreased GPx1 levels in patient (P1–P3) cells compared to controls, 






















Figure 5.35. Western blot analysis of glutathione peroxidase 1 in fibroblasts.  
(A) Western blot analysis of cellular antioxidant proteins GPx1 in patient (P1–P3) and control 
(C1–C3) fibroblasts. Images representative of 3 independent experiments. (B) Densitometric 
quantification of GPx1 normalised to GAPDH P1=0.28±0.16, P2=0.44±0.22, P3=0.76±0.43, 
Controls=1.01±0.53. Data represents mean normalised GPx1±SD of 3 independent experiments. 
No significant difference between groups detected as determined (one-way ANOVA). 
5.3.20.4! Analysis of protein carbonylation in fibroblasts 
Oxidative modification of protein caused by the reaction of ROS with amino acids is a 
major source of post-translational protein modification and has been associated with loss 
of protein function (Cai and Yan 2013). The Oxyblot™ Protein Oxidation Detection Kit 
was used to investigate carbonylation of proteins across the whole proteome as a marker of 
generalised oxidative stress in fibroblasts from patient (P1–P3) and controls (C1–C3). The 
assay detects the derivate product 2,4-dinitrophenylhydrazone. The use of the 
derivatization control solution allows for comparison of proteins that have not been 
modified by oxidation. As such, bands that are present in the treated reaction but absent in 
the negative control can be considered to have undergone oxidative modification. The 
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overall optical density of the bands correlates with the amount of protein oxidation and 
hence provides a semi-quantitative assessment of oxidative stress. However, there was no 
gross difference in total protein carbonylation in patient compared to control cell lines 
(Figure 5.36). 
 
Figure 5.36  Analysis of protein carbonylation in patient and control fibroblasts. 
Oxyblot analysis of cellular lysates from patient (P1–P3) and controls (C1-3). DNPH was added 
for derivatization of carbonyl groups as indicated. Immunoblotting for GAPDH was undertaken to 
control lanes for loading control. Image representative of 3 independent experiments. 
5.3.21! Analysis of retrograde mitonuclear signalling 
Previous work has suggested that activation of the AMPK pathway is an important 
contributor to m.1555A>G pathogenesis (Section 1.13.4) (Raimundo, Song et al. 2012). 
To determine the effect of the SSBP1 and m.1555A>G variants on the AMPK signalling 
pathway we determined the ratio of activated AMPK (phosphorylated at threonine 172, 
pT172, AMPK-P) to total cellular AMPK-Alpha (AMPK-A) from patients (P1–P3) and 
control (C1–C3) fibroblasts. This was undertaken by (i) ELISA and (ii) Western blot 
analysis using the same cellular lysates in each assay to allow direct comparison between 




















































5.3.21.1! Total AMPK-A and AMPK pT172 ELISAs 
Total AMPK-A was quantified using the AMPK–alpha 1 in vitro SimpleStep ELISA. No 
significant difference was detected between patient and control cell lines (Figure 5.37 A). 
There was also no difference in AMPK-P, quantified by the AMPK pT172 Phospho-
ELISA Kit between patients and controls (Figure 5.37 B). It followed that there was no 
significant difference in the AMPK-P:AMPK-A ratio between any of the groups (Figure 
5.37 C). 
 
Figure 5.37. Analysis of cellular AMPK activity in patient and control fibroblasts by 
ELISA (A) Total AMPK-A as quantified by AMPK–alpha 1 in vitro SimpleStep ELISA in patient 
(P1–P3) and control cells (C1–C3) P1=473.5±53.2, P2=485.3±63.0 P3=437.8±95.3, 
Controls=417.9±64.1. Data represents mean AMPK alpha ng/ml±SD of 3 independent 
experiments. (B) AMPK-P as quantified by AMPK pT172 Phospho-ELISA Kit P1=7.70±2.9 
P2=7.81± 2.9, P3=6.51± 1.24, Controls=6.59±1.53 Data represents mean AMPK pT172 activity 
units/ml±SD of 3 independent experiments. (C) Ratio of AMPK-P:AMPK-A as quantified by 
ELISA in (A) and (B) P1=0.017±0.006, P2=0.0166±0.007 P3=0.05±0.00004, 
Controls=0.016±0.004. Data represents mean AMPK alpha ng/ml / mean AMPK pT172 activity 
units/ml±SD of 3 independent experiments. The statistical analysis of data represented in (A), (B) 


































































5.3.21.2! Western blot analysis of total AMPK and AMPK-pT172 
Western blot analysis was then performed with the same lysates as used in the ELISAs 
presented in Section 5.3.21.1. Although there was an apparent increase in AMPK-pT172 
signal in SSBP1 fibroblasts compared to controls, normalisation by AMPK-A reduced this 
difference. However, there remained a trend towards increased AMPK pT172:AMPK-A in 
P1 cells, although this did not reach statistical significance (Figure 5.38). 
 
Figure 5.38  Western blot analysis of cellular AMPK activity. (A) Western blot of 
AMPK-pT172 and AMPK-A in primary patient (P1–P3) and control fibroblast cell lines (C1-3). 
Image representative of 3 independent experiments. (B) Densitometric quantification of AMPK-
pT172 normalised to AMPK-A. P1=0.50±0.097, P2=0.297±0.06, P3=0.328±0.174, 
Controls=0.29±0.139. Data represents mean normalised AMPK-P:AMPK-A±SD of 3 independent 
experiments. No significant difference between groups detected as determined (one-way 
ANOVA). 
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5.3.21.3! Western blot analysis of total S6K and pS6K-Thr 389 
The phosphorylation of ribosomal protein S6 kinase (p70-S6 kinase) is regarded as a 
hallmark of mTOR signalling activation. The AMPK signalling pathway acts to inhibit 
mTOR and thereby control protein synthesis, cell growth, and metabolism (Inoki, Kim et 
al. 2012). To determine whether the SSBP1 and m.1555A>G variants modulated the 
signalling pathways downstream of AMPK, Western blot analysis of total S6K and 
activated S6K (phosphorylated at threonine 389, pT389) was undertaken in patient (P1–
P3) and control (C1–C3) fibroblasts and used to calculate S6K-pT389: total S6K as an 
indicator of S6K activity. There was a trend towards an increase in S6K activity in patient 
fibroblasts however this did not reach statistical significance (Figure 5.39). 
 
Figure 5.39. Western blot analysis of total S6K and S6K-pT389. (A) Western blot of S6K-
pT389 and S6K in primary patient (P1–P3) and control fibroblast cell lines (C1-3). Image 
representative of 3 independent experiments. (B) Densitometric quantification of S6K-pT389 
normalised to total S6K. P1=0.619±0.098, P2=0.629±0.108, P3=0.710±0.0.096, 
Controls=0.557±0.136. Data represents mean normalised S6K-pT389: S6K±SD of 3 independent 
experiments. No significant difference between groups detected (one-way ANOVA). 
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5.3.21.4! Analysis of the effect of heat shock in patient fibroblasts 
SSBP1 has recently been demonstrated to play a critical role in the modulation of the 
cellular heat shock response, specifically by increasing the expression of cytoplasmic 
chaperones including HSP90, HSP40 and HSP70 and mitochondrial chaperones HSP10 
and HSP60, both at the gene and protein level (Tan, Fujimoto et al. 2015). We 
hypothesised that the protein expression induction of HSP70 and HSP60 after heat 
treatment in P1 and P2 fibroblasts would be compromised compared to heat-treated P3 
fibroblasts and controls. We also evaluated endoplasmic reticulum (ER) homeostasis by 
examining the protein levels of BiP, an ER chaperone important in the ER stress response 
(Figure 5.40). 
 
Figure 5.40. Analysis of heat shock in fibroblasts. Western blot of analysis of HSP70, HSP60 
and BiP in primary patient (P1–P3) and control fibroblast cell lines (C1-3) at steady state and after 
heat shock at 42oC for 1 hour and a 4 hour recovery at 37oC. Images representative of 2 
independent experiments. 
There was no statistical difference between the steady state protein expression levels of 
HSP60, HSP70 or BiP between SSBP1 cell lines compared to P3 and control cells (Figure 
5.41 B (i)). Heat treatment robustly induced HSP70 in all cell lines; however, the induction 
of HSP60 expression was noticeably more modest (Figure 5.41B (ii)). Importantly, the 
induction of HSP60 and HSP70 by heat shock, as quantified by the fold change in protein 
expression between the heat treated and steady state, was not different between SSBP1 
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cells and those carrying the wild type variant (P3 and controls). Similarly, there was no 





Figure 5.41. Analysis of heat shock response in patient and control fibroblasts. Densitometric quantification of HSP60, HSP70 and BiP in patient (P1–
P3) and control cell lines (C1–C3) at steady state. No significant difference was detected between patient and control lines (one way ANOVA). The 
quantification data for the assays is presented in Appendix 3. (B) The densitometric quantification of HSP60, HSP70 and BiP in patient (P1–P3) and control 
cell lines (C1–C3) was used to calculate a protein induction fold change (pS:pHS); HSP70 (P1 Heat vs P1 fold change=5.8±2.24, P2 Heat vs P2 fold 
change=3.89±1.62, P3 Heat vs P3 fold change=15.7±11.6 Control Heat vs Control fold change=4.6±1.54). BiP (P1 Heat vs P1 fold change=1.48±0.15, P2 
Heat vs P2 fold change=2.13±0.69, P3 Heat vs P3 fold change=3.49±0.80, Control Heat vs Control fold change=2.17±0.28). HSP60 (P1 Heat vs P1 fold 
change=1.17±0.47, P2 Heat vs P2 fold change=1.08±0.06, P3 Heat vs P3 fold change=1.22±0.05 Control Heat vs Control fold change=1.29±1.04). Data 




















































































































































The data presented in this chapter, including genetic, protein and biochemical analyses 
provide compelling evidence of an interaction between the c.3G>A SSBP1 and 
m.1555A>G variants. Our findings strongly suggest that together these variants act to 
significantly compromise cellular physiology through a combined effect on mtDNA 
maintenance and mtDNA translation manifesting as a tissue specific phenotype. This is 
both the first report of a likely pathological mutation in the core mitochondrial replisome 
protein SSBP1 and the first evidence of a variant in an mtDNA replication gene modifying 
the phenotype of m.1555A>G. 
The c.3G>A SSBP1 variant is predicted to cause the loss of the canonical protein 
translation start site, abolishing a core component of the conserved Kozak sequence 
(gccRccAUGG) required for the ribosome to initiate protein translation (Zur and Tuller 
2013). A number of studies have highlighted start-loss mutations as important contributors 
to human disease, and to date, over 400 pathogenic single base substitutions within the 
ATG (AUG at the mRNA level) of the translation initiation codon (TIC) have been 
reported (Wolf, Caliebe et al. 2011). Loss of the SSBP1 TIC may lead to the activation of 
an alternate reading frame coding for an N-terminal truncated protein. Translation in this 
predicted reading frame generates a 14 amino acid protein lacking the mitochondrial 
targeting sequence (Omura 1998). This likely mis-targets the truncated protein resulting in 
degradation by cytosolic proteostatic quality control mechanisms (Chen, Retzlaff et al. 
2011, Wrobel, Topf et al. 2015). 
Western blot analysis of SSBP1, m.1555A>G and control fibroblasts confirmed the SSBP1 
variant reduced SSBP1 protein levels to approximately 20% of control levels. 
Furthermore, the lack of any detectable SSBP1 isoforms shorter than the annotated protein 
is consistent with the predicted truncated protein being degraded in the cytosol (Kazak, 
Reyes et al. 2013). However, it should be noted that the SSBP1 antibody used in this is 
study is polyclonal, hence it is not possible to determine whether specific shorter forms of 
the protein would be robustly detectable. 
The magnitude of the reduction in SSBP1 protein levels in SSBP1 fibroblasts is surprising 
since an effective null allele, as predicted to result from the SSBP1 variant, would be 
expected to reduce protein levels by a maximum of 50% (Voet 2011). SSBP1 exists within 
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the cell as a homotetramer, thus it is conceivable that the reduction in subunit availability 
caused by the loss of SSBP1 protein translation reduces the efficiency of tetramer 
formation which then triggers enhanced degradation of the remaining free SSBP1 subunits 
(Goldberg 2003). It would be possible to further test this hypothesis by determining 
whether treatment of SSBP1 fibroblasts with an inhibitor of proteasomal degradation, such 
as MG-132, ameliorated the reduction in steady state protein levels (Kisselev, van der 
Linden et al. 2012). Alternatively, there may be an inherent allelic imbalance of SSBP1 
gene expression with the c.3G>A variant directly impacting an allele that is responsible for 
more than 50% of the encoded protein. This process may be accounted for by genomic 
imprinting, that could be further investigated using bisulfite Pyrosequencing methodology 
to determine differential methylated regions within the SSBP1 gene (Barlow and 
Bartolomei 2014, McKeown, Fort et al. 2014). 
The observed reduction of steady state SSBP1 protein levels strongly suggests that the 
SSBP1 variant causes dysfunction in SSBP1 translation. However, more definitive 
evidence of this pathological mechanism could be obtained by creating expression vectors 
containing either fluorescently tagged wild type or mutant c.3G>A SSBP1. These vectors 
could then be transfected into a control cell line with the expectation that the mutant 
SSBP1 would abolish specific immunofluorescence indicative of dysfunctional protein 
expression (Jinda, Poungvarin et al. 2016). Further validation of this mechanism could be 
obtained by performing in vitro translation of mutant and wild type RNA using a rabbit 
reticulocyte lysate system containing radiolabelled methionine (Jackson and Hunt 1983). 
Additionally, and in agreement with previous work characterising the effect of start-loss 
mutations, we found there was no significant difference in the mRNA expression levels of 
SSBP1 between SSBP1, m.1555A>G and control fibroblasts (Sargiannidou, Kim et al. 
2015). This finding is consistent with the SSBP1 variant solely compromising SSBP1 
protein translation without an effect on mRNA expression. 
Mitochondrial histochemical investigation of III-8, P5, an individual from the Finnish 
family carrying the SSBP1 c.3G>A and m.1555A>G variants, revealed the presence of a 
low number of COX-negative fibres (estimated at 3.4%). COX-negative fibres have been 
identified in a range of mitochondrial diseases and generally are only present in healthy 
individuals over the age of 60 years (Brierley, Johnson et al. 1998, Taylor, Schaefer et al. 
2004). Given that III-8 was aged 38 years at the time of biopsy, these changes can be 
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considered to be pathological. It must however be recognised that we were unable to 
obtain a muscle biopsy from P3 who carries m.1555A>G without c.3G>A SSBP1 or from 
the SSBP1 variant carrying children of III-6 and III-10 that are wild type at m.1555. We 
therefore are unable to infer whether each variant could cause this effect in isolation. 
Importantly, a previous study examining skeletal muscle from an m.1555A>G carrier 
detected no overt histochemical evidence of mitochondrial dysfunction although the 
presence of mitochondrial deletions was not assessed (Santorelli, Tanji et al. 1999). 
Incidentally, the presence of muscle ‘minicores’ was noted but given that the subject also 
presented with cardiomyopathy, a second nuclear mutation is likely to account for the 
histological findings in this individual (Santorelli, Tanji et al. 1999, Jungbluth 2007). 
Further analysis of III-10, P4 and III-8, P5 skeletal muscle revealed the presence of 
mtDNA deletions and a reduction in mtDNA copy number to 40% of control levels, 
clearly suggesting the SSBP1 variant causes dysfunction of mtDNA maintenance. 
Consistent with these results, mtDNA deletions are also detectable in skeletal muscle from 
carriers of mutations in other mtDNA maintenance genes such as MGME1 (mitochondrial 
genome maintenance exonuclease 1), MPV17 and RNASEH1 (Blakely, Butterworth et al. 
2012, Kornblum, Nicholls et al. 2013, Reyes, Melchionda et al. 2015). 
The absence of mtDNA deletions in SSBP1 fibroblasts is consistent with a well-recognised 
phenomenon in carriers of mutations in mtDNA maintenance genes, including POLG and 
RNASEH1 (Stewart, Schoeler et al. 2011, Reyes, Melchionda et al. 2015). It has been 
proposed that the deletions are lost in these rapidly dividing cells (Moraes, Ciacci et al. 
1993, Weber, Wilson et al. 1997). 
Interestingly, in contrast to the findings in skeletal muscle, the mtDNA copy number of 
SSBP1 fibroblasts was confirmed by qPCR and Southern blot analysis to be no different to 
m.1555A>G and control fibroblasts. Moreover, there was no observable difference in 
blood mtDNA copy number between carriers of the SSBP1 variant and wild type 
individuals from the family. This is in agreement with a previous study where reduction of 
SSBP1 expression by RNAi did not alter mtDNA copy number in mouse C2C12 cells 
(Arakaki, Nishihama et al. 2006). Contrastingly, reduction of SSBP1 expression in HeLa 
cells has been shown to cause an reduction in mtDNA copy number to 60% of control 
levels (Ruhanen, Borrie et al. 2010). Taken together, these findings strongly suggest that 
there are cell and, potentially, tissue specific differences in the requirement for SSBP1 to 
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maintain mtDNA copy number. This hypothesis is consistent with the finding that tissue 
specific compensatory mechanisms maintain normal mtDNA copy number in fibroblasts 
harbouring mutations in the mtDNA maintenance genes, POLG2 and TK2 (Frangini, 
Rampazzo et al. 2009, Stewart, Schoeler et al. 2011). 
The cellular mechanism by which the SSBP1 variant causes mtDNA deletions in skeletal 
muscle has not been resolved by this study, however, it is known that patients with defects 
in POLG, a critical mtDNA maintenance gene that encodes the mitochondrial DNA 
polymerase, polγ, are thought to accumulate mtDNA deletions by replication stalling at 
homopolymeric tracts (Kunkel and Soni 1988, Hudson and Chinnery 2006). It has been 
proposed that SSBP1 reduces arrests within these tracts, and thus suppresses mtDNA 
deletion formation (Mikhailov and Bogenhagen 1996). SSBP1 also acts to reduce 
replication stalling by stimulating the activity of polγ thereby increasing the processivity of 
the polγ/Twinkle complex (Korhonen, Pham et al. 2004). Moreover, currently unpublished 
work from the laboratory of Maria Falkenberg (University of Gothenburg, Sweden) has 
demonstrated that SSBP1 abolishes mtDNA deletion formation in an in vitro replication 
model by decreasing polγ slippage during L-strand synthesis. This is in concordance with 
the observation that excessive pausing leads to the accumulation of multiple deleted 
species by a process of DNA breakage or recombination (Bailey, Cluett et al. 2009). 
According to the strand displacement model, SSBP1 coats the H-strand whilst single-
stranded during mtDNA replication (Clayton 1982). Therefore, low SSBP1 levels in the 
carriers of the SSBP1 variant may increase mtDNA replication stalling and non-specific 
replication initiation by the non-specific polymerase POLRMT (Miralles Fuste, Shi et al. 
2014). This hypothesis could be further investigated by performing 2D-AGE to delineate 
mitochondrial replication intermediates (mtRIs). An accumulation of mtRIs would signify 
a replication stalling phenotype as seen in fibroblasts carrying pathogenic mutations in 
other mtDNA maintenance genes including TWNK, MGME1, RNASEH1 and POLG 
(Wanrooij, Goffart et al. 2007, Goffart, Cooper et al. 2009, Kornblum, Nicholls et al. 
2013, Reyes, Melchionda et al. 2015) Alternatively, the increased levels of unprotected 
single stranded DNA may lead to degradation by cellular endonucleases precipitating 
mtDNA deletions (Richard, Bolderson et al. 2008). 
Reduction in SSBP1 has also been demonstrated to enhance mtDNA supercoiling, 
evidenced by loss of staining by PicoGreen, a fluorochrome that exclusively binds double 
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stranded DNA but cannot bind to tightly packed genomes (Di Re, Sembongi et al. 2009). It 
is therefore possible that the altered structure of the mtDNA in SSBP1 cells may modulate 
the binding of proteins involved in mtDNA replication leading to the observed reduction 
of mtDNA copy number in skeletal muscle. 
Collectively, these dysregulated processes may combine to ultimately compromise 
replication fidelity leading to tissue-specific mtDNA deletions and mtDNA copy number 
depletion (Miralles Fuste, Shi et al. 2014). 
Mammalian mtDNA molecules contain a triple-stranded region found in the NCR of many 
mitochondrial genomes, formed by the stable incorporation of a third, short DNA strand 
known as 7S DNA. The exact function of 7S DNA is unknown, however, it has been 
proposed to play a role in mtDNA replication as an intermediate of prematurely terminated 
H-strand synthesis. Furthermore, perturbations in the steady state levels of 7S DNA have 
been observed in mtDNA maintenance disorders resulting from mutations in RNASEH1 
and MGME1 (Kornblum, Nicholls et al. 2013, Nicholls and Minczuk 2014, Reyes, 
Melchionda et al. 2015). Given the evidence of dysfunctional mtDNA metabolism 
observed in patient skeletal muscle we further analysed the steady state levels of 7S DNA 
in patient and control fibroblasts. The reduction in the abundance of 7S DNA relative to 
genome length mtDNA molecules in SSBP1 fibroblasts compared to m.1555A>G and 
control fibroblasts was consistent with previous work demonstrating SSBP1 is required for 
the regulation of the mtDNA D-loop by modulating the synthesis of 7S DNA (Ruhanen, 
Borrie et al. 2010). This result provided definitive evidence of mtDNA dysmetabolism in 
SSBP1 fibroblasts. 
To further clarify the effect of the SSBP1 and m.1555A>G variants on mtDNA replication 
we undertook a mitochondrial repopulation assay. We employed the experimental 
paradigm used by Stewart et al. Although, as expected 15 days’ of EtBr depletion resulted 
in depletion of mtDNA copy number, this was accompanied by a profound reduction in 
cell viability that was not experienced by the original authors (Stewart, Schoeler et al. 
2011). It is likely this was a result of a chronic reduction in mtDNA copy number leading 
to respiratory compromise and triggering cell death. The reasons for the increased 
sensitivity of our fibroblasts to mtDNA depletion are unclear although this discrepancy 
may be specific to the cells used in our assay or dependent on cell culture conditions. 
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We therefore used a modified assay consisting of a shorter, 4-day period of depopulation 
followed by 6 days’ of repopulation. This revealed a consistent trend for higher 
repopulation levels in all patients compared to control cells. This is in agreement with the 
increased mtDNA replication efficiency in carriers of the LHON mutation, m.11778A>G 
(Giordano, Iommarini et al. 2014). It is possible therefore that these homoplasmic 
mitochondrial variants produce a compensatory nuclear signal to increase mtDNA 
replication efficiency. To further test this hypothesis qPCR analysis would determine 
whether the m.1555A>G variant causes upregulation of genes associated with mtDNA 
replication even in steady state conditions. 
A closer analysis of the repopulation kinetics revealed the repopulation rate in SSBP1 cells 
was double that of 1555A>G and control cells. This poses the intriguing possibility that 
the reduction in 7S DNA abundance is directly causative of the higher mtDNA 
repopulation rate in SSBP1 fibroblasts. As previously discussed, the function of 7S DNA 
has not yet been fully resolved, although recently it has been suggested that it may act to 
control mtDNA replication by inhibiting the assembly of the replisome at LSP as well as 
replication fork progression (Nicholls and Minczuk 2014). The reduction of 7S DNA in 
SSBP1 fibroblasts therefore may remove this control mechanism and facilitate faster 
mtDNA replication. Consistent with this hypothesis, fibroblasts carrying MGME1 and 
RNASEH1 mutations demonstrate increased 7S DNA levels in conjunction with a 
reduction in mtDNA repopulation rates (Kornblum, Nicholls et al. 2013, Reyes, 
Melchionda et al. 2015). A reduction in 7S DNA abundance would, however, be envisaged 
to only affect a minority of mtDNA molecules, given that only approximately 10% of 
mtDNAs contain a 7S DNA strand (Brown, Shine et al. 1978). On the other hand, it is 
important to recognise that only a proportion of mtDNAs are able to replicate, therefore 
the reduction in 7S DNA may be specific to this subset of mtDNA molecules (unpublished 
observations, Dr Aurelio Reyes, Mitochondrial Biology Unit, Cambridge, UK). 
Alternatively, the reduction in SSBP1 levels may permit faster mtDNA replication by 
speeding the progression of the replication fork, no longer limited by needing to remove 
SSBP1 from single stranded DNA undergoing replication. This hypothesis could be tested 
by measuring active mtDNA replication rates by incorporation of bromodeoxyuridine 
(BrdU) in fibroblasts where nuclear replication has been inhibited by aphidicolin (Lentz, 
Edwards et al. 2010). 
 197 
It must also be noted that SSBP1 is only predicted to coat the H-strand according to the 
strand displacement model of mtDNA replication (Clayton 1982). Therefore, SSBP1 cells 
may replicate mtDNA using the strand coupled or RITOLS replication models that require 
limited quantities of SSBP1 (Holt, Lorimer et al. 2000, Reyes, Kazak et al. 2013). 
Furthermore, cultured cells depleted of mtDNA by EtBr have been shown to 
predominantly use strand-coupled replication in the ensuing repopulation phase 
(Yasukawa, Yang et al. 2005). The forced requirement to switch replication modes in the 
m.1555A>G and control cells may account for the difference in repopulation rates 
compared to the SSBP1 cells that are already adapted to using strand coupled replication. 
In order to dissect the mechanistic link between reduced 7S DNA levels and enhanced 
mtDNA replication, wild type SSBP1 could be expressed in SSBP1 cells with the 
expectation that this would increase 7S DNA levels and result in a reduced mtDNA 
repopulation rate. Besides SSBP1, studies have demonstrated 7S DNA synthesis is 
promoted by a number of other factors, including, TFAM and Twinkle helicase (Gensler, 
Weber et al. 2001, Milenkovic, Matic et al. 2013). Overexpression of either of these factors 
in SSBP1 cells would similarly be expected to increase 7S DNA levels and subsequently 
reduce the mtDNA repopulation rate. Potentially this strategy would distinguish whether 
the repopulation rate depends on 7S DNA per se or whether it is contingent on another 
function of SSBP1. It should be considered, however, that overexpression of these factors 
may also dysregulate other cellular processes, confounding the results of the analysis. 
It is tempting to speculate that the faster mtDNA replication coupled with increased single 
stranded regions of DNA that are liable to undergo oxidative damage in SSBP1 cells may 
lead to an increase in replication errors by polγ. This would be expected to result in the 
accumulation of point mutations. This hypothesis could be further investigated by 
undertaking ultra-deep sequencing, using NGS technology, to examine for low level 
heteroplasmic mutations in SSBP1 fibroblasts (McElhoe, Holland et al. 2014). Further, the 
distribution of the mutations within the mitochondrial genome may reflect the non-linear 
distribution of SSBP1 occupancy across mtDNA. It has been demonstrated that SSBP1 
occupancy is highest at MT-CYB and falls to a minimum at MT-CO1 (Miralles Fuste, Shi 
et al. 2014). Hence, given that the MT-CYB region remains single stranded for longer 
during replication, it would be expected that this region would be enriched in point 
mutations (Reyes, Gissi et al. 1998). 
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The replication and transcription machineries are spatially linked by nature of the DNA 
and RNA polymerases sharing a common DNA template. There are, therefore, collisions 
between these machineries, which pose a substantial risk to genomic integrity (Mirkin and 
Mirkin 2007). Recent work has highlighted the transcription elongation factor, TEFM as a 
critical molecular switch between the two processes (Agaronyan, Morozov et al. 2015). It 
has also been suggested that the D-loop triple strand structure plays a regulatory role in 
this process. By acting to inhibit replication fork progression, the D-loop structure prevents 
replication fork collisions as well as collisions between the replication and transcription 
machineries. Therefore, in SSBP1 cells an increase in these collisions may ultimately be 
detrimental to genome stability and potentially result in mtDNA deletions and depletion. 
(Rudolph, Upton et al. 2013, Nicholls and Minczuk 2014). 
Interestingly, a common breakpoint for mtDNA deletions occurs immediately downstream 
of the 3’end of the D-loop (Zeviani, Servidei et al. 1989). This has been explained by 
demonstrating that the triple stranded D-loop in fact promotes deletion formation by 
increasing accessibility for strand invasion (Berk and Clayton 1974). Therefore, a 
reduction in 7S DNA is predicted to decrease the likelihood of forming this specific 
mtDNA deletion, however regions downstream of this area would still be prone to 
deletions. Ultimately, the mechanisms linking these phenomena in our patients clearly 
warrant closer examination. 
Given the importance of the 12S rRNA gene in mitochondrial translation we subsequently 
examined the effect of the variants on de novo and steady state levels of mitochondrial 
proteins. Fibroblasts from all patients carrying the m.1555A>G variant showed reduced 
intra-mitochondrial protein synthesis and steady state levels of complex IV subunits, MT-
CO1 and MT-CO2, compared to controls. These results are in keeping with previous 
studies demonstrating the m.1555A>G variant causes mitochondrial translation 
dysfunction and reduces the rate of de novo protein synthesis (Guan, Fischel-Ghodsian et 
al. 1996, Santorelli, Mak et al. 1996, Guan, Fischel-Ghodsian et al. 2000). Similarly, a 
study using transmitochondrial cybrids harbouring the complementary 12S rRNA variant, 
m.1494C>T, also demonstrated a significant reduction in mitochondrial steady state 
protein levels (Yu, Zheng et al. 2014). Additionally, we found no difference in steady state 
levels of the nuclear encoded mitochondrial proteins, ATP5A and SDHA, or in the 
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mitochondrial gene MT-CYB mRNA expression, indicating this deficit was specific to 
mitochondrial translation. 
Having identified evidence of OXPHOS dysfunction in the SSBP1 muscle biopsy we 
further studied the effect of the variants on mitochondrial bioenergetics in primary 
fibroblasts. To this effect, OXPHOS function was determined by measurement of 
mitochondrial respiration, cell growth in forced OXPHOS conditions and cellular ROS 
levels. There was no significant compromise to OXPHOS as determined by Seahorse 
analysis, however consistent with three previous studies, fibroblasts carrying the 
m.1555A>G variant displayed a trend towards lower maximal respiration (Guan, Fischel-
Ghodsian et al. 1996, Santorelli, Tanji et al. 1999, Meng, Cang et al. 2017). Further 
analysis of respiratory function could be performed using the Oxygraph-2k respirometer, a 
technology that has been shown to provide a higher resolution analysis of OXPHOS 
deficits (Horan, Pichaud et al. 2012). 
In vivo cells primarily rely on OXPHOS to generate cellular ATP. In contrast, cells grown 
in glucose culture medium generate the majority of their ATP via glycolysis, a 
phenomenon known as the Crabtree effect (Mot, Liddell et al. 2016). To recapitulate in 
vivo conditions in cell culture, it is useful to adapt the cell culture environment such that 
cells are less glycolytic and are thus forced to rely on OXPHOS to generate cellular ATP 
(Marroquin, Hynes et al. 2007, Aguer, Gambarotta et al. 2011). This can be achieved by 
substituting glucose in the culture medium with galactose that is only slowly metabolised 
to pyruvate by glycolysis (Dott, Mistry et al. 2014). In agreement with previous work, 
under these conditions all patient cells carrying the m.1555A>G variant had significantly 
increased doubling times (Guan, Fischel-Ghodsian et al. 1996, Santorelli, Tanji et al. 
1999). This finding likely reflects the reduction in maximal respiration, total protein 
synthesis and steady state levels of the respiratory chain subunits, MT-CO1 and MT-CO2 
that is found in these cells. 
Together, these findings reveal a primary defect in mitochondrial respiration mediated by 
m.1555A>G compromising mitochondrial translation that was no more severe in the 
presence of the SSBP1 variant. 
Mitochondrial generated ROS are a critical component of cellular homeostasis, but in excess 
ROS play an important role in the pathological mechanism underlying a number of diseases 
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including neurodegeneration, cancer and hearing loss (Uttara, Singh et al. 2009, Raimundo, 
Song et al. 2012, Kamogashira, Fujimoto et al. 2015). However, the role of mitochondrial 
dysfunction in the generation of excessive ROS remains controversial and importantly, there 
have been a number of mouse models with severe respiratory chain compromise with neither 
increased levels of cellular ROS nor evidence of oxidative mtDNA damage (Kujoth, Hiona 
et al. 2005, Trifunovic, Hansson et al. 2005, Murphy, Holmgren et al. 2011). 
Given the suggestion by Raimundo et al that ROS may directly mediate m.1555A>G 
pathology, we wished to determine whether the SSBP1 c.3G>A and m.1555A>G variants 
resulted in increased ROS levels and oxidative stress in primary fibroblasts (Raimundo, 
Song et al. 2012). Cellular ROS levels were therefore assessed by the H2DCFDA assay, 
but no significant difference was detected between patient or control fibroblast cells. This 
result however must be considered in the context of the known limitations of the assay. 
Importantly, DCFH metabolism is complex, requiring peroxidation involving a transition 
metal catalyst (Zhu, Bannenberg et al. 1994). Additionally, artefactual redox cycling and 
the ability of DCFH to react with a broad range of one electron oxidizing species have 
been described as potential confounding factors (Wardman 2007, Kalyanaraman, Darley-
Usmar et al. 2012). 
Therefore, in line with the recommendations of Murphy et al, we attempted to circumvent 
the limitations of redox sensitive probes by corroborating our findings using orthogonal 
techniques (Murphy, Holmgren et al. 2011). We therefore set out to determine whether we 
could detect differences in the downstream effects of ROS between patients and controls. 
However, in this regard, we detected no difference between patients and controls in the 
predominant marker of free radical induced oxidative damage to cellular DNA, 8-OHdG. 
Similarly, no differences in protein carbonylation levels were detected as assessed by 
Oxyblot analysis. Importantly, it must be considered that the link between the 
accumulation of an oxidative stress biomarker, such as protein carbonylation, and 
excessive ROS is indirect (Grimsrud, Xie et al. 2008). For example, the induction of 
protein mistranslation in Escherichia coli by streptomycin treatment results in increased 
levels of protein carbonylation but without a change in cellular ROS caused by the 
increased tendency of misfolded proteins to undergo oxidative modification (Dukan, 
Farewell et al. 2000). Similarly, measurement of 8-OHdG may be confounded by chemical 
modifications which occur during the DNA extraction process (Halliwell 2000). 
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Unexpectedly, steady state levels of GPx1, a critical cellular antioxidant, were reduced in 
patient compared to control fibroblasts, although the significance of this finding is unclear. 
Further insight into cellular antioxidant metabolism could be gained by assaying 
glutathione peroxidase activity levels with measurement of the reduced glutathione (GSH) 
to oxidized glutathione (GSSG) ratio (Townsend, Tew et al. 2003). Together with qPCR of 
antioxidant genes these assays would provide a comprehensive analysis of the cellular 
antioxidant status (Sarkar, Mukherjee et al. 2017). 
Notwithstanding the limitations of the assays performed in this study, together these 
findings suggest the c.3G>A SSBP1 and m.1555A>G variants do not contribute to 
increased oxidative stress in the primary fibroblasts used in this study and ROS are 
unlikely to be a major contributory factor in causing disease in our patients. This contrasts 
with one previous study analysing ROS levels in m.1555A>G fibroblast cells. However, it 
is noteworthy that although the authors observed a significant difference between 
m.1555A>G carriers and controls, a closer analysis of their data reveals the difference 
does not meet their own definition of statistical significance (ROS levels in m.1555A>G 
carriers vs. controls p=0.053, p<0.05 defined as statistical significant) (Meng, Cang et al. 
2017). 
Given the evident impairment to the mitochondrial bioenergetic and protein synthesis 
capacity of the patient cells, we hypothesised that we may detect alteration in 
mitochondrial morphology either as a response to cellular stress or as a compensatory 
mechanism to maintain mitochondrial function. We observed that at steady state P1 
fibroblasts had a noticeably more fragmented mitochondrial network, a significantly 
reduced mitochondrial average length and an increased number of mitochondrial 
fragments per cell compared to controls. On closer analysis, there was a significant 
increase in shorter mitochondrial fragments (fragment length ≤1 to 5 µm) with a reduction 
in larger fragments (fragment length 5 to >10 µm) in both P1, P2 and to a lesser degree P3, 
compared to controls. 
Examination of the steady state levels of proteins regulating mitochondrial dynamics 
revealed a trend towards increased levels of OPA1 in P1 and P2 compared to P3 and 
controls. It is important to recognise that the expression of OPA1 is primarily regulated at 
the post-transcriptional level and the alternative splicing of OPA1 mRNA gives rise to 8 
distinct protein isoforms that are expressed in a tissue specific manner (Delettre, Griffoin 
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et al. 2001, Ishihara, Fujita et al. 2006). These isoforms fulfil divergent cellular processes 
with the short and long forms critical for mitochondrial fusion and fission respectively 
(Anand, Wai et al. 2014). However, the Western blot analysis performed in this study is 
unable to distinguish between OPA1 isoforms. This increase in OPA1 levels may therefore 
signify a compensatory response to the cellular stress caused by the m.1555A>G and 
SSBP1 variants, although the definitive mechanism requires further clarification. 
Alternatively, the increased network fragmentation may be indicative of increased 
mitophagy, a primary process in mitochondrial quality control that facilitates the removal 
of dysfunctional mitochondria. Super-resolution structured illuminated microscopy to co-
localise the autophagosome marker LC3 (microtubule associated protein 1A/1B light chain 
3) protein with the mitochondrial marker TOMM20 could be used to further investigate 
this process (Wei, Chiang et al. 2017). Additionally, transmission electron microscopy 
may reveal the presence of mitochondria within autophagosomes and provide direct 
evidence of mitophagy (Ding and Yin 2012). Although there was no difference in the 
steady state levels of the pro-fission proteins, DRP1 and MFN2, measurement of post-
translational modifications that are known to alter their cellular function and localisation 
may provide further insight into the molecular mechanism of the increased fragmentation 
observed in SSBP1 cells (Harder, Zunino et al. 2004, Ko, Hyun et al. 2016). For example, 
SUMOylation and phosphorylation levels of DRP1 could be examined by Western blot 
analysis (Chang and Blackstone 2010, Prudent, Zunino et al. 2015) 
The reasons for the increased fragmentation of the mitochondrial network in P1 compared 
to P2 is currently unclear but may be determined by yet uncharacterised cell specific 
factors. It is possible that exchanging the cell culture medium for galactose may increase 
network fragmentation, an effect seen in cells carrying OPA1 mutations, thereby 
enhancing the difference between SSBP1 and control cells (Nasca, Rizza et al. 2017). It is 
an intriguing possibility that increasing cellular dysfunction in SSBP1 fibroblasts 
compared to those carrying m.1555A>G alone or controls manifests as a shift of the 
mitochondrial fragment length distribution towards shorter fragments. Previous work has 
demonstrated an increase in mitochondrial network fusion in mouse C2C12 cells treated 
with RNAi to reduce SSBP1 levels (Arakaki, Nishihama et al. 2006). This may represent 
the recognised process of ‘stress-induced mitochondrial hyperfusion’, a cellular response 
to various physiological stressors (Tondera, Grandemange et al. 2009). Alternatively, this 
may be a feature of an artificially acute reduction in SSBP1 that does not resemble the 
 203 
phenotype of our SSBP1 cells that have chronically reduced SSBP1 levels. It is 
conceivable that the additional cellular dysfunction caused by the m.1555A>G variant 
exceeds the limit of compensation permitted by network fusion triggering network 
fragmentation, and possibly mitophagy as a means to remove dysfunctional mitochondria 
(Wai and Langer 2016). Consistent with this hypothesis, transmitochondrial cybrids 
carrying the 12S rRNA mutation m.1494C>T display mitochondrial network 
fragmentation triggering mitophagy when treated with gentamicin, essentially acting as an 
additional cellular stressor corresponding to the effect of the SSBP1 variant. (Yu, Zheng et 
al. 2014). 
Further investigation is required to determine the mechanisms underlying these 
observations. However, importantly, these results are consistent with previous studies 
demonstrating that mammalian cells with defects of the respiratory chain have fragmented 
mitochondria (Koopman, Visch et al. 2005, Sauvanet, Duvezin-Caubet et al. 2010). 
Additionally, yeast cells with deletions in critical OXPHOS genes display defects in fusion 
of the IMM, suggesting fragmentation of the mitochondrial network is a conserved effect 
of mitochondrial dysfunction (Sauvanet, Duvezin-Caubet et al. 2012). It has also been 
demonstrated that OXPHOS upregulates IMM fusion by enhancing the cleavage of OPA1 
by YME1L1. Furthermore, ATP is known to be required for mitochondrial fusion 
(Meeusen, McCaffery et al. 2004, Mishra, Carelli et al. 2014). Therefore, the compromised 
OXPHOS function in our patient cells may link to the observed effect on mitochondrial 
morphology through a defect in cellular ATP production. 
Mutations in the mitochondrial fusion genes OPA1 and MFN2 cause multi-system 
phenotypes characterised by the acquisition of multiple mtDNA deletions and depletion in 
post mitotic tissues (Yu-Wai-Man, Votruba et al. 2016). OPA1 and MFN2 patient derived 
cells also display mitochondrial fragmentation (Spinazzi, Cazzola et al. 2008). Together, 
these observations strongly suggest that mitochondrial dynamics are a key regulator of 
mtDNA maintenance (Yu-Wai-Man, Votruba et al. 2016). It is possible that clonal 
expansion of an mtDNA deletion results from increased mitochondrial fragmentation by 
impairing the effective complementation of deleted mtDNA species by wild type species. 
This process could thereby couple the mitochondrial network fragmentation to the 
presence of mtDNA deletions in our patients (Chen, Vermulst et al. 2010). 
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SSBP1 is a core component of mitochondrial nucleoids and additionally it has been 
proposed that the mitochondrial D-loop functions to segregate multiple copies of mtDNA 
into nucleoids via interaction with the AAA+ ATPase, ATAD3 (Holt, He et al. 2007). 
Therefore, we examined the mitochondrial nucleoids in patient and control cells using 
immunochemistry observing no gross morphological or quantitative deficit in SSBP1 cells 
compared to m.1555A>G or controls. These results are in agreement with evidence that 
SSBP1 RNAi knockdown in HeLa cells does not alter the organisation of mitochondrial 
nucleoids (Ruhanen, Borrie et al. 2010). Together, this evidence indicates that normal 
levels of SSBP1 and 7S DNA are not essential for the organisation of mitochondrial 
nucleoids in fibroblasts. 
It has been suggested that the m.1555A>G variant results in the activation of the AMPK 
pathway by TFB1M mediated hypermethylation of m.1583 and m.1584 (m6 2A). As such, 
it has been proposed to play an important role in m.1555A>G pathogenesis (Raimundo, 
Song et al. 2012). However, no significant difference in AMPK activity was found 
between patient and control fibroblasts by either Western blot or ELISA. Interestingly, 
Western blot analysis revealed that P1 had a trend towards increased AMPK activity, 
however this finding was not replicated by the ELISA methodology. It is possible that this 
discrepancy may reflect the reported higher sensitivity of Western blotting over ELISA 
(Porsch-Ozcurumez, Kischel et al. 2004, Beck, Leite et al. 2005). Recently, AMPK has 
been identified as a regulator of mitochondrial network fission in response to 
mitochondrial stress by phosphorylating the mitochondrial fission factor, MFF that acts a 
receptor for DRP1 (Toyama, Herzig et al. 2016). It is an interesting possibility that 
increased AMPK activity in P1 may drive mitochondrial network fragmentation. Analysis 
of MFF phosphorylation levels using phosphomotif antibodies recognising phosphorylated 
Ser172 MFF may provide some insight into these processes (Toyama, Herzig et al. 2016). 
Nevertheless, it is important to consider our inability to demonstrate a significant increase 
in AMPK signalling in the context of two recent studies that have drawn the conclusion of 
Raimundo et al into question (Raimundo, Song et al. 2012). Firstly, O’Sullivan et al 
demonstrated primary lymphocytes and fibroblasts from m.1555A>G carriers and controls 
display equivalent levels of m62A indicating hypermethylation is not a physiological 
process (O'Sullivan, Rutland et al. 2015). Secondly, Lee et al generated a mouse 
overexpressing TFB1M on a C57BL/6N background to attempt to recapitulate the findings 
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of Raimundo et al, that TFB1M was overexpressed on a C57BL/6J background caused 
cochlear cell death and hearing impairment. The mouse of Lee et al displayed fully 
methylated m62A that could not be further methylated in vivo. The mouse had hearing 
comparable with wild type controls, leading the authors to conclude that m62A 
hypermethylation may in fact be an artefact of experimental conditions employed by the 
previous authors (Lee, Rose et al. 2015). Furthermore, the model posited by Raimundo et 
al is unable to comprehensively account for the variable penetrance seen in the Finnish 
family given that in isolation m.1555A>G is clearly not pathological in these individuals. 
Together this evidence suggests that, in contrast to other fibroblast models of 
mitochondrial disease, AMPK is not a major contributor to the cellular phenotype in our 
patient fibroblasts (Wu and Wei 2012, Distelmaier, Valsecchi et al. 2015). 
We next evaluated the mTOR pathway, a master regulator of cellular protein synthesis, in 
our primary fibroblasts by analysing the activity of S6 Kinase. This revealed a trend 
towards increased S6K phosphorylation suggesting increased activity of mTOR in the 
patient cells. AMPK is known to inhibit Rheb, the primary activator of mTOR, and 
therefore this further suggests that AMPK is not hyperactivated in our patient derived 
primary fibroblasts (Distelmaier, Valsecchi et al. 2015). 
Mitochondrial translation dysfunction has been demonstrated to trigger an integrated stress 
response culminating in the phosphorylation of eukaryotic translation initiation factor 2A 
(eIF2α) and a reduction in cytosolic protein translation (Pakos-Zebrucka, Koryga et al. 
2016). It is plausible that the increased activity of S6K may represent a compensatory 
nuclear response to dysfunctional mitochondrial protein synthesis seen in our patient cells. 
Consistent with these observations, mouse models of mitochondrial disease such as Leigh 
syndrome and focal-segmental-glomerulosclerosis-like-renal disease have shown increased 
mTOR signalling (Johnson, Tsai et al. 2000, Peng, Ostrovsky et al. 2015). However, 
mechanistic insight into the interaction between mitochondrial and cytosolic translation is 
only recently emerging (Couvillion, Soto et al. 2016, Munch and Harper 2016, D'Amico, 
Sorrentino et al. 2017). 
There was no evidence of ER stress observed in patient fibroblasts by Western blot 
analysis of the ER chaperone BiP, indicating that in basal conditions the SSBP1 and 
m.1555A>G variants do not result in ER stress in primary fibroblast cell lines. Similarly, 
there was no observable difference in mitochondrial chaperone HSP60 or cytosolic HSP70 
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suggesting no evidence of elevated mitochondrial or proteostatic stress in patient fibroblast 
cells. Consistent with these results, the mitochondrial aspartyl-tRNA synthetase (DARS2) 
knockout mouse also displays compromised protein synthesis, however proteostatic stress 
signalling is only triggered in cardiomyocytes. Together these findings further highlight 
tissue specificity as an important feature of mitochondrial disease (discussed further in 
Chapter 6) (Dogan, Pujol et al. 2014). 
There was also no significant compromise to the upregulation of HSP60 and HSP70 with 
heat shock in SSBP1 fibroblasts as predicted by the work of Tan et al (Tan, Fujimoto et al. 
2015). This may indicate functional redundancy in the SSBP1 signalling pathway in our 
fibroblast model or that sufficient SSBP1 is present in the cell to mediate the effect. It is 
important to consider, however, that due to high levels of endogenous expression of 
HSP60, it is difficult to detect small changes in protein levels and therefore it may not be a 
suitable marker of the mitochondrial UPR in cell culture (Seiferling 2015). 
In summary, the data presented in this chapter is consistent with an additive effect of the 
SSBP1 and m.1555A>G variants, manifesting as tissue specific phenotype primarily 





This chapter provides an overview of the primary findings of this thesis in conjunction 
with a critical evaluation of the strengths and limitations of the principal research 
strategies. The salient investigations required to extend the implications of these results are 
also presented. 
Man is by nature a social animal, and by restricting interpersonal communication, hearing 
loss can lead to profound isolation affecting both mental and physical health. 
Sensorineural hearing loss is a well-recognised feature of mitochondrial disease, and as 
such a more complete understanding of the underlying cellular and molecular mechanisms 
has the potential to deliver significant benefits to patients. The work presented in this 
thesis aimed to address this need. Specifically, this study set out to identify and 
characterise nuclear genetic variants accounting for the variable penetrance of hearing loss 
associated with the m.1555A>G variant in the 12S rRNA gene, MT-RNR1. 
In Chapter 3 we determined the importance of the m.1555A>G variant as a cause of 
hearing loss in the UK population by surveying the 5 laboratories in the UK providing 
either specific genetic testing for m.1555A>G or whole mitochondrial genome sequencing 
incorporating the MT-RNR1 gene. We found the variant was not present at a higher 
frequency than in the background population in a cohort of patients with hearing loss. We 
therefore concluded that the variant is not a significant cause of hearing loss in the UK 
population. This finding provided further evidence that in isolation the m.1555A>G 
variant is not pathogenic. 
Aminoglycosides are an important risk factor for hearing loss in m.1555A>G carriers, 
however, the identification of families segregating the variant that contain hearing-
impaired individuals that have not been exposed to aminoglycosides strongly suggested 
that other genetic factors are required to cause hearing loss. This evidence, together with 
the findings of our survey, motivated the design of an exome sequencing approach, 
presented in Chapter 4, to isolate nuclear genetic modifiers in familial and sporadic 
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carriers of the m.1555A>G variant. We addressed the hypothesis that a nuclear variant 
accounted for the variable penetrance of hearing loss associated with m.1555A>G by 
performing exome sequencing in selected Finnish familial (n=5) and Spanish sporadic 
cases (n=4). This strategy identified the heterozygous variant c.3G>A in the SSBP1 gene, 
resulting in a start-loss mutation of SSBP1, a core component of the mtDNA replisome 
machinery. The variant was then established to co-segregate with m.1555A>G and hearing 
loss in a large multi-generational Finnish family. 
Our study is the first reported use of WES technology in carriers of m.1555A>G and in 
isolating the SSBP1 variant in the Finnish family we provide a demonstration that WES 
coupled with segregation analysis is a powerful tool for dissecting the cause of 
mitochondrial disease. Prior to this work, no pathogenic mutations in SSBP1 had been 
associated with human mitochondrial disease. 
We were unable to identify a cause of hearing loss in any of the Spanish sporadic cases. It 
remains a possibility that WGS could be used to successfully delineate causative genes in 
these ‘unsolved’ individuals. When evaluating our experimental strategy, it should be 
considered that exome sequencing offers definite advantages over WGS: it is significantly 
less expensive, more easily understood for functional interpretation, faster to analyse, and 
an easy dataset to manage. However, aside from the additional ability to interrogate non-
coding regions of the genome, WGS permits reliable detection of CNVs and improved 
detection of ‘off target’ mtDNA reads and would thereby maximize the chance of defining 
a genomic cause for disease in these individuals (Girirajan, Brkanac et al. 2011). 
Although a potentially attractive strategy in these individuals, realising the benefits of 
WGS in discovering novel genetic causes of disease crucially depends on the concurrent 
development of improved bioinformatic tools to reduce potential false negative and false 
positive variant calls. This must also be allied with improvements in the prediction and 
functional annotation of potentially deleterious variants. Nevertheless, it is expected that in 
the coming years, as costs continue to fall, this technology will come to predominate in 
both research and clinical settings (Mardis 2017). 
The use of WGS in these ‘unsolved’ m.1555A>G carriers would be particularly apposite 
given the recent discovery that the non-coding part of the genome performs vital functions 
in controlling gene expression (Gerstein, Kundaje et al. 2012). Expression quantitative trait 
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loci (eQTLs) are non-coding genetic elements that directly contribute to variation in 
expression of mRNAs (Nica and Dermitzakis 2013). Thus, the analysis of SSBP1 
expression levels in patient derived fibroblasts or blood, for example by qPCR, coupled 
with knowledge of genotypic variation ascertained by WGS may identify an eQTL that 
alters the expression of SSBP1. This would constitute an additional mechanism for the 
nuclear genetic modification of m.1555A>G in these individuals. 
The functional data presented in Chapter 5 provides compelling evidence of an additive 
effect of the c.3G>A SSBP1 and m.1555A>G variants, manifesting as a tissue specific 
phenotype through a combined effect on mtDNA maintenance and mitochondrial 
translation. The SSBP1 variant reduced SSBP1 protein levels and decreased 7S DNA in 
fibroblasts, and was associated with multiple deletions of mtDNA and mtDNA depletion 
in skeletal muscle. Analysis of the mitochondrial copy number repopulation kinetics after 
a period of enforced depopulation by treatment with EtBr, revealed SSBP1 fibroblasts 
repopulated at double the rate of 1555A>G and control cells. Fibroblasts from these 
patients also showed reduced mtDNA encoded protein synthesis in keeping with the co-
existing m.1555A>G variant, leading to reduced proliferation rates under conditions of 
forced mitochondrial respiration (Robinson, Petrova-Benedict et al. 1992, Guan, Fischel-
Ghodsian et al. 1996). Additionally, SSBP1 cells displayed a more fragmented 
mitochondrial network. Whether this alteration in mitochondrial network dynamics 
represents an epiphenomenon or a primary pathological process, for example, by allowing 
clonal expansion of deleted mtDNA species, remains to be determined (Gorman, Pfeffer et 
al. 2015). 
The SSBP1 variant is unlikely to be pathogenic in isolation given that individuals carrying 
the variant in conjunction with wild type m.1555A have normal hearing (Family D and 
Family E). This is paralleled by the heterozygous knockout mouse Ssbp1tm1a(KOMP)Wtsi that 
displays hearing levels no different to wild-type littermates (Brown and Moore 2012). This 
evidence suggests that the SSBP1 variant likely has a sub-threshold effect that is 
exacerbated by m.1555A>G resulting in the cellular phenotype. However, definitive 
demonstration of this would require the functional analysis of cells derived from 
individuals in Family D and E. 
It is of vital importance to determine the mechanistic link between the SSBP1 and 
m.1555A>G variants and tissue specific mtDNA deletions and depletion. Our 
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investigations have highlighted the potential role of 7S DNA in the dysfunctional 
replication of mtDNA, with the reduced abundance of steady state 7S DNA potentially 
altering the mtDNA copy number repopulation kinetics. However, further experimental 
evidence is required to fully define this interaction. It also remains imperative to confirm 
the changes seen in fibroblasts and skeletal muscle are paralleled with disease processes in 
the cochleae of affected individuals. 
Our research employed in vitro cellular models consisting of patient derived skin 
fibroblasts and myoblasts in addition to the analysis of skeletal muscle biopsies to define 
the cellular effects of the variants. These tissue types are readily obtainable by outpatient-
based procedures that can be undertaken by any suitably trained healthcare professional 
after appropriate informed consent. Fibroblast cells are robust in culture and easily 
propagated providing a reliable in vitro system to determine disease specific biochemical 
parameters. However, as a result of the generally slow growth of primary fibroblasts a 
prolonged period in culture is required to generate sufficient biomaterial for genetic and 
biochemical assays. This can potentially increase the risk of confounding factors including 
bacterial contamination and cellular senescence (Hayflick 1965). In this study we 
attempted to control for these factors by undertaking regular quality control and using 
fibroblasts at similar passage number when performing experiments. To overcome the 
limitations of primary fibroblasts we also immortalised these cells. The resulting cells have 
far shorter doubling times and moreover the effect of cellular aging is negligible 
(Sprenger, Kuttner et al. 2010). Nevertheless, one must be mindful that these cells have 
been subjected to a transforming virus and hence display a disparate gene expression and 
epigenetic profile compared to their primary fibroblast ancestors (Oh, Jin et al. 2007). It 
must also be considered that the use of a fibroblast cell model cannot control for the 
nuclear background of the individual cell lines, which has the potential to confound 
results. To overcome this, transmitochondrial cybrids could be used to study the SSBP1 
and m.1555A>G variants on an otherwise constant nuclear background. 
This work therefore highlights some of the inherent difficulties of the use of in vitro 
cellular models in the study of mitochondrial disease. Although these models potentially 
offer valuable insights into disease mechanisms, their reductive simplicity may permit the 
over interpretation of results (Fearon, Gaca et al. 2013). Taking this into account, we must 
be careful when attempting to translate the physiological effects observed in a fibroblast 
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model to those that exist in the complex tissues such as the cochlea that consists of highly 
specialized inter-dependent cell types within a unique ionic microenvironment. 
With these limitations aside, fibroblasts carrying the c.3G>A SSBP1 and m.1555A>G 
variants demonstrated physiological dysfunction consistent with the known biological 
functions of the SSBP1 and MT-RNR1 genes and hence, particularly when taken in the 
context of the result in skeletal muscle, provide a useful biological model to define 
molecular mechanisms in these individuals. 
Although we have demonstrated significant pathology in our cellular models, a 
fundamental question still remains – why do the carriers of the c.3G>A SSBP1/ 
m.1555A>G variants solely present with hearing loss? The findings presented in Chapter 
5 clearly demonstrate pathological processes that are only apparent in a restricted subset of 
tissues, a common feature of mitochondrial disease. This phenomenon of tissue specificity 
is one of, if not the most pertinent unresolved issue in mitochondrial biology (Vafai and 
Mootha 2012). In addressing this question, it must be considered that although hearing loss 
was the foremost presenting feature in the SSBP1 and m.1555A>G variant carriers, our 
results indicate that these patients may also have a subclinical myopathy typified by the 
presence of mtDNA deletions and depletion. Hearing thresholds are easily quantifiable by 
audiological assessment, however diagnosis of other features of mitochondrial disease 
such as muscle weakness and fatigue may be harder to define, contributing to under- 
diagnosis and poorer clinical management (Filler, Lyon et al. 2014).  
‘Deep phenotyping’, defined as the precise and comprehensive analysis of phenotypic 
abnormalities, is emerging as an essential partner to modern genomic technologies in 
advancing the understanding of the pathological mechanisms of disease (Robinson 2012). 
Our results highlight the importance of fully phenotyping all patients with suspected 
mitochondrial disease, with a low threshold for requesting specialist testing, for example 
cardiac MRI and metabolic profiling. These investigations will collectively inform 
prognosis and could potentially define suitable biomarkers of this mitochondrial disease 
(Partington, Givertz et al. 2011, Lehtonen, Forsstrom et al. 2016). 
To date, there has been limited progress in defining the cellular mechanisms of tissue 
specificity. For heteroplasmic mutations it has been suggested that inter-tissue heterogeneity 
in heteroplasmy levels may contribute to differential tissue specific disease burdens. 
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Although this cannot account for the hearing loss associated with m.1555A>G, that is 
assumed to be homoplasmic in all tissues (Li, Schroder et al. 2015). Recent work has 
implicated modulation of one-carbon metabolism as an important process in mitochondrial 
disease. Specifically, tissue-restricted dysfunction in serine metabolism leads to 
cystathionine synthesis and activation of mitochondrial stress signalling leading to mtDNA 
deletions (Bao, Ong et al. 2016, Nikkanen, Forsstrom et al. 2016). Whether this or other 
metabolic dysfunctions are relevant processes to disease in our patients would require the 
study of cochlea or neuronal cells. However, these cells, although representing the affected 
tissue type in our patients, are prohibitively difficult to acquire from living individuals. 
To circumvent this, in collaboration with Professor Ludovic Vallier, (Cambridge Stem 
Cell Institute, Cambridge, UK), we are currently generating induced pluripotent stem cell 
(iPSC) lines from the two fibroblast cell lines carrying the c.3G>A SSBP1 and 
m.1555A>G variants (P1, P2) and from a fibroblast cell line carrying m.1555A>G alone 
(P3). The ability to generate iPSCs that can subsequently be differentiated down an otic 
lineage has the potential to be an effective technique in clarifying disease relevant 
processes. There has been limited success in developing cochlear hair cells from iPSCs 
(Oshima, Shin et al. 2010), however, recent work has focussed on the use of three-
dimensional culture systems to develop inner ear organoids from human pluripotent stem 
cells that contain nascent hair cells (Koehler, Nie et al. 2017). Alternatively, the 
development of auditory neurones from human iPSCs may provide a more tractable model 
to interrogate cell specific pathology (Gunewardene, Crombie et al. 2016). Using this 
approach, it would be interesting to determine whether cochlear cells or auditory neurones 
derived from SSBP1 iPSCs demonstrated the same, or perhaps enhanced dysregulation of 
mtDNA maintenance and translation detected in our current cellular models. 
There is particular hope that this may prove a fruitful strategy given seminal work from the 
laboratory of Anu Suomalainen (University of Helsinki, Finland). These researchers 
generated iPSCs carrying the heteroplasmic m.3243A>G MELAS mutation on an isogenic 
nuclear background with similar mtDNA levels (Hamalainen, Manninen et al. 2013). 
Neuronal cells and an array of tissue types derived from iPSC induced teratomas displayed 
distinct abnormalities in respiratory capacity indicating the importance of tissue specific 
factors in modifying phenotypes in mitochondrial disease. 
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More broadly, the generation of patient derived cochlear cells has the potential to define 
the mechanism underpinning the selective vulnerability of cochlear cells to mitochondrial 
dysfunction. Heart, skeletal muscle and the cochlea are the most affected tissues in patients 
with mitochondrial disease (Gorman, Chinnery et al. 2016). Hence, it would be fascinating 
to verify whether, as proposed, cochlear cells accumulate high levels of mtDNA mutations 
and deletions due to their post mitotic state and low cellular turn over (Fernandez and 
Hinojosa 1974, Pickrell and Youle 2013). Moreover, comparative transcriptomic and 
proteomic signatures of cochlear cells derived from patient and control iPSCs may offer 
novel insight into disease relevant signalling pathways. 
Albeit with a number of practical and ethical concerns, the use of an in vivo model is 
another potentially advantageous strategy to broaden the understanding of pathological 
molecular mechanisms in our patients. Due to their physiological and genetic similarity to 
humans, mice provide a reliable model of mitochondrial disease (Dunn, Cannon et al. 
2012). There presently exist a number of mouse models of nuclear encoded OXPHOS 
subunit and mitochondrial maintenance genetic diseases (Torraco, Peralta et al. 2015). 
However, while these models of nuclear mitochondrial disease have led to important 
insights into mitochondrial biology, the difficulty of manipulating a multi-copy mtDNA 
genome enclosed within the bilayer mitochondrial membrane has meant there has been far 
less progress in designing models of mtDNA mutations (Wallace 1999, Khan, Smigrodzki 
et al. 2007). 
Current technology does not permit the creation of a mouse carrying the m.1555A>G 
variant. In the absence of this specific model, it would be possible to create a mouse 
carrying a deleterious variant in a nuclear gene encoding a mitochondrial translation 
protein together with the SSBP1 variant. Determination of hearing thresholds in this mouse 
would delineate whether a translation specific effect of the m.1555A>G variant causes 
hearing loss or whether an ancillary function of 12S rRNA may also be relevant to the 
disease process. The recent identification of MOTS-c, a mitochondrial derived peptide 
regulating cellular metabolism that is encoded by a short opening reading frame (sORF) 
within the MT-RNR1 gene, makes this a particular interesting hypothesis to explore (Lee, 
Zeng et al. 2015). The work of Tan et al has highlighted additional functions of SSBP1, 
therefore, the phenotype of a mouse carrying combined mutations in nuclear genes 
encoding mitochondrial translation and mtDNA replication proteins would reveal whether 
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the abrogation of a non-replication function of SSBP1 might play a contributory role to the 
disease process in our patients (Tan, Fujimoto et al. 2015). 
Animal models with spontaneous mtDNA mutations can also provide useful insights into 
the mechanisms of mitochondrial disease (Li, Cuddon et al. 2006). The m.1555A>G 
variant is known to be the wild type allele in Old World Monkeys and therefore knocking 
out SSBP1 or reproducing the human mutation in these animals, for example using 
CRISPR/Cas9 technology, may provide an interesting in vivo model to gain further 
mechanistic insights into the pathology in the Finnish family (Pacheu-Grau, Gomez-Duran 
et al. 2011). 
Previous studies have indicated genes encoding mitochondrial translation proteins as 
candidate genetic modifiers of m.1555A>G (Bykhovskaya, Mengesha et al. 2004, Guan, 
Yan et al. 2006). Our work provides the first evidence of a gene encoding a mitochondrial 
replication protein as a potential modifier of m.1555A>G. Together, these findings suggest 
that nuclear genetic variants that modulate the phenotype of m.1555A>G may be found in 
genes involved in different aspects of mitochondrial biology and in some instances the 
variants may be private to individual families. Only by improving our understanding of the 
complex genetic architecture resulting in hearing loss in our patients can we begin to give 
comprehensive genetic counselling to carriers and their families. 
Although we have made concerted efforts to find additional carriers of pathogenic SSBP1 
mutations we have so far been unsuccessful. This is reflected in the small number of 
patient samples used in the functional analyses presented in Chapter 5. The identification 
of further families carrying deleterious variants in SSBP1 and m.1555A>G is important, as 
the identification of these unrelated carriers would be considered the highest level of proof 
of pathogenicity (MacArthur, Manolio et al. 2014). 
Given the SSBP1 variant is only pathogenic when segregating with m.1555A>G, finding 
individuals carrying these two rare alleles poses a major obstacle in conclusively 
validating the pathogenicity of the SSBP1 variant. The collation of large numbers of 
genetically and phenotypically characterised patients for example in the NIHR Bioresource 
may permit the screening of large numbers of patients to seek out carriers of the 
m.1555A>G variant. Hearing impaired carriers could then be examined for variants in 
mitochondrial replication genes, that may imply a conserved mechanism underlies the 
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phenotype in other m.1555A>G carriers and further validate the pathogenicity of the 
SSBP1 variant (McClellan and King 2010). 
There are no drug-based therapies for sensorineural hearing loss in clinical use and in the 
majority of cases, the treatment options for patients with mitochondrial associated hearing 
loss are limited to lifestyle modification and auditory amplification by hearing aids used 
with or without hearing assistive technology systems. In cases of severe hearing loss 
cochlear implantation may be indicated and has been used effectively in patients with 
m.3243A>G, OPA1 related auditory neuropathy, KSS and MNGIE syndrome 
(Yamaguchi, Himi et al. 1997, Li, Han et al. 2011, Scarpelli, Zappini et al. 2012, 
Santarelli, Rossi et al. 2015). In the majority of cases cochlear implantation is a safe, well-
tolerated procedure delivering substantial improvements in patient quality of life (Klop, 
Briaire et al. 2007, Mosnier, Bebear et al. 2015). However, cochlear implantation carries 
with it the associated risks of anaesthesia, as well as the potential for serious complications 
including damage to the facial nerve and in specific circumstances the possibility of CSF 
leaks resulting in meningitis (Terry, Kelt et al. 2015, Saeed, Powell et al. 2016). 
Additionally, cochlear implantation is not appropriate for a proportion of patients with 
auditory neuropathy (Ji, Li et al. 2015). This procedure has nevertheless proved to be an 
extraordinarily successful treatment for over 300,000 patients worldwide (Macherey and 
Carlyon 2014). The primary motivation of the work presented in this thesis was to further 
the understanding of disease mechanisms in mitochondrial hearing loss to facilitate the 
design of effective treatments for hearing restoration. However, it must be recognised that 
the efficacy of any future biological or genetic therapies must exceed that of cochlear 
implants to make them a viable alternative. 
In summary, the results presented in this thesis provide novel and original insights into the 
mechanisms of mitochondrial hearing loss by the identification and characterisation of a 
nuclear modifier of the m.1555A>G variant. Using in vitro cellular models, this study 
provides further evidence that trans-acting modifiers contribute to a complex interplay 
between nucleus and mitochondria. It is hoped that this work will contribute to a fuller 
understanding of pathological genetic mechanisms in mitochondrial disease. In time, these 
advances will inform genetic counselling, improve prognostication and lead to the design 




Summary of Conclusions 
7.1! Conclusions 
•! Our survey of the 5 laboratories in the UK testing the m.1555A>G variant 
determined it was not a significant cause of hearing loss. This provided further 
evidence that in isolation the m.1555A>G variant is not pathogenic. This suggested 
nuclear modifiers may act in concert with the variant to account for the variable 
hearing phenotype. 
 
•! Exome sequencing was employed for the first time in carriers of the m.1555A>G 
variant. This defined the primary novel finding of the thesis: the identification of 
the c.3G>A SSBP1 variant. This is the first pathogenic mutation discovered in this 
gene, and this work reveals it acts as a nuclear modifier of m.1555A>G and 
accounts for the variable hearing phenotype in this Finnish family. 
 
•! Together these variants act to dysregulate both mtDNA translation and mtDNA 
maintenance resulting in a tissue specific disease. These findings extend our 
understanding of mitochondrial-nuclear interactions in human disease. 
 
7.2! Limitations 
•! The SSBP1 variant was only found in one family and hence the ultimate proof of 
pathogenicity would require finding pathological variants in this gene in other 
m.1555A>G carriers.   
 
•! This research employed in vitro cellular models consisting of patient fibroblasts, 
myoblasts and skeletal muscle. Although these tissues display physiological 
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dysfunction corresponding to the biological role of the m.1555A>G and SSBP1 
variants whether these findings can account for the cochlear dysfunction of our 
patients has yet to be determined. 
7.3! Future work 
 
•! Access to larger cohorts of m.1555A>G carriers through large genetically and 
phenotypically characterised patient databases may enable a powerful approach to 
finding novel nuclear modifiers.  
 
•! Undertaking WGS in additional carriers of m.1555A>G would maximize the 
chance of defining a genetic cause for hearing loss in these individuals. 
 
•! The generation of patient specific iPSCs that could be differentiated down an otic 
lineage has the potential to be a highly informative technique to further delineate 




Appendix 1! Analysis of mitochondrial network 
Table A1.1. Distribution of mitochondrial fragment length in P1  
P1 (Relative frequency) 
Mitochondrial 
length (µm) Mean SD 
N 
(cells) 
p-value (vs. control) 
≤1 0.07 0.08 26 <0.0001 
1 to 2 0.40 0.16 26 <0.0001 
2 to 5 0.41 0.16 26 0.0017 
5 to 10 0.10 0.07 26 <0.0001 
>10 0.30 0.03 26 0.0055 
Table A1.2. Distribution of mitochondrial fragment length in P2 
P2 (Relative frequency) 
Mitochondrial 
length (µm) Mean SD 
N 
(cells) 
p-value (vs. control) 
≤1 0.04 0.03 16 0.0006 
1 to 2 0.41 0.07 16 <0.0001 
2 to 5 0.36 0.06 16 <0.0001 
5 to 10 0.13 0.05 16 0.0055 
>10 0.06 0.04 16 >0.99 
Table A1.3. Distribution of mitochondrial fragment length in P3 
P3 (Relative frequency) 
Mitochondrial 
length (µm) 
Mean SD N 
(cells) 
p-value (vs. control) 
≤1 0.01 0.014 18 >0.99 
1 to 2 0.35 0.111 18 0.0039 
2 to 5 0.46 0.08 18 0.0994 
5 to 10 0.12 0.04 18 0.0006 
>10 0.08 0.04 18 0.1339 
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Table A1.4. Distribution of mitochondrial fragment length in controls 
Controls (Relative frequency) 
Mitochondrial length (µm) Mean SD N (cells) 
≤1 0.01 0.03 63 
1 to 2 0.23 0.16 63 
2 to 5 0.51 0.12 63 
5 to 10 0.19 0.08 63 
>10 0.06 0.05 63 
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Appendix 2! Mitochondrial repopulation assay 
Table A2.1. Repopulation levels from optimisation experiment. N.D = not determined 
 P1 P2 C1 C2 
Time (days) Repopulation level (mtDNA copy number treated:untreated) ± SD 
0 1 1 1 1 
3 0.562±0.031 0.313±0.017 0.364±0.03 N.D 
6 0.175±0.007 0.078±0.003 0.143±0.003 0.251±0.017 
15 0.063±0.004 0.031±0.002 0.069±0.008 N.D 
23 0.026±0.001 0.074±0.002 0.042±0.004 0.031±0.004 
29 0.338±0.052 0.215±0.012 0.215±0.011 0.199±0.005 
36 0.481±0.021 0.204±0.028 0.119±0.06 0.086±0.053 
Table A2.2. Repopulation levels from modified protocol experiment 1 
 P1 P2 P3 C1 C2 
Time (days) Repopulation level (mtDNA copy number treated:untreated) 
0 1 1 1 1 1 
4 0.589 0.452 0.872 0.857 0.549 
6 0.330 0.192 0.419 0.217 0.529 
8 0.897 0.568 1.021 0.396 0.387 
10 1.135 1.714 1.383 0.752 0.800 
Table A2.3. Repopulation levels from modified protocol experiment 2 
 P1 P2 P3 C1 C2 
Time (days) Repopulation level (mtDNA copy number treated:untreated) 
0 1 1 1 1 1 
4 0. 864 0.725 0.921 1.175 0.686 
6 0. 493 0.4 0.575 0.418 0.546 
8 1.1567 1.034 1.065 0.729 0.494 
10 1.567 1.391 1.111 1.089 0.863 
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Table A2.4. Repopulation levels from modified protocol experiment 3 
 P1 P2 P3 C1 C2 
Time (days) Repopulation level (mtDNA copy number treated:untreated) 
0 1 1 1 1 1 
4 0.725 0.232 n.r 0.975 0.466 
6 0.128 0.128 0.740 0.457 0.248 
8 1.251 0.975 1.236 0.606 0.621 
10 1.902 1.233 1.472 1.549 0.932 
Table A2.5. Mean repopulation of the 3 modified protocol experiments  
 P1 P2 P3 C1 C2 
Time Mean repopulation level (mtDNA copy number treated:untreated) ± SD 
0 1 1 1 1 1 
4 0.721±0.142 0.469±0.248 0.897±0.034 0.565±0.111 1.001±0.160 
6 0.314±0.186 0.237±0.145 0.578±0.161 0.438±0.167 0.365±0.129 
8 1.101±0.182 0.861±0.254 1.106±0.113 0.501±0.117 0.577±0.168 
10 1.534±0.384 1.445±0.245 1.294±0.180 0.864±0.067 1.127±0.400 
Table A2.6. Repopulation rates calculated from the 3 modified protocol experiments  
Repopulation rates 
 P1 P2 P3 C1 C2 
Expt 1 0.890 0.555 0.365 0.267 0.136 
Expt 2 0.537 0.495 0.268 0.336 0.159 
Expt 3 0.402 0.761 0.440 0.540 0.345 
Mean±SD 0.610±0.25 0.6037±0.14 0.3577±0.09 0.381±0.14 0.213±0.11 
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Appendix 3! Heat shock response assay 
Table A3.1. Western blot analysis of BiP basal levels (GAPDH loading control)  
Fibroblast cell line BiP (basal) SD Repeats (n=) 
P1 0.4729 0.1317 3 
P2 0.3429 0.1679 3 
P3 0.3321 0.2034 3 
Controls 0.3621 0.108 3 
Table A3.2. Western blot analysis of HSP60 basal levels (GAPDH loading control) 
Fibroblast cell line HSP60 (basal) SD Repeats (n=) 
P1 1.214 0.5011 3 
P2 1.07 0.1831 3 
P3 0.8252 0.1762 3 
Controls 0.8542 0.1419 3 
Table A3.3. Western blot analysis of HSP70 basal levels (GAPDH loading control) 
Fibroblast cell line HSP70 (basal) SD Repeats (n=) 
P1 0.2955 0.06518 2 
P2 0.3014 0.03491 2 
P3 0.1839 0.1422 2 
Controls 0.2262 0.2088 2 







(Heat) SD Repeats (n=) 
P1 2.295 1.163 3.309 1.372 2 
P2 1.161 0.3316 2.369 0.1001 2 
P3 0.8168 0.07647 2.888 0.9276 2 
Controls 1.24 0.2221 2.654 0.3574 2 
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Table A3.5. Western blot analysis of HSP60 basal and post heat shock levels (GAPDH 




(basal) SD HSP60 (Heat) SD Repeats (n=) 
P1 1.041 0.241 1.285 0.7791 2 
P2 1.105 0.3453 1.215 0.4428 2 
P3 0.9817 0.02442 1.194 0.08633 2 
Controls 1.068 0.375 1.113 0.168 2 
Table A3.6. Western blot analysis of HSP70 basal and post heat shock levels (GAPDH 




(basal) SD HSP70 (Heat) SD Repeats (n=) 
P1 0.2955 0.06518 1.799 1.045 2 
P2 0.3014 0.03491 1.145 0.3546 2 
P3 0.1839 0.1422 2.063 0.09938 2 
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